ICL (ICL) 20-F28 Feb 232022 FY Annual report (foreign)Financial data

Company Profile

Document and Entity Information

Document and Entity Information	12 Months Ended
Document and Entity Information	Dec. 31, 2022 shares
Document Information [Line Items]
Entity Registrant Name	ICL GROUP LTD.
Entity Central Index Key	0000941221
Document Type	20-F
Amendment Flag	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding	1,289,178,854
Entity Emerging Growth Company	false
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-13742
Entity Incorporation, State or Country Code	L3
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Address, Address Line One	Millennium Tower
Entity Address, Address Line Two	23 Aranha Street
Entity Address, Address Line Three	P.O. Box 20245
Entity Address, City or Town	Tel Aviv
Entity Address Country	IL
Entity Address, Postal Zip Code	61202
Trading Symbol	ICL
Security Exchange Name	NYSE
Title of 12(b) Security	Ordinary Shares, par value NIS 1.00 per share
Document Accounting Standard	International Financial Reporting Standards
ICFR Auditor Attestation Flag	true
Auditor Name	Somekh Chaikin
Auditor Location	Israel
Auditor Firm ID	1057
Business Contact [Member]
Document Information [Line Items]
Entity Address, Address Line One	Millennium Tower
Entity Address, Address Line Two	23 Aranha St.
Entity Address, City or Town	Tel-Aviv
Entity Address Country	IL
Entity Address, Postal Zip Code	6120201
City Area Code	972
Local Phone Number	(3) 6844440
Contact Personnel Name	Aya Landman

Consolidated Statements of Fina

Consolidated Statements of Financial Position - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 417	$ 473
Short-term investments and deposits	91	91
Trade receivables	1,583	1,418
Inventories	2,134	1,570
Prepaid expenses and other receivables	323	357
Total current assets	4,548	3,909
Non-current assets
Deferred tax assets	150	147
Property, plant and equipment	5,969	5,754
Intangible assets	852	867
Other non-current assets	231	403
Total non-current assets	7,202	7,171
Total assets	11,750	11,080
Current liabilities
Short-term debt	512	577
Trade payables	1,006	1,064
Provisions	81	59
Other payables	1,007	912
Total current liabilities	2,606	2,612
Non-current liabilities
Long-term debt and debentures	2,312	2,436
Deferred tax liabilities	423	384
Long-term employee liabilities	402	564
Long-term provisions and accruals	234	278
Other	60	70
Total non-current liabilities	3,431	3,732
Total liabilities	6,037	6,344
Equity
Total shareholders' equity	5,464	4,527
Non-controlling interests	249	209
Total equity	5,713	4,736
Total liabilities and equity	$ 11,750	$ 11,080

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statements of Income [Abstract]
Sales	$ 10,015	$ 6,955	$ 5,043
Cost of sales	4,983	4,344	3,553
Gross profit	5,032	2,611	1,490
Selling, transport and marketing expenses	1,181	1,067	766
General and administrative expenses	291	276	232
Research and development expenses	68	64	54
Other expenses	30	57	256
Other income	(54)	(63)	(20)
Operating income	3,516	1,210	202
Finance expenses	327	216	219
Finance income	(214)	(94)	(61)
Finance expenses, net	113	122	158
Share in earnings of equity-accounted investees	1	4	5
Income before taxes on income	3,404	1,092	49
Taxes on income	1,185	260	25
Net income	2,219	832	24
Net income attributable to the non-controlling interests	60	49	13
Net income attributable to the shareholders of the Company	$ 2,159	$ 783	$ 11
Earnings per share attributable to the shareholders of the Company:
Basic earnings per share (in dollars)	$ 1.68	$ 0.61	$ 0.01
Diluted earnings per share (in dollars)	$ 1.67	$ 0.6	$ 0.01
Weighted-average number of ordinary shares outstanding:
Basic (in thousands)	1,287,304	1,282,807	1,280,026
Diluted (in thousands)	1,289,947	1,287,051	1,280,273

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statements of Comprehensive Income [Abstract]
Net income	$ 2,219	$ 832	$ 24
Components of other comprehensive income that will be reclassified subsequently to net income
Foreign currency translation differences	(146)	(105)	118
Change in fair value of cash flow hedges transferred to the statement of income	101	(15)	(54)
Effective portion of the change in fair value of cash flow hedges	(119)	13	53
Tax relating to items that will be reclassified subsequently to net income	4	0	0
Total	(160)	(107)	117
Components of other comprehensive income that will not be reclassified to net income
Net changes of investments at fair value through other comprehensive income	0	155	18
Actuarial gains (losses) from defined benefit plans	83	85	(15)
Tax relating to items that will not be reclassified to net income	(12)	(44)	(6)
Total	71	196	(3)
Total comprehensive income	2,130	921	138
Comprehensive income attributable to the non-controlling interests	40	54	23
Comprehensive income attributable to the shareholders of the Company	$ 2,090	$ 867	$ 115

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Millions	Total	Attributable to the shareholders of the Company [Member]	Share capital [Member]	Share premium [Member]	Cumulative translation adjustment [Member]	Capital reserves [Member]	Treasury shares, at cost [Member]	Retained earnings [Member]	Non-controlling interests [Member]
Balance as at Start of Period at Dec. 31, 2019	$ 4,061	$ 3,925	$ 546	$ 198	$ (442)	$ 3	$ (260)	$ 3,880	$ 136
Share-based compensation	8	8	0	6	0	2	0	0	0
Dividends	(119)	(118)	0	0	0	0	0	(118)	(1)
Total Comprehensive income	138	115	0	0	108	17	0	(10)	23
Balance as at End of Period at Dec. 31, 2020	4,088	3,930	546	204	(334)	22	(260)	3,752	158
Share-based compensation	6	6	2	20	0	(16)	0	0	0
Dividends	(279)	(276)	0	0	0	0	0	(276)	(3)
Total Comprehensive income	921	867	0	0	(110)	132	0	845	54
Balance as at End of Period at Dec. 31, 2021	4,736	4,527	548	224	(444)	138	(260)	4,321	209
Share-based compensation	13	13	1	9	0	3	0	0	0
Dividends	(1,166)	(1,166)	0	0	0	0	0	(1,166)	0
Total Comprehensive income	2,130	2,090	0	0	(126)	(14)	0	2,230	40
Balance as at End of Period at Dec. 31, 2022	$ 5,713	$ 5,464	$ 549	$ 233	$ (570)	$ 127	$ (260)	$ 5,385	$ 249

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net income	$ 2,219	$ 832	$ 24
Adjustments for
Depreciation and amortization	498	490	489
Fixed assets impairment (reversal of)	0	(6)	90
Exchange rate, interest and derivative, net	157	99	88
Tax expenses	1,185	260	25
Change in provisions	(83)	(4)	113
Other	(15)	(21)	5
Adjustments for reconcile profit loss	1,742	818	810
Change in inventories	(527)	(267)	54
Change in trade receivables	(215)	(426)	(89)
Change in trade payables	(42)	274	84
Change in other receivables	(46)	9	5
Change in other payables	107	107	54
Net change in operating assets and liabilities	(723)	(303)	108
Interest paid, net	(106)	(89)	(107)
Income taxes paid, net of refund	(1,107)	(193)	(31)
Net cash provided by operating activities	2,025	1,065	804
Cash flows from investing activities
Proceeds (payments) from deposits, net	(36)	355	34
Business combinations	(18)	(365)	(27)
Purchases of property, plant and equipment and intangible assets	(747)	(611)	(626)
Proceeds from divestiture of assets and businesses, net of transaction expenses	33	39	29
Other	14	3	7
Net cash used in investing activities	(754)	(579)	(583)
Cash flows from financing activities
Dividends paid to the Company's shareholders	(1,166)	(276)	(118)
Receipt of long-term debt	1,045	1,230	1,175
Repayments of long-term debt	(1,181)	(1,120)	(1,133)
Repayments of short-term debt	(21)	(58)	(52)
Receipts (payments) from transactions in derivatives	20	(17)	24
Other	0	(3)	(1)
Net cash used in financing activities	(1,303)	(244)	(105)
Net change in cash and cash equivalents	(32)	242	116
Cash and cash equivalents as of the beginning of the year	473	214	95
Net effect of currency translation on cash and cash equivalents	(24)	17	3
Cash and cash equivalents as of the end of the year	$ 417	$ 473	$ 214

General

General	12 Months Ended
General	Dec. 31, 2022
General Information About Financial Statements [Abstract]
Note 1 - General	Note 1 – General A. The Reporting Entity ICL Group Ltd. (hereinafter – the Company), is a company incorporated and domiciled in Israel. The Company's shares are traded on both the Tel-Aviv Stock Exchange (TASE) and the New York Stock Exchange (NYSE) under the ticker: ICL. The address of the Company’s registered headquarters is 23 Aranha St., Tel Aviv, Israel. The Company is a subsidiary of Israel Corporation Ltd., a public company traded on the TASE under the ticker: ILCO:TA. The State of Israel holds a Special State Share in ICL and in some of its subsidiaries, entitling the State the right to safeguard the State of Israel vital interests. For additional information, see Note 19 - Equity. The Company, together with its subsidiaries, associated companies and joint ventures (hereinafter - the Group or ICL), is a leading specialty minerals group that operates a unique, integrated business model. The Company competitively extracts certain minerals as raw materials and utilizes processing and product formulation technologies to add value to customers in two main end-markets: agriculture and industrial (including food). ICL’s products are used mainly in agriculture, electronics, food, fuel and gas exploration, water purification and desalination, construction, detergents, cosmetics, pharmaceuticals and automotive. B. Definitions 1. Subsidiary – a company over which the Company has control and the financial statements of which are fully consolidated with the Company's statements as part of the consolidated financial statements. 2. Investee company – Subsidiaries, including a partnership or joint venture, which is accounted for using the equity method. 3. Related party – As in IAS 24 (2009), “Related Party Disclosures”.

Basis of Preparation of the Fin

Basis of Preparation of the Financial Statements	12 Months Ended
Basis of Preparation of the Financial Statements	Dec. 31, 2022
Basis Of Preparation Of Financial Statements [Abstract]
Note 2 - Basis of Preparation of the Financial Statements	Note 2 - Basis of Preparation of the Financial Statements A. Statement of compliance with International Financial Reporting Standards The consolidated financial statements were prepared by ICL in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Boards (IASB). The consolidated financial statements were authorized for issuance by the Company’s Board of Directors on February 27, 2023. B. Functional and presentation currency The consolidated financial statements are presented in United States Dollars (“US Dollars”; $), which is the functional currency of the Company and have been rounded to the nearest million, except when otherwise indicated. Items included in the consolidated financial statements of the Company are measured using the currency of the primary economic environment in which the individual entity operates (“the functional currency”). C. Basis of measurement The consolidated financial statements were prepared using the depreciated historical cost basis except for the following assets and liabilities: Financial instruments measured at fair value through profit or loss, financial instruments measured at fair value through other comprehensive income, Investments in associates, deferred tax assets and liabilities, assets and liabilities in respect of employee benefits. For further information regarding the measurement of assets and liabilities, see Note 3. D. Operating cycle The Company’s regular operating cycle is up to one year. As a result, the current assets and the current liabilities include items for which the realization is intended and anticipated to take place within one year. E. Classifications The Company made a number of insignificant adjustments to the classification of comparative figures in order to adjust them to the manner of classification in the current financial statements. The said classifications have no effect on the total profit (loss). F. Use of estimates and judgment The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. The evaluation of accounting estimates used in the preparation of ICL’s Financial Statements requires the Company's management to make assumptions regarding interpretations of laws which apply to the Company, circumstances and events involving considerable uncertainty. The Company's management prepares the estimates based on past experience, various facts, external circumstances, and reasonable assumptions relating to the pertinent circumstances of each estimate. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Information about assumptions made by ICL with respect to the future and other reasons for uncertainty with respect to estimates that have a significant risk of resulting in a material adjustment to carrying amounts of assets and liabilities in future financial years are included in the following table: Estimate Principal assumptions Possible effects Reference Concessions, permits and business licenses Forecast of obtaining renewed concessions, permits and business licenses which constitute the basis for the Company's continued operations and the Company's expectations regarding the holding of the operating assets by it and / or by a subsidiary until the end of their useful lives Impact on the value of the operation, depreciation periods and residual values of related assets. See Note 18 - Concessions. Recoverable amount of a cash generating unit, among other things, containing goodwill Expected cash-flow forecasts including estimates of mineral reserves, discount rate, market risk and the forecasted growth rate. Change in impairment valuation. See Note 12 - impairment testing. Probability assessment of contingent and environmental liabilities including cost of waste removal/ restoration Whether it is more likely than not that an outflow of economic resources will be required in respect of potential liabilities under the environmental protection laws and legal claims pending against ICL and the estimation of their amounts. The waste removal/ restoration obligations depend on the reliability of the estimates of future removal costs and interpretation of regulations. A change in the Company's estimated provisions for a claim and/or environmental liability, including waste removal and restoration. See Note 18 - contingent liabilities.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
Significant Accounting Policies	Dec. 31, 2022
Summary Of Significant Accounting Policies [Abstract]
Note 3 - Significant Accounting Policies	Note 3 - Significant Accounting Policies The accounting policies in accordance with IFRS are consistently applied by ICL companies for all the periods presented in these consolidated financial statements. A. Basis for Consolidation 1. Business combinations ICL implements the acquisition method to all business combinations. The acquisition date is the date on which the acquirer obtains control over the acquiree. Control exists when ICL is exposed or has rights to variable returns from its involvement with the acquiree and it could affect those returns through its power over the acquiree. Substantive rights held by ICL and others are considered when assessing control. ICL recognizes goodwill on an acquisition according to the fair value of the consideration transferred including any amounts recognized in respect of non-controlling interest in the acquiree as well as the fair value at the acquisition date of any pre-existing equity right of ICL in the acquiree, less the net amount of the identifiable assets acquired, and the liabilities assumed. Costs associated with the acquisition that were incurred by ICL in a business combination such as advisory, legal, valuation and other professional or consulting fees, other than those associated with an issue of debt or equity instruments connected to the business combination, are expensed in the period the services are received. 2. Subsidiaries Subsidiaries are entities controlled by ICL. The financial statements of the subsidiaries are included in the consolidated financial statements from the date control commenced until the date control ceases to exist. The financial statements of subsidiaries have been changed when necessary to align them with ICL's accounting policies. 3. Non-controlling interests Non-controlling interests comprise of the subsidiary's equity that cannot be attributed, directly or indirectly, to the parent company. Profit or loss and any part of other comprehensive income are allocated to the owners of the Company and the non-controlling interests, even if the result is a negative balance of non-controlling interests. Measurement on the date of the business combination – Non‑controlling interests that are instruments that give rise to a present ownership interest and entitle the holder to a share of net assets in the event of liquidation, are measured at the date of the business combination at either fair value, or at their proportionate interest in the identifiable assets and liabilities of the acquiree, on a transaction-by-transaction basis. Transactions with non-controlling interests, while retaining control - are accounted for as equity transactions. Any difference between the consideration paid or received and the change in non‑controlling interests is included in the share of the owners of the company directly in a separate category in equity. 4. Loss of control Upon the loss of control, ICL derecognizes the assets and liabilities of the subsidiary, any non-controlling interests and the other components of equity related to the subsidiary. If ICL retains any interest in the previous subsidiary, then such interest is measured at fair value at the date that control is lost. The difference between the sum of the proceeds and fair value of the retained interest, and the derecognized balances is recognized in profit or loss as other income or other expenses. The amounts recognized in capital reserves through other comprehensive income with respect to the same subsidiary are reclassified to profit or loss or to retained earnings. 5. Transactions eliminated in consolidation Intra-group balances, transactions, unrealized income and expenses and gains and losses arising from intra-group transactions, are eliminated in preparing the consolidated financial statements. 6. Investment in associated companies and joint ventures Joint ventures are joint arrangements in which ICL has rights to the net assets of the arrangement. Associates and joint ventures are accounted for using the equity method (equity accounted investees) and are recognized initially at cost. B. Foreign Currency 1. Transactions in foreign currency Transactions in foreign currency are translated to the functional currency based on the exchange rate in effect on the dates of the transactions. Monetary assets and liabilities denominated in foreign currency on the report date are translated into the functional currency based on the exchange rate in effect on that date. Non‑monetary items denominated in foreign currency measured at historical cost are translated using the exchange rate at the date of the transaction. 2. Foreign operations The assets and liabilities of foreign operations, including goodwill and fair value adjustments from acquisition, are translated to USD at exchange rates at the reporting date. The income and expenses of foreign operations are translated to USD at exchange rates at the dates of the transactions. Foreign currency differences are recognized in other comprehensive income and are presented in equity in the foreign currency translation reserve (hereinafter –Translation Reserve). When the foreign operation is a non-wholly owned subsidiary of the Company, then the relevant proportionate share of the foreign operation translation difference is allocated to the non-controlling interests. When a foreign operation is disposed of, the cumulative amount in the Translation Reserve is reclassified to profit or loss as a part of the capital gain or loss on disposal. Generally, foreign currency differences from a monetary item receivable from or payable to a foreign operation, including foreign operations that are subsidiaries, are recognized in profit or loss in the consolidated financial statements. Foreign exchange gains or losses arising from a monetary item receivable from or payable to a foreign operation, the settlement of which is neither planned nor likely in the foreseeable future, are considered to form part of a net investment in a foreign operation and are recognized in other comprehensive income and are presented within equity in the Translation Reserve. C. Financial Instruments 1. Non-derivative financial assets (IFRS9) Initial recognition of financial assets: ICL initially recognizes trade receivables and debt instruments issued on the date that they are originated and for all other financial assets at the trade date in which ICL becomes a party to the contractual provisions of the instrument. A financial asset is initially measured at fair value plus direct transaction costs. Derecognition of financial assets: Derecognition of financial assets occurs when the contractual rights of ICL to the cash flows from the asset expire, or when ICL transfers the rights to receive the contractual cash flows and substantially all the risks and rewards of ownership of the financial asset. When ICL retains substantially all the said risks and rewards, it continues to recognize the financial asset. Classification of financial assets into categories and the accounting treatment of each category: Financial assets are classified at initial recognition to one of the following measurement categories: (1) amortized cost; (2) fair value through other comprehensive income – investments in debt instruments; (3) fair value through other comprehensive income – investments in equity instruments; or (4) fair value through profit or loss. The reclassification of the financial assets in subsequent periods will only occur if ICL's changes its financial debt assets business model. A financial asset is measured at amortized cost if it meets both of the following conditions and is not designated at fair value through profit or loss: (1) It is held within a business model whose objective is to hold assets so as to collect contractual cash flows; and (2) the contractual terms of the financial asset give rise to cash flows representing solely payments of principal and interest on the principal amount outstanding on specified dates. These assets are subsequently measured at amortized cost using the effective interest method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognized in profit or loss. Any gain or loss on derecognition is recognized in profit or loss. ICL has balances of trade and other receivables and deposits that are held within a business model whose objective is collecting contractual cash flows, which represent solely payments of principal and interest (for the time value and the credit risk). Accordingly, these financial assets are measured at amortized cost. Financial assets at fair value through profit or loss - are subsequently measured at fair value. Net gains or losses, including any interest income or dividend income, are recognized in profit or loss (other than certain derivatives designated as accounting hedging instruments). Investments in equity instruments at fair value through other comprehensive income - are subsequently measured at fair value. Dividends are recognized as income in profit or loss, unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognized in other comprehensive income and are never reclassified to profit or loss. 2. Non-derivative financial liabilities Non-derivative financial liabilities include bank overdrafts, loans and borrowings from banks and others, marketable debt instruments, lease liabilities, and trade and other payables. ICL initially recognizes debt securities issued on the date that they originated. All other financial liabilities are recognized initially on the trade date at which ICL becomes a party to the contractual provisions of the instrument. Subsequent to initial recognition these financial liabilities are measured at amortized cost using the effective interest method. Derecognition of the financial liabilities occur when the obligation of ICL, as specified in the agreement, expires or when it is discharged or cancelled. Change in terms of debt instruments: A substantial modification of the terms of an existing financial liability or part of it and an exchange of debt instruments having substantially different terms, between an existing borrower and lender is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability at fair value. In such cases the entire difference between the amortized cost of the original financial liability and the fair value of the new financial liability is recognized in profit or loss as financing income or expense. Substantially different terms - if the discounted present value of the cash flows according to the new terms and discounted using the original effective interest rate, is different by at least ten percent (10%) from the discounted present value of the remaining cash flows of the original financial liability. In addition to the aforesaid quantitative criterion, ICL examines, inter alia, whether there have also been changes in various economic parameters inherent in the exchanged debt instruments (e.g. linkage). In a non-substantial modification of terms (or exchange) of debt instruments, the new cash flows are discounted using the original effective interest rate, and the difference between the present value of the new financial liability and the present value of the original financial liability is recognized in profit or loss. Offset of financial instruments: Financial assets and liabilities are offset, and the net amount is presented in the statement of financial position when, and only when, ICL currently has a legal right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously. 3. Derivative financial instruments ICL holds derivative financial instruments in order to reduce exposure to foreign currency risks, marine shipping prices, and interest. Derivatives are recognized according to fair value and the changes in value are recorded in the statement of income as financing income or expense, except for derivatives used to hedge cash flows (accounting hedging). The attributable transaction costs are recorded in the statement of income as incurred. Cash flow hedges Changes in the fair value of derivatives used to hedge cash flows, in accordance with the effective portion of the hedge, are recorded through other comprehensive income directly in a hedging reserve. With respect to the non‑effective part, changes in the fair value are recognized in the statement of income. The amount accumulated in the capital reserve is reclassified and included in the statement of income in the same period as the hedged cash flows affected profit or loss under the same line item in the statement of income as the hedged item. If the hedging instrument no longer meets the criteria for hedge accounting, expires or is sold, terminated or exercised, then hedge accounting is discontinued. The cumulative gain or loss remains in other comprehensive income and is presented in the hedging reserve in equity until the forecasted transaction occurs or is no longer expected to occur and then is reclassified to the statements of income. 4. CPI-linked assets and liabilities not measured at fair value The value of index-linked financial assets and liabilities, which are not measured at fair value, is re‑measured every period in accordance with the actual increase/ decrease in the CPI. 5. Share capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares and share options are recognized as a deduction from equity, net of any tax effects. Incremental costs directly attributable to an expected issuance of an equity instrument are deducted from the equity upon the initial recognition of the equity instruments or are amortized as financing expenses in the statement of income when the issuance is no longer expected to take place. Treasury shares - when shares recognized as equity are repurchased by the Group, the amount of the consideration paid, which includes directly attributable costs, net of any tax effects, is recognized as a deduction from equity. When treasury shares are sold or reissued subsequently, the amount received is recognized as an increase in equity, and the resulting surplus on the transaction is carried to share premium, whereas a deficit on the transaction is deducted from retained earnings. D. Property, plant and equipment 1. Recognition and measurement Property, plant and equipment in the consolidated statements are presented at cost less accumulated depreciation and provision for impairment. The cost includes expenses that can be directly attributed to the acquisition of the asset after deducting the related amounts of government grants. The cost of assets that were self-constructed includes the cost of the materials and direct labor, as well as any additional costs that are directly attributable to bringing the asset to the required position and condition so that it will be able to function as management intended, as well as an estimate of the costs to dismantle, remove and restore, where there is an obligation for such, and capitalized borrowing costs. Gains and losses on disposal of a property, plant or equipment item are determined by comparing the proceeds from disposal of the carrying amount of the asset and are recognized net in the income statement. 2. Subsequent Costs (after initial recognition) The cost of replacing part of an item of property, plant and equipment and other subsequent costs is recognized as part of the book value of the item, if it is expected that the future economic benefit inherent therein will flow to ICL and that its cost can be reliably measured. The book value of the part that was replaced is derecognized. Routine maintenance costs are charged to the statement of income as incurred. 3. Depreciation Depreciation is a systematic allocation of the depreciable amount of an asset over its estimated useful life. The depreciable amount is the cost of the asset, or other amount substituted for cost, less its residual value. Depreciation of an item of property, plant and equipment begins when the asset is available for its intended use, that is, when it has reached the place and condition required in order that it can be used in the manner contemplated for it by Management. Depreciation is recorded in the statement of income according to the straight-line method over the estimated useful life of each significant component of the property, plant and equipment items, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. Owned land is not depreciated. The estimated useful life is as follows: In Years Buildings 15 - 30 Technical equipment and machinery (1) 5 - 33 Dikes and evaporating ponds (2) 20 - 40 Other 3 - 10 (1) Mainly 33 years (2) Mainly 40 years The Company reviews, at least at the end of every reporting year, the estimates regarding the depreciation method, useful lives and the residual value, and adjusts them if appropriate. Over the years, the Company has succeeded to extend the useful lives of part of property, plant and equipment items beyond the original estimated useful life, as a result of investments therein and other current, ongoing maintenance thereof. E. Intangible Assets 1. Goodwill Goodwill recorded consequent to the acquisition of subsidiaries is presented at cost less accumulated impairment charges, under intangible assets. 2. Research and development Expenditures for research activities are expensed as incurred. Development expenditures are recognized as intangible asset only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and ICL has the intention and sufficient resources to complete development and to use or sell the asset. 3. Other intangible assets Other intangible assets with a defined useful life, are measured according to cost less accumulated amortization and accumulated losses from impairment. Intangible assets with indefinite useful lives are measured according to cost less accumulated losses from impairment. 4. Subsequent costs Subsequent costs are recognized as an intangible asset only when they increase the future economic benefit inherent in the asset for which they were incurred. All other costs are charged to the statement of income as incurred. 5. Amortization Amortization is a systematic allocation of the amortizable amount of an intangible asset over its useful life. The amortizable amount is the cost of the asset less its residual value. Amortization is recorded in the statement of income according to the straight-line method from the date the assets are available for use, over the estimated useful economic life of the intangible assets, except for customer relationships and geological surveys, which are amortized according to the rate of consumption of the economic benefits expected from the asset based on cash flow forecasts. Goodwill and intangible assets having an indefinite lifespan are not amortized on a systematic basis but, rather, are examined at least once a year for impairment in value. Internally generated intangible assets are not systematically amortized as long as they are not available for use, i.e. they are not yet on site or in working condition for their intended use. Accordingly, these intangible assets, such as development costs, are tested for impairment at least once a year, until such date as they are available for use. The estimated useful life is as follows: In Years Concessions and mining rights – over the remaining duration of the rights granted Trademarks 15 - 20 Technology / patents 7 - 20 Customer relationships 15 - 25 Computer applications 3 - 10 ICL periodically examines the estimated useful life of an intangible asset that is not amortized, at least once a year, in order to determine if events and circumstances continue to support the determination that the intangible asset has an indefinite life. Deferred expenses in respect of geological surveys are amortized over their useful life based on a geological estimate of the amount of the material that will be produced from the mining site. The estimates regarding the amortization method and useful life are reviewed, at a minimum, at the end of every reporting year and are adjusted where necessary. ICL assesses the useful life of the customer relationships on an ongoing basis, based on an analysis of all the relevant factors and evidence, considering the experience the Company has with respect to recurring orders and churn rates and considering the future economic benefits expected to flow to the Company from these customer relationships. F. Inventories Inventories are measured at the lower of cost or net realizable value. The cost of the inventories includes the costs of purchasing the inventories and bringing them to their present location and condition. In the case of work in process and finished goods, the cost includes the proportionate part of the manufacturing overhead based on normal capacity. Net realizable value is the estimated selling price in the ordinary course of business, after deduction of the estimated cost of completion and the estimated costs required to execute the sale. The cost of the inventories of raw and auxiliary materials, maintenance materials, finished goods and goods in process, is determined mainly according to the “moving average” method. If the benefit from stripping costs (costs of removing waste produced as part of a mine's mining activities during its production stage) is attributable to inventories, the Company accounts for these stripping costs as inventories. In a case where the benefit is improved access to the quarry, the Company recognizes the costs as a non‑current addition to the asset, provided the criteria presented in IFRIC 20 are met. Inventories which are expected to be sold in a period of more than 12 months from the reporting date are presented as non-current inventories, as part of non-current assets. G. Capitalization of Borrowing Costs A qualifying asset is an asset that requires a significant period of time to prepare for its intended use or sale. Specific and non-specific borrowing costs are capitalized to qualifying assets during the period required for their completion and establishment, until the time when they are ready for their intended use. Other borrowing costs are charged to "financing expenses" in the statement of income as incurred. H. Impairment 1. Non-derivative financial assets Provision for expected credit losses in respect of a financial asset at amortized cost, including trade receivables, is measured at an amount equal to the full lifetime of expected credit losses. Expected credit losses are a probability-weighted estimate of credit losses. With respect to other debt instruments, provision for expected credit losses is measured at an amount equal to 12-month expected credit losses, unless their credit risk has increased significantly since initial recognition. Provision for such losses in respect of a financial asset at amortized cost, is presented net of the gross book value of the asset. 2. Non-financial assets In each reporting period, an examination is made with respect to whether there are signs indicating impairment in the value of ICL’s non-financial assets, other than inventories and deferred tax assets. If such signs exist, the estimated recoverable amount of the asset is calculated. ICL conducts an annual examination, on the same date, of the recoverable amount of goodwill and intangible assets with indefinite useful lives or those that are not available for use – or more frequently if there are indications of impairment. Assets that cannot be tested individually are grouped together into the smallest group of assets that generate cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the “cash-generating unit”). The recoverable amount of an asset or a cash-generating unit is the higher of its value in use or the net selling price (fair value less cost of disposal). When determining the value in use, ICL discounts the anticipated future cash flows according to an after-tax discount rate that reflects the evaluations of the market's participants regarding the time value of money and the specific risks relating to the asset or to the cash-generating unit, in respect of which the future cash flows expected to derive from the asset or the cash-generating unit were not adjusted. Assets of the Company's headquarters and administrative facilities do not produce separate cash flows and they serve more than one cash-generating unit. Such assets are allocated to cash-generating units on a reasonable and consistent basis and are examined for impairment as part of the examination of impairment of the cash-generating units to which they are allocated. Impairment losses are recognized if the carrying amount of an asset or cash-generating unit exceeds its estimated recoverable amount and are recognized in the statement of income. For operating segments that include goodwill, an impairment loss is recognized when the book value of the operating segment exceeds its recoverable value. Impairment losses in respect of an operating segment are allocated first to reduce the carrying amount of its goodwill and then to reduce the carrying amounts of the other assets of that segment on a proportionate basis. An impairment loss is allocated between the owners of the Company and the non-controlling interests on the same basis that the profit or loss is allocated. A loss from impairment in value of goodwill recognized in previous periods is not reversible prospectively. A loss from impairment of other assets recognized in previous periods is examined in future periods to assess whether there are signs indicating that these losses have decreased or no longer exist. A loss from impairment of value is reversed if there is a change in the estimates used to determine the recoverable value, only if the book value of the asset, after reversal of the loss from impairment of value, does not exceed the book value, after deduction of depreciation or amortization, that would have been determined if the loss from impairment of value had not been recognized. I. Employee Benefits ICL has several post-employment benefit plans. The plans are funded partly by deposits with insurance companies, financial institutions or funds managed by a trustee. The plans are classified as defined contribution plans and as defined benefit plans. 1. Defined contribution plans A post-employment benefit plan under which ICL pays fixed contributions into a separate entity and has no legal or constructive obligation to pay further amounts. ICL’s obligation to deposit in a defined contribution plan is recorded as an expense in the statement of income in the periods in which the employees provided the services. Retirement benefit plans that are not defined contribution plans: ICL’s net obligation is calculated for each plan separately, by estimating the future amount of the benefit to which an employee will be entitled as compensation for services in the current and past periods. The benefit is presented at present value after deducting the fair value of the plan's assets. The discount rate for ICL companies operating in countries having a “deep” market for high quality corporate bonds is the yield on such corporate bonds, including Israel. The discount rate for ICL companies operating in countries not having a “deep” market for high quality corporate bonds is in accordance with the yield on government bonds – the currency and redemption date of which are similar to the terms binding ICL. The calculations are performed by a qualified actuary using the projected unit credit method 2. Defined benefit plans When a net asset is created for ICL, the asset is recognized up to the net present value of the available economic benefits in the form of a refund from the plan or by a reduction in future deposits to the plan. An economic benefit in the form of a refund from the plan or a reduction in future deposits will be considered available when it can be realized in the lifetime of the plan or after settlement of the obligation. The movement in the net liability in respect of a defined benefit plan that is recognized in every accounting period in the statement of income is comprised of the following: (1) Current service costs – the increase in the present value of the liability deriving from employees’ service in the current period; (2) The net financing income (expense) is calculated by multiplying the net defined benefit liability (asset) by the discount rate used for measuring the defined benefit liability, as determined at the beginning of the annual reporting period; (3) Exchange rate differences; (4) Past service costs and plan reduction – the change in the present value of the liability in the current period as a result of a change in post-employment benefits attributed to prior periods. The difference, as of the date of the report, between the net liability at the beginning of the year plus the movement in the net liability as detailed above, and the actuarial liability less the fair value of the fund assets at the end of the year, reflects the balance of the actuarial income or expenses recognized in other comprehensive income and is recorded in retained earnings. The current interest costs and return on plan assets are recognized as expenses and interest income in the respective financing category. Costs in respect of past services are recognized immediately and without reference to whether the benefits have vested. 3. Other long-term employee benefits Some of the Company’s employees are entitled to other long-term benefits that do not relate to a post-retirement benefit plan. Actuarial gains and losses are recorded directly to the statement of income in the period in which they arise. 4. Early Retirement Pay Early retirement pay is recognized as an expense and as a liability when ICL has clearly undertaken to pay it, without any reasonable chance of cancellation, in respect of termination of employees, before they reach the customary age of retirement according to a formal, detailed plan. The benefits provided to employees upon voluntary retirement are charged when ICL proposes the plan to the employees, it is expected that the proposal will be accepted, and it is possible to reliably estimate the number of employees that will accept the proposal. If benefits are payable more than 12 months after the reporting period, then they are discounted to their present value. The discount rate is the yield at the reporting date on high-quality, index-linked corporate debentures, the denominated currency of which is the payment currency, and that have maturity dates approximating the terms of ICL’s obligations. 5. Short‑term benefits Obligations for short-term employee benefits are measured on a non-discounted basis, and the expense is recorded at the time the service is provided or upon the actual absence of the employee when the benefit is not accumulated (such as maternity leave). A provision for short-term employee benefits in respect of cash bonuses or profit-sharing plans is recognized for the amount expected to be paid, when ICL has a current legal or implied obligation and it is possible to reliably estimate the obligation. Classification of employee benefits is determined based on ICL's expectation with respect to full utilization of the benefits and not based on the date on which the employee is entitled to utilize the benefit. 6. Share-based compensation The fair value on the grant date of share-based compensation awards granted to employees is recognized as a salary expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards. The amount recognized as an expense in respect of share-based compensation awards that are conditional upon meeting vesting conditions that are service conditions and non-market performance conditions, is adjusted to reflect the number of awards that are expected to vest. J. Provisions A provision is recognized when ICL has a present legal or implied obligation, as the result of an event that occurred in the past, that can be reliably estimated, and when it is expected that an outflow of economic benefits will be required in order to settle the obligation. The provisions are made by means of discount

Determination of Fair Values

Determination of Fair Values	12 Months Ended
Determination of Fair Values	Dec. 31, 2022
Fair Value Measurement [Abstract]
Note 4 - Determination of Fair Values	Note 4 - Determination of Fair Values As part of the accounting policies and disclosures, ICL is required to determine the fair value of both financial and non-financial assets and liabilities. The fair values have been determined for measurement and/or disclosure purposes based on the methods described below. Further information about the assumptions made in determining the fair values is disclosed in the notes specific to that asset or liability. A. Investments in equity securities The fair value of investments in equity instruments classified as fair value through other comprehensive income - investments in equity instruments and as fair value through profit and loss, is determined based on their market price at date of the report. B. Derivatives The fair value of forward contracts on foreign currency is determined by averaging the exchange rate and the appropriate interest coefficient for the period of the transaction and the relevant currency index. The fair value of interest rate swap contracts is determined by discounting the estimated amount of the future cash flows based on the terms and length of period to maturity of each contract, while using market interest rates of similar instruments at the date of measurement. Future contracts on energy and marine shipping prices are presented at fair value based on quotes of the prices of products on an ongoing basis. The reasonableness of the fair value is examined by comparing it to banks’ quotations. C. Liabilities in respect of debentures The fair value of liabilities including debentures is determined for disclosure purposes only and is calculated based on the present value of future cash flows in respect of the principal and interest components, discounted at the market rate of interest as of the reporting date. The fair value of marketable debentures is determined based on the stock market prices as of the date of the report.

Operating Segments

Operating Segments	12 Months Ended
Operating Segments	Dec. 31, 2022
Disclosure of operating segments [abstract]
Note 5 - Operating Segments	Note 5 - Operating Segments A. General 1. Information on operating segments: ICL is a global specialty minerals company operating bromine, potash and phosphate mineral value chains in a unique, integrated business model. Our operations are organized under four segments: Industrial Products, Potash, Phosphate Solutions and Growing Solutions (formerly, Innovative Ag Solutions). As the Company continues to focus on targeting long-term growth through its diversified specialty solutions, it decided to change its managerial structure so that, as of January 2022, the activities of ICL Boulby and other European business components were allocated from the potash and phosphate solutions segments, respectively, to the Growing Solutions segment. Comparative figures have been restated to reflect the structural change of the reportable segments. Industrial Products – The Industrial Products segment produces bromine derived from a solution that is a by-product of the potash production process in Sodom, Israel, as well as bromine based compounds. Industrial Products uses most of the bromine it produces for its own production of bromine compounds at its production sites in Israel, the Netherlands and China. In addition, the Industrial Products segment produces several grades of salt, magnesium chloride and some other specialty mineral products. Industrial Products is also engaged in the production and marketing of phosphorous-based flame retardants and additional phosphorus-based products. Potash – The Potash segment produces and sells primarily potash, salt, magnesium, as well as electricity. Potash is produced in Israel and Spain using an evaporation process to extract potash from the Dead Sea in Israel, and from conventional mining of an underground mine in Spain. The segment also produces and sells pure magnesium and magnesium alloys, as well as chlorine and sylvinite. In addition, the segment sells salt products produced at its potash site in Spain. The Company operates a power plant in Sodom which supplies electricity to ICL companies in Israel (as well as surplus electricity to external customers) and steam to all facilities at the Sodom site. Phosphate Solutions – The Phosphate Solutions segment is based on a phosphate value chain which uses phosphate commodity products, such as phosphate rock and fertilizer-grade phosphoric acid (“green phosphoric acid”), to produce specialty products with higher added value. The segment also produces and markets phosphate-based fertilizers. Phosphate rock is mined and processed from open pit mines, three of which are located in the Negev Desert in Israel, while the fourth is situated in Yunnan province in China. Sulphuric acid, green phosphoric acid and phosphate fertilizers are also produced in the facilities in Israel and China. The Phosphate Solutions segment manufactures pure phosphoric acid by purifying green phosphoric acid. Pure phosphoric acid and green phosphoric acid are used to manufacture downstream products with high added value, such as phosphate salts and acids, for a wide range of food and industrial applications. Phosphate salts and acids are used in various industrial end markets such as oral care, cleaning products, paints and coatings, energy storage solutions, water treatment, asphalt modification, construction, metal treatment and more. The segment's products for the food industry include functional food ingredients and phosphate additives which provide texture and stability solutions for processed meat, meat alternatives, poultry, seafood, dairy products, beverages and baked goods. In addition, the segment supplies pure phosphoric acid to ICL’s specialty fertilizers business and produces organic milk components and whey proteins for the food ingredients industry. Growing Solutions – The Growing Solutions segment aims to achieve global leadership in plant nutrition markets by enhancing its positions in its core markets of specialty agriculture, ornamental horticulture, turf and landscaping, targeting high-growth markets such as Brazil, India and China, by leveraging its unique R&D capabilities, substantial agronomic experience, global footprint, backward integration to potash, phosphate and polysulphate and chemistry know-how, while integrating and generating synergies from acquired businesses. ICL is continuously working to expand its broad portfolio of specialty plant nutrition, plant stimulation and plant health solutions, which consists of enhanced efficiency and controlled release fertilizers (CRF), organic fertilizers, water soluble fertilizers (WSF), liquid fertilizers and straights (MKP/MAP/PeKacid), soil and foliar micronutrients, secondary nutrients, biostimulants, soil conditioners, seed treatment products, and adjuvants. The Growing Solutions segment develops, manufactures, markets and sells its products globally, mainly in South America, Europe, Asia, North America and Israel. It produces water soluble specialty fertilizers in Belgium, Israel and Spain, organic, ornamental horticulture, turf and landscaping products in the UK and the Netherlands, liquid fertilizers in Israel, Spain and China, straights soluble fertilizers in China and Israel, controlled-release fertilizers in the Netherlands, Brazil and the United States, as well as secondary nutrients, biostimulants, soil conditioners, seed treatment products, and adjuvants in Brazil. Other Activities 2. Segment capital investments Capital investments made by the segments for each of the reporting periods include mainly property, plant and equipment as well as intangible assets acquired in the ordinary course of business and as part of business combinations. 3. Inter–segment transfers and unallocated income (expenses) Segment revenue, expenses and results include inter-segment transfers, which are based on transactions prices in the ordinary course of business. This is aligned with reports that are regularly reviewed by the Chief Operating Decision Maker. Inter-segment transfers are eliminated as part of the financial statements' consolidation process. The Segment profit is measured based on the operating income, without the allocation of certain expenses to the operating segments, as presented in the reports regularly reviewed by the Chief Operating Decision Maker. This is the basis for analyzing segment results, since management believes that it is the most relevant measure for the assessment of such results. B. Operating segment data Industrial Products Potash Phosphate Solutions Growing Solutions Other Activities Reconciliations Consolidated $ millions For the year ended December 31, 2022 Sales to external parties 1,737 3,031 2,851 2,376 20 - 10,015 Inter-segment sales 29 282 255 46 3 (615) - Total sales 1,766 3,313 3,106 2,422 23 (615) 10,015 Segment operating income (loss) 628 1,822 777 378 (9) (87) 3,509 Other income not allocated to the segments 7 Operating income 3,516 Financing expenses, net (113) Share in earnings of equity-accounted investees 1 Income before income taxes 3,404 Depreciation and amortization 61 166 189 70 3 9 498 Capital expenditures 90 346 259 101 9 17 822 Industrial Products Potash Phosphate Solutions Growing Solutions Other Activities Reconciliations Consolidated $ millions For the year ended December 31, 2021 Sales to external parties 1,601 1,598 2,087 1,644 25 - 6,955 Inter-segment sales 16 178 167 26 3 (390) - Total sales 1,617 1,776 2,254 1,670 28 (390) 6,955 Segment operating income (loss) 435 399 294 135 (8) (61) 1,194 Other income not allocated to the segments 16 Operating income 1,210 Financing expenses, net (122) Share in earnings of equity-accounted investees 4 Income before income taxes 1,092 Depreciation amortization and impairment 65 148 207 62 2 - 484 Capital expenditures 74 270 228 74 6 17 669 Capital expenditures as part of business combination - - - 377 - - 377 Industrial Products Potash Phosphate Solutions Growing Solutions Other Activities Reconciliations Consolidated $ millions For the year ended December 31, 2020 Sales to external parties 1,242 1,091 1,663 1,016 31 - 5,043 Inter-segment sales 13 177 153 17 4 (364) - Total sales 1,255 1,268 1,816 1,033 35 (364) 5,043 Segment profit (loss) 303 121 88 17 (5) (15) 509 Other expenses not allocated to the segments (307) Operating income 202 Financing expenses, net (158) Share in earnings of equity-accounted investees 5 Income before income taxes 49 Depreciation, amortization and impairment 77 152 204 45 3 98 579 Capital expenditures 84 270 267 54 6 15 696 Capital expenditures as part of business combination - - - - 26 - 26 C. Information based on geographical location The following table presents the distribution of ICL’s sales by geographical location of the customer: 2022 2021 2020 $ millions % of sales $ millions % of sales $ millions % of sales Brazil 2,200 22 1,178 17 447 9 China 1,495 15 1,060 15 806 16 USA 1,457 15 1,091 16 793 16 India 505 5 213 3 194 4 United Kingdom 448 4 386 6 336 7 Germany 417 4 345 5 327 6 Spain 365 4 280 4 243 5 Israel 344 3 291 4 260 5 France 305 3 270 4 238 5 Netherlands 264 3 127 2 95 2 All other 2,215 22 1,714 24 1,304 25 Total 10,015 100 6,955 100 5,043 100 The following table presents the distribution of the operating segments sales by geographical location of the customer: Industrial Products Potash Phosphate Solutions Growing Solutions Other Activities Reconciliations Consolidated $ millions For the year ended December 31, 2022 Europe 574 698 881 880 18 (242) 2,809 Asia 664 1,008 817 286 — (32) 2,743 South America 40 938 496 849 — (8) 2,315 North America 401 365 654 166 1 (10) 1,577 Rest of the world 87 304 258 241 4 (323) 571 Total 1,766 3,313 3,106 2,422 23 (615) 10,015 Industrial Products Potash Phosphate Solutions Growing Solutions Other Activities Reconciliations Consolidated $ millions For the year ended December 31, 2021 Europe 530 430 611 727 23 (162) 2,159 Asia 597 478 617 206 1 (23) 1,876 South America 64 467 343 436 — (5) 1,305 North America 363 209 491 127 1 (5) 1,186 Rest of the world 63 192 192 174 3 (195) 429 Total 1,617 1,776 2,254 1,670 28 (390) 6,955 Industrial Products Potash Phosphate Solutions Growing Solutions Other Activities Reconciliations Consolidated $ millions For the year ended December 31, 2020 Europe 458 376 557 561 30 (160) 1,822 Asia 405 412 477 161 1 (24) 1,432 North America 299 84 372 106 2 (4) 859 South America 40 212 210 56 - (1) 517 Rest of the world 53 184 200 149 2 (175) 413 Total 1,255 1,268 1,816 1,033 35 (364) 5,043 The following table presents the distribution of the Company’s sales by geographical location of the main facilities from which they were produced. For the year ended December 31 2022 2021 2020 $millions $millions $millions Israel 5,611 3,526 2,636 Europe 3,361 2,437 2,014 South America 1,994 1,095 424 Asia 1,123 861 643 North America 1,038 897 757 Other 61 56 48 13,188 8,872 6,522 Intercompany sales (3,173) (1,917) (1,479) Total 10,015 6,955 5,043 The following table presents operating income by geographical location of the assets from which it was produced: For the year ended December 31 2022 2021 2020 $millions $millions $millions Israel 2,668 863 105 Europe 445 7 (50) Asia 221 179 64 South America 184 95 35 North America 131 71 47 Other 5 4 4 Intercompany eliminations (138) (9) (3) Total 3,516 1,210 202 The following table present the non-current assets by geographical location of the assets () As of December 31 2022 2021 $ millions $ millions Israel 4,208 4,079 Europe 1,474 1,505 Asia 461 483 South America 407 391 North America 346 333 Other 4 5 Total 6,900 6,796 () Mainly consist of property, plant and equipment, intangible assets and non-current inventories.

Inventories

Inventories	12 Months Ended
Inventories	Dec. 31, 2022
Classes of current inventories [abstract]
Note 6 - Inventories	Note 6 – In ventories As of December 31 2022 2021 $ millions $ millions Finished products 1,348 946 Raw materials 490 349 Work in progress 233 299 Spare parts 128 125 Total inventories 2,199 1,719 Of which: Non-current inventories - mainly raw materials (presented as non-current assets) 65 149 Current inventories 2,134 1,570

Prepaid expenses and other rece

Prepaid expenses and other receivables	12 Months Ended
Prepaid expenses and other receivables	Dec. 31, 2022
Trade and other receivables [abstract]
Note 7 - Prepaid expenses and other receivables	Note 7 - Prepaid expenses and other receivables As of December 31 2022 2021 $ millions $ millions Government institutions 111 97 Prepaid expenses 70 51 Current tax assets 53 97 Derivative instruments 10 48 Other 79 64 323 357

Investments In Subsidiaries

Investments In Subsidiaries	12 Months Ended
Investments In Subsidiaries	Dec. 31, 2022
Disclosure of subsidiaries [abstract]
Note 8 - Investments in Subsidiaries	Note 8 - Investments in Subsidiaries A. Non-controlling interests in subsidiaries The following tables present information with respect to non-controlling interests in a subsidiary, YPH (at the rate of 50%), before elimination of inter-company transactions. The information includes fair value adjustments that were made on the acquisition date, other than goodwill and presented without adjustments for the ownership rates held by the Company. As of December 31 2022 2021 $ millions $ millions Current assets 267 231 Non-current assets 392 408 Current liabilities (145) (168) Non-current liabilities (48) (83) Equity (466) (388) For the year ended December 31 2022 2021 2020 $ millions $ millions $ millions Sales 723 528 359 Operating Income 146 105 29 Depreciation and amortization 34 38 37 Operating income before depreciation and amortization 180 143 66 Net Income 116 96 23 Total Comprehensive income 78 104 40 B. Business Acquisition and Divestiture (1) A s part of the Company's strategy to divest low synergy businesses and non-core business activities, in March 2022, the Company completed the sale of its 50% share in its joint venture, Novetide Ltd., for a consideration of $33 million, of which $8 million represents an estimate for the fair value of a contingent consideration. As a result, the Company recognized a capital gain of $22 million. (2) Further to the acquisition of Nobian’s holding in Sal Vesta (51%) in 2021, which was part of the partnership termination agreement between the Company and Nobian, on February 3, 2023, the Company signed an agreement for the sale of its 100% shares in Sal Vesta to Salins Group for a consideration of $13 million.

Other non-current assets

Other non-current assets	12 Months Ended
Other non-current assets	Dec. 31, 2022
Other Noncurrent Assets [Abstract]
Note 9 - Other non-current assets	Note 9 - Other non-current assets As of December 31 2022 2021 $ millions $ millions Surplus in employees' defined benefit plans (1) 97 115 Non-current inventories 65 149 Receivables from equity-accounted investees sale (2) 22 - Derivative designated as a cash flow hedge 19 97 Investments in equity-accounted investees 3 26 Other 25 16 231 403 (1) See Note 16. (2) See Note 8B(1).

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
Property, Plant and Equipment	Dec. 31, 2022
Disclosure of detailed information about property, plant and equipment [abstract]
Note 10 - Property, Plant and Equipment	Note 10 - Property, Plant and Equipment A. Composition Land and buildings Technical equipment and machinery Dikes and evaporating ponds Plants under construction (1) Other Right of use asset (2) Total $ millions Cost Balance as of January 1, 2022 1,107 7,664 1,465 664 1,073 518 12,491 Additions 30 358 388 (128) 77 64 789 Disposals (15) (27) - - - (27) (69) Translation differences (36) (130) (19) (18) (6) (22) (231) Balance as of December 31, 2022 1,086 7,865 1,834 518 1,144 533 12,980 Accumulated depreciation Balance as of January 1, 2022 502 4,410 797 - 881 147 6,737 Depreciation 35 243 47 - 59 74 458 Disposals (7) (25) - - - (27) (59) Translation differences (18) (83) (15) - (4) (5) (125) Balance as of December 31, 2022 512 4,545 829 - 936 189 7,011 Depreciated balance as of December 31, 2022 574 3,320 1,005 518 208 344 5,969 (1) The additions are presented net of items for which construction has been completed and accordingly were reclassified to other categories in the “property, plant and equipment” section. (2) The total additions were recorded against lease liabilities (IFRS 16). Land and buildings Technical equipment and machinery Dikes and evaporating ponds Plants under construction (1) Other Right of use asset (2) Total $ millions Cost Balance as of January 1, 2021 880 7,419 1,441 778 1,003 496 12,017 Additions in respect of business combinations 85 20 - 9 2 9 125 Additions 193 382 51 (99) 78 37 642 Disposals (2) (44) (1) - (6) (20) (73) Exit from consolidation (9) (21) - - (1) (2) (33) Translation differences (40) (92) (26) (24) (3) (2) (187) Balance as of December 31, 2021 1,107 7,664 1,465 664 1,073 518 12,491 Accumulated depreciation Balance as of January 1, 2021 491 4,300 763 - 817 96 6,467 Depreciation 30 227 55 - 71 71 454 Reversal of impairment - (6) - - - - (6) Disposals (5) (34) - - (4) (19) (62) Exit from consolidation (3) (19) - - - - (22) Translation differences (11) (58) (21) - (3) (1) (94) Balance as of December 31, 2021 502 4,410 797 - 881 147 6,737 Depreciated balance as of December 31, 2021 605 3,254 668 664 192 371 5,754 (1) The additions are presented net of items for which construction has been completed and accordingly were reclassified to other categories in the “property, plant and equipment” section. (2) The total additions were recorded against lease liabilities (IFRS 16).

Intangible Assets

Intangible Assets	12 Months Ended
Intangible Assets	Dec. 31, 2022
Intangible assets and goodwill [abstract]
Note 11 - Intangible Assets	Note 11 - Intangible Assets A. Composition Goodwill Concessions and mining rights Trademarks Technology / patents Customer relationships Computer application Others Total $ millions Cost Balance as of January 1, 2022 522 215 88 97 203 124 70 1,319 Additions - 2 - 9 - 20 2 33 Adjustment to PPA (1) 5 - - 6 (6) - - 5 Translation differences (1) (7) (4) (4) (3) (2) (3) (24) Balance as of December 31, 2022 526 210 84 108 194 142 69 1,333 Amortization Balance as of January 1, 2022 20 80 34 58 131 74 55 452 Amortization for the year - 6 2 5 15 9 3 40 Translation differences ( 1 ) (1) ( 2) ( 3) ( 2) ( 1) ( 1) ( 11) Balance as of December 31, 2022 19 85 34 60 144 82 57 481 Amortized Balance as of December 31 ,2022 507 125 50 48 50 60 12 852 (1) In July 2022, the Company completed the ADS’s Purchase Price Allocation (PPA). Goodwill Concessions and mining rights Trademarks Technology / patents Customer Computer application Others Total $ millions Cost Balance as of January 1, 2021 341 218 92 93 172 118 73 1,107 Additions in respect of business combinations 210 - 1 2 39 - - 252 Additions - - - 6 1 19 1 27 Translation differences (29) (3) (5) (4) (9) (13) (4) (67) Balance as of December 31, 2021 522 215 88 97 203 124 70 1,319 Amortization Balance as of January 1, 2021 21 74 34 55 123 76 54 437 Amortization for the year - 6 3 5 12 7 3 36 Translation differences (1) - (3) (2) (4) (9) (2) (21) Balance as of December 31, 2021 20 80 34 58 131 74 55 452 Amortized Balance as of December 31 ,2021 502 135 54 39 72 50 15 867 B . Total book value of intangible assets having defined useful lives and those having indefinite useful lives are as follows: As of December 31 2022 2021 $ millions $ millions Intangible assets having a defined useful life 313 333 Intangible assets having an indefinite useful life 539 534 852 867

Impairment Testing

Impairment Testing	12 Months Ended
Impairment Testing	Dec. 31, 2022
Impairment Testing [Abstract]
Note 12 - Impairment Testing	Note 12 - Impairment Testing Impairment testing for intangible assets with an indefinite useful life Goodwill and intangible assets having an indefinite lifespan are not amortized on a systematic basis but, rather, are examined at least once a year for impairment. The goodwill is not monitored for internal reporting purposes and, accordingly, it is allocated to the Company’s operating segments and not to the cash-generating units, the level of which is lower than the operating segment, as long as the acquired unit is presented in the Company's reportable segments. The examination of impairment of the carrying amount of the goodwill is made accordingly. For impairment testing purpose, the trademarks with indefinite useful life were allocated to the cash-generating units, which represent the lowest level within the Company. The carrying amounts of intangible assets with an indefinite useful life are as follows: As of December 31 2022 2021 $ millions $ millions Goodwill Phosphate Solutions 110 114 Industrial Products 90 91 Growing Solutions 271 260 Potash 20 19 Other 16 18 507 502 Trademarks 32 32 539 534 The Company conducted its annual impairment test of goodwill and did not identify any impairment. The recoverable amount of the operating segments was determined based on their value in use, which is based on an internal valuation of the discounted future cash flows generated from the continuing operations of the operating segments. The future cash flow of each operating segment was based on the segment approved five-year plan, which includes segment estimations for revenues, operating income and other factors, such as working capital and capital expenditures. The segments' projections were based, among other things, on the assumed sales volume growth rates according to long-term expectations, internal selling prices and raw materials prices based on external data sources, when applicable and relevant. The key assumptions used to calculate the operating segments’ recoverable amounts are a nominal after‑tax discount rate of 10.4% and a long‑term growth rate of 2.6%, reflecting the industries and markets in which the Company is engaged.

Credit from Banks and Others

Credit from Banks and Others	12 Months Ended
Credit from Banks and Others	Dec. 31, 2022
Credit From Banks And Others [Abstract]
Note 13 - Credit from Banks and Others	Note 13 - Credit from Banks and Others A. Composition As of December 31 2022 2021 $ millions $ millions Short-term debt From financial institutions 313 327 Current maturities of: Debentures 116 131 Long-term loans from financial institutions 15 56 Lease Liability 68 63 199 250 Total Short-Term debt 512 577 Long- term debt and debentures Long term lease liability 270 299 Loans from financial institutions 721 679 991 978 Marketable debentures 1,329 1,517 Non-marketable debentures 191 191 1,520 1,708 2,511 2,686 Less – current maturities of: Debentures 116 131 Long-term loans from financial institutions 15 56 Lease liability 68 63 199 250 Total Long- term debt and debentures 2,312 2,436 For further information, see Note 21. B. Yearly movement in Credit from Banks and Others () As of December 31 2022 2021 $ millions $ millions Balance as of January 1 2,914 2,660 Changes from financing cash flows Additions in respect of business combination - 171 Receipt of long-term debts 1,045 1,230 Repayment of long-term debt (1,181) (1,120) Repayment of short-term credit (21) (58) Interest paid (113) (112) Receipt (payments) from transaction in derivatives 20 (17) Total net financing cash flows (250) 94 Initial recognition of lease liability 64 37 Interest expenses 148 126 Effect of changes in foreign exchange rates ( 97 (21) Change in fair value of derivatives 67 (24) Other changes (33) 42 Balance as of December 31 2,813 2,914 () The balance includes Short-term debt, derivatives on loans and debentures, loans and debentures and interest payables. C. Sale of receivables under securitization transaction In September 2020, the Company and certain subsidiaries (hereinafter – the Subsidiaries) signed a series of agreements regarding a securitization transaction with three international banks (hereinafter – the Lending Banks) for the sale of their trade receivables to a special company which was established specifically for this purpose (hereinafter – the Acquiring Company). The new securitization agreements were signed with a committed amount of $300 million and an additional uncommitted amount of $100 million, maturing in September 2025 (hereinafter – the Agreements). These Agreements replace the prior securitization agreements, which expired in September 2020. The structure and terms of the Agreements are very similar to the prior securitization agreement. The Company’s policy is to utilize the securitization limit based on its cash flow needs, alternative financing sources and market conditions. According to the Agreements, the Company undertook to comply with a financial covenant according to which the ratio of net debt to EBITDA will not exceed 4.75. If the Company does not meet this ratio, the Acquiring Company can discontinue acquiring new trade receivables (without affecting existing acquisitions). As of the reporting date, the Company complies with the above financial covenant. The Acquiring Company finances acquisition of the debts through a loan received from a financial institution that is not affiliated with the Company. The period during which the Subsidiaries are entitled to sell their trade receivables to the Acquiring Company is five years from the closing date of the transaction, both parties have the option, at the end of each year, to notify for the transaction’s cancellation. Once the Company has transferred its trade receivables, it no longer has the right to sell them to another party. The selling price of the trade receivables is the amount of the debt sold, less the calculated interest cost based on the expected period between the sale date of the customer debt and its repayment date. Upon acquisition of the debt, the Acquiring Company pays part of the debt price in cash and the remainder in a subordinated note, which is paid after collection of the debt sold. The rate of the cash consideration varies depending on the composition and behavior of the customer portfolio. The Subsidiaries continue to handle the collection of the trade receivables included in the securitization transaction, on behalf of the Acquiring Company. In addition, the Agreements set several conditions regarding the quality of the customer portfolios, which give the Lending Banks the option of terminating the undertaking or excluding the subsidiaries whose customer portfolios do not meet the provided conditions from the Agreements. The trade receivables are fully presented in the Company's statements of financial position and the receipts received from the Acquiring Company are presented as a financial liability under short-term credit. As of December 31, 2022, utilization of the securitization facility within this framework amounted to $233 million (December 31, 2021 - $180 million). D. Information on material loans and debentures outstanding as of December 31, 2022: Instrument type Loan date Original principal (millions) Currency Carrying amount ($ millions) Interest rate Principal repayment date Additional information Debentures - Series F May 2018, December 2020 693 US Dollar 714 6.38% May 2038 (3), (4) Debentures - Series E April 2016 1,569 Israeli Shekel 223 2.45% 2021- 2024 (Annual installment) Partially repaid (1), (3) Debentures (private offering) – 3 series January 2014 275 US Dollar 145 46 5.16% 5.31% January 2024 January 2026 (3), (4) Debentures - Series G January/May 2020 766 Israeli Shekel 208 2.40% 2022- 2034 (Annual installment) (1), (3) Debentures - Series D December 2014 184 US Dollar 184 4.50% December 2024 (3), (4) SLL September 2021 250 Euro 266 0.80% September 2026 (5) Loan - European Bank September 2021 25 Euro 27 0.95% June 2025 Loan-Israeli institutions November 2013 300 Israeli Shekel 40 4.74% 2015-2024 (Annual installment) Partially repaid A dditional Information: (1) In March 2022, the Company repaid, as scheduled, NIS 392 million (approx. $123 million) of Series E Bond. In December 2022, the Company repaid NIS 15 million (approx. $4 million) of Series G Bond, as scheduled. (2) In April 2022, the Company prepaid its MUFG credit facility loan of BRL180 million and terminated its BRL 230 million (about $48 million) credit facility in Brazil. (3) As of July 5, 2022, the S&P credit rating agency reaffirmed the Company’s international credit rating and senior unsecured rating of 'BBB-'. In addition, the S&P Maalot credit rating agency reaffirmed the Company’s credit rating of 'ilAA' with a stable rating outlook. (4) In June 2022, Fitch Ratings reaffirmed the Company’s long-term issuer default rating and senior unsecured rating at 'BBB-'. The outlook on the long-term issuer default rating is stable. (5) The loan includes three sustainability performance targets: (1) an annual 4% to 5% reduction in direct and indirect Scope 1 and Scope 2 CO 2 (6) As of December 31, 2022, the Company is in compliance with all its financial covenants set forth in its financing agreements. See item F below. E. Credit facilities: Issuer Group of international banks European bank Date of the credit facility March 2015 December 2016 Date of credit facility termination March 2025 May 2024 The amount of the credit facility USD 1,100 million (1) USD 30 million Credit facility has been utilized Euro 330 million USD 30 million Interest rate Up to 33% use of the credit: Libor/Euribor + 0.70%. From 33% to 66% use of the credit: Libor/Euribor + 0.80% 66% or more use of the credit: Libor/Euribor + 0.95% Libor + 0.80% Loan currency type USD and Euro loans USD loans Pledges and restrictions Financial covenants - see Section D, a cross-default mechanism and a negative pledge. Financial covenants - see Section D and a negative pledge. Non-utilization fee 0.21% - (1) In July 2022, the long-term credit facility decreased by $100 million following an agreement on early termination with one of the banks, a few months prior to the official termination date. The updated total credit facility is $1,100 million. most banks signed on to continue the credit facility agreement, and from March 2023 to March 2025, the total credit facility will amount to $1,000 million. F. Restrictions on the Group relating to the receipt of credit As part of the loan agreements the Company has signed, various restrictions apply including sustainability performance targets and financial covenants, a cross‑default mechanism and a negative pledge. Set forth below is information regarding the financial covenants applicable to the Company as part of the loan agreements and the compliance therewith. For the Company’s sustainability performance targets see item D(5) above. Financial Covenants: Financial Covenants (1) Financial Ratio Required under the Agreement Financial Ratio December 31, 2022 Total shareholder’s equity Equity greater than $2,000 million $5,464 million Ratio of EBITDA to the net interest expenses Equal to or greater than 3.5 39.79 Ratio of the net financial debt to EBITDA Less than 3.5 0.53 Ratio of certain subsidiaries loans to the total assets of the consolidated company Less than 10% 2.69% (1) The examination of compliance with the financial covenants is based on the Company’s consolidated financial statements. As of December 31, 2022, the Company complies with all of its financial covenants. G. Pledges and Restrictions Placed in Respect of Liabilities (1) The Company has undertaken various obligations in respect of loans and credit lines from banks, including a negative pledge, whereby the Company committed, among other things, in favor of the lenders, to limit guarantees and indemnities to third parties (other than guarantees in respect of subsidiaries) up to an agreed amount of $550 million. The Company has also committed to grant loans only to subsidiaries and to associated companies, in which it holds at least 25% of the voting rights. The Company has further committed not to grant any credit, other than in the ordinary course of business, and not to register any charges on its existing and future assets and income. For further information regarding the covenants in respect of these loans and credit lines, see item F above. (2) As of December 31, 2022, the total guarantees provided by the Company were in the amount of $127 million (December 31, 2021 - $93 million).

Other Payables

Other Payables	12 Months Ended
Other Payables	Dec. 31, 2022
Trade and other payables [abstract]
Note 14 - Other Payables	Note 14 – Other Payables As of December 31 2022 2021 $ millions $ millions Employees 368 414 Current tax liabilities 177 183 Governmental (mainly in respect of royalties) 168 103 Accrued expenses 98 75 Derivative instruments 44 3 Income received in advance 41 33 Others 111 101 1,007 912

Taxes on Income

Taxes on Income	12 Months Ended
Taxes on Income	Dec. 31, 2022
Major components of tax expense (income) [abstract]
Note 15 - Taxes on Income	Note 15 - Taxes on Income A. Taxation of companies in Israel The current and deferred taxes expenses of Israeli entities are booked under the applicable tax rates below: 1. Income tax rate The Israeli statutory primary income tax rate is 23%. 2. Tax benefits under the Israeli Law for the Encouragement of Capital Investments, 1959 (hereinafter – the Encouragement Law) a) Beneficiary Enterprises The production facilities of some of the Company’s subsidiaries in Israel (hereinafter – the Subsidiaries) have received “Beneficiary Enterprise” status under the Encouragement law after Amendment No. 60 to the Law was published in April 2005. The main benefit granted to the Subsidiaries is a preferred tax rate. Under the “Ireland” track, the C ompany paid a re duced tax rate of 11.5% as of 2008 on parts of its income. The benefit deriving from the "Ireland" track ended in 2017, excluding a single entity in Israel for which the entitlement ended in 2021 . The part of taxable income entitled to benefits at reduced tax rates is calculated based on the ratio of the “Beneficiary Enterprise” turnover to a company’s total turnover. The turnover attributed to the “Beneficiary Enterprise” is generally calculated according to the increase in the turnover compared to a “base” turnover, which is the average turnover in the three years prior to the election year of the “Beneficiary Enterprise”. A company having a “Beneficiary Enterprise” that distributes a dividend out of exempt income, will be subject to corporate tax in the year in which the dividend was distributed on the amount distributed (including corporate tax applicable amount due to the distribution) at the tax rate applicable under the Encouragement Law in the year in which the income was generated, had it not been exempt from tax. On November 15, 2021, the Israeli Economic Efficiency Law for the years 2021 and 2022 was published, which consists of numerous legislative amendments and arrangements, including an amendment to Section 74 of the Encouragement Law, which deals with the identification of sources of dividend distributions as of August 15, 2021 (hereinafter - the amendment). The amendment stipulates that in any dividend distribution from companies holding accumulated profits that were exempt from tax until their distribution as a dividend ("trapped earnings"), a certain part of the distribution will be considered a distribution of those trapped earnings, which will be fully taxed upon release. In addition, a temporary provision to the Encouragement Law was published, which was valid until November 14, 2022, offered a reduced tax payment arrangement to companies that have trapped earnings. The eligibility for beneficiary tax rate provided, among others, making investments in the companies' industrial plants over five years, in accordance with the formula set forth in the amendment. In December 2021, due to the Company's settlement agreement with the Israeli Tax Authorities, regarding tax assessments for the years 2015-2019, and as a result of the Company's decision to apply the said temporary provision, the Company recognized a tax provision for the release of trapped earnings in the total amount of $47 million. Accordingly, no additional tax provision is required in respect of the unreleased trapped earnings which as of December 31, 2022, amounted to about NIS 950 million ($270 million). b) Preferred Enterprises In December 2010, the Israeli Knesset approved the Economic Policy Law for 2011‑2012, whereby the Encouragement law, was amended (hereinafter – the Amendment). The Amendment is effective from January 1, 2011 and its provisions apply to preferred income, derived or accrued by a Preferred Enterprise, as defined in the Amendment, in 2011 and thereafter. The Amendment does not apply to an Industrial Enterprise that is a mine, or any other facility for production of minerals or a facility for exploration of fuel. Therefore, ICL plants that are defined as mining plants and mineral producers will not be able to take advantage of the tax rates included as part of the Amendment. The tax rates applicable to Preferred Enterprises in Israel: 1) Preferred Enterprises located in Development Area A – 7.5%. 2) Preferred Enterprises located in the rest of the country – 16%. In November 2015, the Knesset passed the Economic Efficiency Law, which expanded the exception to all of the Enterprise’s activities up to the time of the first marketable product (for additional details – see Section 4 below). However, tax benefits to which a Beneficiary Plant was entitled were not cancelled in respect of investments made up to December 31, 2012. Therefore, such plants are able to utilize the tax benefits in respect of such investments, in accordance with the provisions of the old law. It is further provided in the Amendment that tax will not apply to a dividend distributed out of preferred income to a shareholder that is an Israeli‑resident company. A dividend distributed out of preferred income to a shareholder that is an individual or a foreign resident is subject to tax at a rate of 20%, unless a lower tax rate applies under a relevant treaty for prevention of double taxation. 3. The Law for the Encouragement of Industry (Taxation), 1969 a) Some of the Company’s Israeli subsidiaries are “Industrial Enterprise”, as defined in the abovementioned law. In respect of buildings, machinery and equipment owned and used by any "Industrial Enterprise", the Company is entitled to claim accelerated depreciation as provided by the Income Tax Regulations – Adjustments for Inflation (Depreciation Rates), 1986 which allow accelerated depreciation to any "Industrial Enterprise" as of the tax year in which each asset is first placed in service. b) The Industrial Enterprises owned by some of the Company's Israeli subsidiaries have a common line of production or similar industrial branch activity and, therefore, they file, together with the Company, a consolidated tax return in accordance with Section 23 of the Law for the Encouragement of Industry. Accordingly, each of the said companies is entitled to offset its tax losses against the taxable income of the other companies. 4. Taxation of Profits Natural Resources The government take on natural resources in Israel includes three elements: Royalties, Corporate Income Tax and Surplus Profit Levy. The highlights of the Law are set forth below: 4.1 Royalties In accordance with the Mines Ordinance, the rate of the royalties, in connection with resources produced from the quarries, will be 5%. For production of phosphates, the royalty rate is 5% of the value of the sold quantity produced. In accordance with the Israeli Dead Sea Concession Law, 1961, the royalty rate for potash, bromine and magnesium is 5% of the value of the sold quantity . 4.2 Imposition of Surplus Profit Levy The Law for Taxation of Profits from Natural Resources (hereinafter – the Law), is effective since January 1, 2016. The law is applied for the bromine, phosphate and magnesium minerals from 2016 and for potash from 2017. The tax base, which will be calculated for every mineral separately, is the mineral’s operating income, in accordance with the accounting statement of income, to which certain adjustments will be made. The taxable profit is based on the first traded product mineral operating income, as adjusted, after a deduction of 5% of the mineral’s year end working capital, and an amount that reflects a yield of 14% on the value of property, plant and equipment used for production and sale of the quarried material (hereinafter – Yield). On the tax base, as stated, a progressive tax will be imposed at a rate to be determined based on the Yield in that year. For a Yield between 14% and 20%, Natural Resources Tax will be imposed at the rate of 25%, while Yield in excess of 20% will be subject to Natural Resources Tax at the rate of 42%. In years in which the Natural Resources Tax base is negative, the negative amount will be carried forward from year to year and will constitute a tax shield in the succeeding tax year. The above computations, including the right to use prior years’ losses, are made separately, without considering setoffs, for each natural resource production and sale activity. Limitations on the Natural Resources Tax – the Natural Resources Tax will only apply to profits deriving from the actual production and sale of each of the following resources: potash, bromine, magnesium and phosphates, and not to the profits deriving from the downstream industrial activities. Calculation of the Natural Resources Tax will be made separately for every mineral mining concession. Nonetheless, regarding magnesium, it was provided that commencing from 2017, upon sale of Carnalite by DSW to magnesium and reacquisition of a Sylvinite by‑product by DSW, magnesium will charge DSW $100 per tonne of potash, which is produced from the Sylvinite (linked to the CPI). A mechanism was provided for determination of the market price, with respect to transactions in natural resources executed between related parties in Israel, as well as a mechanism for calculation of the manner for costs allocation between the production and sale of the natural resource, on the one hand, and the downstream activities, on the other hand. Regarding the bromine resource, the sale price of bromine sold to related parties, in and outside of Israel, who use the bromine for bromine compounds manufacturing activities, shall be, in each tax year, the higher of: 1) Actual price in the sale transaction. 2) A price which will provide an operating profit for the bromine compounds manufacturer of 12% out of the revenue it generates from bromine compounds sales. Regarding the phosphate resource, the sale price of phosphate sold to related parties for purposes of downstream manufacturing activities shall be, in each tax year, the higher of: 3) Actual price in the sale transaction. 4) A price which will keep an operating profit with the downstream products manufacturer of 12% out of the revenue it generates from downstream phosphate made of products sales. 5) The production and operating costs attributable to a unit of phosphate. The Company took an alternative tax filing position, according to which, all the Dead Sea minerals should be taxed as a unified mineral under the above-mentioned mechanism as the natural resource that is used by the company is the Dead-Sea brine. Amendment number 3 to the Law In November 2021, Amendment number 3 to the Law was approved by the Israeli Kneset, according to which the arrangement of tax collection will be altered so that companies will be required to pay 75% of the disputed tax, after objecting to a tax assessment by appeal to the district court, and prior to a Court ruling. Prior to this amendment, the full payment of the Surplus Profit Levy in dispute was not required until a Court ruling is rendered . Assessment agreement - Surplus Profit Levy In March 2021, the ITA issued an assessment for the years 2016-2017, which includes a demand for payment of Surplus Profit Levy, in the amount of approximately $77 million, plus interest and linkage. The amount represents, in essence, the different interpretation regarding the measurement of operational property, plant and equipment. In June 2022, a settlement agreement was signed with the Israeli Tax Authority, which entered into force on July 26, 2022. The settlement agreement provides final assessments for the tax years 2016-2020, as well as outlines understandings for the calculation of the surplus profit levy for the years from 2021 onwards. In the second quarter of 2022, the Company recorded tax expenses for prior years in the amount of $188 million, including interest and linkage and net of corporate income tax, of which $124 million was in connection with the understandings reached regarding the measurement of fixed assets in the said final assessments (for 2016-2020). 4.3 Corporate income Tax: The Law for Encouragement of Capital Investments was revised such that the definition of a “Plant for Production of Quarries” will include all the plant’s activities up to production of the first marketable natural resource of potash, bromine, magnesium and phosphates. Accordingly, activities involved with production of the first traded resource will not be entitled to tax benefits under the Law, whereas activities relating to downstream products, such as bromine compounds, acids, fertilizers, etc. will be entitled to tax benefits under the Law. The Natural Resource Tax will be deductible from the Company's taxable income and the Company will pay the Corporate Tax on the balance as is customary in Israel. B. Taxation of non-Israeli subsidiaries Subsidiaries incorporated outside of Israel are assessed for tax under the tax laws in their countries of residence. The principal tax rates applicable to the major subsidiaries outside Israel are as follows: Country Tax rate Note Brazil 34% Germany 29% United States 26% (1) Netherlands 25.8% Spain 25% China 25% United Kingdom 19% (1) The tax rate is an estimated average and includes federal and states tax. Different rate may apply in each specific year, as a result of different allocation of income between the different states. C. Carried forward tax losses As of December 31, 202 2 , the balances of the carryforward tax losses of subsidiaries for which deferred taxes were recorded, is about $ 384 million (December 31, 20 21 – about $ 286 million). As of December 31, 202 2 , the balances of the carryforward tax losses to future years of subsidiaries for which deferred taxes were not recorded, is about $ 109 million (December 31, 20 21 – about $ 338 milli on). As of December 31, 2022, the capital losses for tax purposes available for carryforward to future years for which deferred taxes were not recorded is about $142 million (December 31, 2021 – about $161 million) D. Tax assessments (1) The Company and the main operational companies in Israel (DSW, Rotem, Bromine, DSM, and BCL), have received final tax assessments up to and including 2019. Other companies in Israel received final tax assessments up to and including 2017. The main subsidiaries outside of Israel have final tax assessments up to and including 2015. E. Deferred income taxes 1. The composition of the deferred taxes and the changes therein, are as follows: In respect of financial position In respect of carry forward tax losses Total Depreciable property, plant and equipment and intangible assets Inventories Provisions for employee benefits Other $millions Balance as of January 1, 2021 (439) 38 94 (7) 115 (199) Changes in 2021: Additions in respect of business combinations - 1 1 9 2 13 Amounts recorded in the statement of income 16 - 2 (14) (24) (20) Amounts recorded to a capital reserve - - (22) (1) - (23) Translation differences 2 - (2) (3) (5) (8) Balance as of December 31, 2021 (421) 39 73 (16) 88 (237) Changes in 2022: Amounts recorded in the statement of income (127) 33 4 31 35 (24) Amounts recorded to a capital reserve - - (12) 4 - (8) Translation differences 1 - (1) - (4) (4) Balance as of December 31, 2022 (547) 72 64 19 119 (273) 2. The currencies in which the deferred taxes are denominated: As of December 31 2022 2021 $millions $millions Israeli Shekels (368) (327) Euro 51 84 Brazilian Real 28 13 British Pound 16 - U.S Dollar (8) (10) Other 8 3 (273) (237) F. Taxes on income included in the income statements 1. Composition of income tax expenses (income) For the year ended December 31 2022 2021 2020 $ millions $ millions $ millions Current taxes 869 145 70 Deferred taxes 45 22 (43) Taxes in respect of prior years 271 93 (2) 1,185 260 25 2. Theoretical tax Following is a reconciliation of the theoretical tax expense, assuming all income is taxed at the regular tax rates in Israel (see A(2) above) and the tax expense presented in the statements of income: For the year ended December 31 2022 2021 2020 $ millions $ millions $ millions Income before taxes on income, as reported in the statements of income 3,404 1,092 49 Statutory tax rate (in Israel) 23% 23% 23% Theoretical tax expense 783 251 11 Add (less) – the tax effect of: Surplus Profit Levy tax 265 - - Reduced tax due to tax benefits (95) (64) (6) Differences deriving from additional deduction and different tax rates applicable to foreign subsidiaries 1 (10) (4) Tax on dividend 5 3 2 Deductible temporary differences and their reversal (including carryforward losses) for which deferred taxes assets were not recorded and non–deductible expenses (29) (8) 14 Taxes in respect of prior years* 271 93 (2) Differences in measurement basis (21) (8) 10 Other differences 5 3 - Taxes on income included in the income statements 1,185 260 25 * For 2022, included $275 million $188 in respect of the settlement agreement as mentioned above. G. Taxes on income relating to items recorded in equity For the year ended December 31 2022 2021 2020 $ millions $ millions $ millions Tax recorded in other comprehensive income Actuarial gains from defined benefit plan (12) (22) (6) Change in investments at fair value through other comprehensive income - (21) - Change in fair value of hedging derivatives 4 - - Taxes in respect of exchange rate differences on equity loan to a subsidiary included in translation adjustment (11) (1) (3) Total (19) (44) (9)

Employee Benefits

Employee Benefits	12 Months Ended
Employee Benefits	Dec. 31, 2022
Classes of employee benefits expense [abstract]
Note 16 - Employee Benefits	Note 16 - Employee Benefits A. Composition Composition of employee benefits: As of December 31 2022 2021 $ millions $ millions Fair value of plan assets 432 648 Termination benefits (86) (135) Defined benefit obligation (664) (993) (318) (480) Composition of fair value of the plan assets: As of December 31 2022 2021 $ millions $ millions Equity instruments With quoted market price 126 230 Without quoted market price 40 50 166 280 Debt instruments With quoted market price 232 337 Without quoted market price 10 3 242 340 Deposits with insurance companies 24 28 432 648 B. Severance Pay 1. Israeli companies The labor laws in Israel require the Company to pay severance pay to employees who were dismissed or have retired (including those who left the Company in other specific circumstances). The liability for the payment of severance pay is calculated according to the labor agreements in effect on the basis of salary components which, in the opinion of Company management, create an obligation to pay severance pay. The Company has two severance pay plans: one plan according to the provisions of section 14 of the Severance Pay Law, which is accounted for as a defined contribution plan; and the other for employees to whom section 14 does not apply, which is accounted for as a defined benefit plan. The Company’s liability in Israel for the payment of severance pay to employees is mostly covered by current deposits in the names of the employees in recognized pension and severance pay funds, and by the acquisition of insurance policies, which are accounted for as plan assets. 2. Certain subsidiaries outside Israel In countries wherein subsidiaries operate that have no law requiring payment of severance pay, the subsidiaries have not recorded a provision in the financial statements for possible eventual future severance payments to employees, except in cases where part of the activities of the enterprise is discontinued and, as a result, the employees are dismissed. C. Pension and Early Retirement (1) Some of the Company’s employees in and outside of Israel have defined benefit pension plans for their retirement, which are controlled by the Company. Generally, according to the terms of the plans, as stated, the employees are entitled to receive pension payments based on, among other things, their number of years of service (in certain cases up to 70% of their last base salary) or computed, in certain cases, based on a fixed salary. Some employees of a subsidiary in Israel are entitled to early retirement if they meet certain conditions, including age and seniority at the time of retirement. (2) Some subsidiaries have signed plans with funds – and with a pension fund for some of the employees – under which such subsidiaries make current deposits with that fund which releases them from their liability for making a pension payment under the labor agreements to their employees upon reaching a retirement age. The amounts funded are not reflected in the statements of financial position, since they are not under the control and management of the subsidiaries. D. Post-employment retirement benefits Some of the Company retirees receive, aside from the pension payments from a pension fund, benefits that are primarily holiday gifts and paid vacations. The company’s liability for these costs accrues during the employment period. The Company includes in its financial statements the projected costs in the post-employment period according to an actuarial calculation. E. Movement in net defined benefit obligation and in its components: Fair value of plan assets Defined benefit obligation Defined benefit obligation, net 2022 2021 2022 2021 2022 2021 $ millions $ millions $ millions $ millions $ millions $ millions Balance as of January 1 648 629 (993) (1,075) (345) (446) Income (costs) included in profit or loss: Current service costs - - (23) (24) (23) (24) Interest income (expenses) 12 6 (20) (14) (8) (8) Past service cost - - - 12 - 12 Effect of movements in exchange rates, net (32) 8 56 (16) 24 (8) Included in other comprehensive income: Actuarial profits (losses) deriving from changes in financial assumptions - - 230 68 230 68 Other actuarial gains (147) 17 - - (147) 17 Change with respect to translation differences, net (34) (10) 43 21 9 11 Other movements: Benefits received (paid) (20) (6) 43 35 23 29 Employer contribution 5 4 - - 5 4 Balance as of December 31 432 648 (664) (993) (232) (345) The actual return on plan assets in 2022 is $(135) million, compared with $23 million in 2021 and $14 million in 2020. F. Actuarial assumptions Principal actuarial assumptions as of the reporting date (expressed as weighted averages): For the year ended December 31 2022 2021 2020 % % % Discount rate as of December 31 4.7 2.1 1.7 Future salary increases 3.9 3.9 3.4 Future pension increase 2.8 2.3 2.0 G. Sensitivity analysis Assuming all other assumptions remain constant, the following reasonably December 2022 Decrease 10% Decrease 5% Increase 5% Increase 10% $ millions Significant actuarial assumptions Salary increases (11) (6) 6 11 Discount rate 28 14 (14) (28) Mortality table 13 6 (6) (13) The assumptions regarding the future mortality rates are based on published statistics and accepted mortality tables. H. The Effect of the plans on the Company's future cash flows The expenses recorded in respect of defined contribution plans in 2022 are $39 million The Company estimates that the expected deposits in 2023 to fund defined benefit plans are about $8 million. As of December 31, 2022, the Company estimates that the life of the defined benefit plans, based on a weighted average, is about 11 years (compared with 13.6 years in 2021). I. Long-term incentive plan (1) In February 2023, the Company’s HR & Compensation Committee and the Board of Directors approved a new biennial equity grant for the years 2023-2024 in the form of options exercisable to the Company's ordinary shares. For further information, see Note 19. (2) In November 2021, Company's HR & Compensation Committee and the Board of Directors approved a new Cash LTI plan, according to which, other senior managers will be awarded a cash incentive in 2025, the fair value of the grant as of the reporting date is about $37 million. The grant is subject to achievement of certain financial targets over the three years and can be affected by the change in share price.

Provisions

Provisions	12 Months Ended
Provisions	Dec. 31, 2022
Disclosure Of Provision [Abstract]
Note 17 - Provisions	Note 17 – Provisions A. Composition and changes in the provision Site restoration and equipment dismantling (1) Legal claims Other Total $ millions Balance as of January 1, 2022 283 13 41 337 Provisions recorded during the year - 36 3 39 Provisions reversed during the year (10) (1) (1) (12) Effect of change in discount rate (18) - - (18) Payments during the year (17) (3) (1) (21) Translation differences (10) - - ( 10) Balance as of December 31, 2022 228 45 42 315 (1) Main items under 'Site restoration and equipment dismantling': a. Spain – In 2018, a new restoration plan was approved for the Suria and Sallent sites, which included a plan for handling the salt piles and dismantling of facilities. The restoration plan for the Suria site is scheduled to extend until 2094, and for the Sallent site up to 2075. Estimation of the projected costs for the closure and restoration of the Sallent site – the main portion of the estimated costs for closure and restoration is attributed to restoration of the salt pile. The Company is treating the salt pile, by both utilizing the salt for production and sale for, among others, de-icing purposes, and by processing the material and removing it to the sea via a Collector. As of December 31, 2022, the total provision for the closure and restoration of the Sallent site amounts to $74 million. The estimation is based on a long-term forecast, covering a period of more than 50 years, b. Rotem Israel – as of December 31, 2022, according to the Company's estimation, the provision for the restoration of the mining sites and waste repositories, for Rotem Israel's operations, amounted to $75 million. The provision is measured based on the present value of the cash flows, which relies on the Company's estimation of the future expense required for the restoration of the mining sites. The actual costs that may be required may differ, even substantially, from the current provision, as a result of the inherent complexity of such estimation, the Company's future decisions regarding the facilities and regulatory requirements. c. Bromine Israel (Neot Hovav) – pursuant to the Ministry of Environmental Protection, the Company is required to treat both solid waste of past periods which is stored in a designated defined area on the site's premises, and currently-produced waste created during the ongoing production processes in the plant. Waste treatment is partly conducted through a hydro-bromine acid recovering facility (BRU), operated by the Company. Part of the waste is sent for external designated treatment. As of December 31, 2022, the provision for prior periods waste treatment amounted to $27 million. In the Company's estimation, based on the information currently available to it, the provision included in its financial statements covers the estimated cost for treating prior periods waste.

Commitments, Concessions and Co

Commitments, Concessions and Contingent Liabilities	12 Months Ended
Commitments, Concessions and Contingent Liabilities	Dec. 31, 2022
Capital commitments [abstract]
Note 18 - Commitments, Concessions and Contingent Liabilities	Note 18 - Commitments, Concessions and Contingent Liabilities A. Commitments (1) Several of the Group’s subsidiaries have entered into agreements with suppliers for the purchase of raw materials and energy in the ordinary course of business, for various periods ending on December 31, 2036. As of December 31, 2022, the total amount of the commitments is about $2.6 billion. This amount includes the agreements described below. (2) Several of the Group’s subsidiaries have entered into agreements with suppliers for the acquisition of property, plant and equipment. As of December 31, 2022, the subsidiaries have capital expenditures commitments of about $684 million. This amount includes the agreements described below. (3) As part of the collaboration between ICL's subsidiary in Spain (ICL Iberia) and the government of Catalonia to achieve environmental sustainability goals, the Company has undertaken to carry out restoration of the salt piles at its sites, mainly by processing and removing them to the sea via a collector. In 2021, the Company signed an agreement with the Catalan Water Agency for the construction and operation of a collector. The main highlights of the agreement include, among other things, guidelines by which the project will be managed, financing aspects of the project, the definition of project costs and determination of the operational maintenance mechanism, including usage costs. Based on said agreement and Spain's water law, it was determined that ICL Iberia will assume up to 90% of the project's cost (approximately $110 million) which will be paid throughout the construction and operating periods. Construction, which has already begun, is expected to extend over a four-year period and the operational period is expected to be over 25 years. (4) In 2017, the Company entered into a gas purchase agreement with Energean Israel Limited (hereinafter - Energean) who holds a license for the development of the Karish and Tanin gas reservoirs. Under the agreement, Energean is expected to supply the Company with natural gas (NG) at a quantity of up to 13 BCM at a value of $2 billion over a period of 15 years, commencing with the commercial operation of Karish and Tanin. The NG from the reservoirs will be used to operate ICL’s factories and power stations in Israel. Following Energean announcement of potential expected delays in the supply of NG under the "Force Majeure" clause within the GSPA, in 2020 the Company signed an exclusive agreement with Tamar reservoir to supply the full amount of NG consumed by the Company until December 2022, at a price of about $4 per MMBTU. After continued delays, in the fourth quarter of 2022, Energean began NG production activities and supply as part of its commissioning phase. In order to ensure sufficient NG for ICL’s facilities, beyond the supplied NG from Energean, the Company signed NG supply agreements with additional market sources, including Leviathan reservoir, which are valid until the end of the first quarter of 2023 and is taking additional measures to further secure its NG supply. The Company believes it is more likely than not that it will obtain sufficient NG for its facilities in Israel until Energean enters commercial production and fully supply the required NG. The Company intends to exercise all its legal rights in connection with Energean's continued delays. (5) In 2020, the Company entered into a long-term lease agreement with a third party according to which ICL will lease an office building in Be'er Sheva Israel for a period of 15 years, with a 10-year extension option, at an annual rent of about $3 million. The lease period is expected to commence in 2024 (on the completion of the building’s construction). (6) The Articles of Association of the Company and its Israeli subsidiaries include provisions that permit exemption, indemnification and insurance of liability of officers and directors, all in accordance with the provisions of the Companies Law. The Company, with the approval of its HR & Compensation Committee, the Board of Directors and the shareholders, granted its officers and directors a letter of exemption and indemnification, and also maintains an insurance policy, covering directors' and officers' liability, which is renewed annually. The directors' and officers' liability insurance and the exemption and indemnity undertaking do not apply to those cases specified in Section 263 of the Companies Law. The exemption is from liability for damages caused and/or that will be caused, by those officers and directors as a result of a breach of the duty of care to the Company. Regarding directors who are office holders of Israel Corp., who may serve from time to time, on January 5, 2021, shareholders approved the extension of the period for exemption and indemnification entered into with such office holders for an additional nine years commencing November 30, 2020, provided that the exemption shall not apply to liabilities arising in connection with a transaction or resolution in which a controlling shareholder or an office holder, including an office holder who is other than the office holder party to the agreement, has a personal interest (within the meaning of the Companies Law). The amount of the indemnification payable by the Company under the letters of indemnification, in addition to amounts received from an insurance company, if any, for all of the officers and directors on an aggregate basis, for one or more of the events detailed therein, is limited to $300 million. B. Concessions (1) Dead Sea Works Ltd. (hereinafter – DSW) Pursuant to the Israeli Dead Sea Concession Law, 1961 (hereinafter – the Concession Law), as amended in 1986, and the concession deed attached as an addendum to the Concession Law, DSW was granted a concession to utilize the resources of the Dead Sea and to lease the land required for its plants in Sodom for a period ending on March 31, 2030. According to the Concession Law, should the government decide to offer a new concession after the expiration date, to another party, it will first offer the new concession to DSW on terms that are no less attractive than those it may offer to that party. In accordance with section 24 (a) of the Supplement to the Concession Law, it is stated, among other things, that at the end of the concession period all the tangible assets located in the concession area will be transferred to the government, in exchange for their amortized replacement value – the value of the assets as if they are purchased as new at the end of the concession period, less their technical depreciation based on their maintenance condition and the unique characteristics of the Dead Sea area. Pursuant to section 24 (b) of the Supplement to the Concession Law, it is stated that capital investments made during the 10-year period prior to the end of the concession require the prior consent of the Government, unless they can be fully deducted for tax purposes before the end of the concession period. However, the Government's consent to any fundamental investment that may be necessary for the proper operation of the plant will not be unreasonably delayed or denied. In 2020, an agreement was concluded between the Company and the Israeli Government for the purpose of implementing section 24(b). The agreement determines, among other things, the manner of examining new investments and the consent process. In addition, the agreement determines the Company's commitment to invest in fixed assets, including for preservation and infrastructure, as well as for ongoing maintenance of the facilities in the concession area (for the period beginning in 2026) and the Company's commitment to continue production of potassium chloride and elemental bromine (for the period commencing 2028), all subject to the conditions specified in the agreement. Such commitments do not change the way the Company currently operates. The Company engages with the Israeli Government in accordance with the agreement and obtains investment approvals as required. In 2015, the Minister of Finance appointed a team to determine the “governmental activities to be conducted towards the end of the concession period”. The public’s comments in this matter were submitted to an inter-ministerial team. Based on the interim report and its recommendations published in May 2018, and following a public hearing in January 2019, the Israeli Ministry of Finance released the final report of the inter-ministry team headed by Mr. Yoel Naveh, former Chief Economist, which includes a series of guidelines and recommendations regarding the actions that the government should take towards the end of the concession period. Since the report includes guiding principles and a recommendation to establish sub‑teams to implement such principles, the Company is unable to assess the concrete implications of these guidelines and recommendations, or, if the recommendations will be implemented in practice, as well as the relevant timing of their implementation. In addition, there is no certainty as to how the Government will interpret the Concession Law and implement processes accordingly. In addition, in 2015, the Minister of Finance appointed a team headed by the (former) Accountant General to evaluate the manner in which, according to the current concession, the replacement value of DSW’s tangible assets would be calculated, assuming that these assets would be returned to the Government at the end of the concession period. The determination date of the actual calculation is only at the end of the concession period. As far as the Company is aware, this work has not yet been completed. The consolidated Financial Statements were prepared under management's belief that it is more likely than not, that DSW will continue to operate the relevant assets for their remaining useful lives, which extends beyond the term of the current concession period, by obtaining a renewed concession or by operating the assets for an alternative holder. The consolidated depreciation expenses in 2022 relating to the assets located within the concession area amounted to about $108 million. It is expected that the value of the Property, Plant and Equipment at the end of the concession period will change as time passes and as a result of purchase and disposals of assets. Royalties In consideration of the concession, DSW pays royalties to the Government of Israel calculated at a rate of 5% of the value of the products at the plant gate, less certain expenses. DSW granted a sub‑concession to Dead Sea Bromine Ltd. to produce bromine and its compounds from the Dead Sea, the expiration date of which is concurrent with the DSW concession. The royalties in respect of the products manufactured by Dead Sea Bromine are received by DSW, which then pays them to the State of Israel. Royalties are also paid by Dead Sea Magnesium on the basis of carnallite used for production of magnesium. (2) Rotem Amfert Israel (hereinafter – “Rotem Israel”) Rotem Israel has been mining phosphates in the Negev in Israel for more than sixty years. Mining is conducted in accordance with phosphate mining concessions, which are granted as required by the Ministry of Energy under the Mines Ordinance, by the Supervisor of Mines, as well as mining authorizations issued by the Israel Lands Authority (hereinafter – the Authority). The concessions relate to quarries (phosphate rock), whereas the authorizations cover the use of land as active mining areas. Mining Concessions Rotem Israel has a unified mining concession which includes Rotem Field, including Hatrurim, and Zafir Field, including Oron-Zin, until the end of 2024. In order to comply with the concession's provisions, the Company undertook, among other things, to assure that Rotem meets its existing obligations to rehabilitate its mining and plants areas according to outlined requirements attached to the new concession, as well as by means of a bank guarantee in the amount of $19 million. As part of the Company’s efforts to locate phosphate rock resources in Israel, in January 2022, the Ministry of Energy granted Rotem Israel an exploration license for phosphate in an area of 263 acres, north of the Oron Concession. In December 2022, following the completion of a geological survey, the Company received a discovery certificate, which gives it the exclusive right to request a mining license in that area. The Company is working to apply for a concession for approximately 76.6 acres and activity thereon is expected to continue at least until 2025. Lease Agreements Rotem Israel has two lease agreements in effect until 2024 and 2041 as well as an additional lease agreement for the Oron plant, which expired in 2017. As of the reporting date, the Company has an agreement in principle, with the Israel Land Authority - Southern Region, regarding the receipt of a license agreement for Oron plant until the end of 2025. The license agreement is subject to the approval of the Israel Land Authority management. Mining Royalties According to the terms of the concession, Rotem Israel is required to pay royalties to the State of Israel for Phosphate mining. In accordance with the Mines Ordinance (Third Addendum A), the royalty rate for production of phosphates is 5% of the value of the quarried material. As part of the process of extending the concession which occurred in 2021, an order was issued by the Ministry of Energy to amend the Third Addendum A which is intended to anchor and clarify the basis for calculating the royalties and its components. Planning and Building The mining and quarrying activities require a zoning approval of the site based on a plan in accordance with the Israeli Planning and Building Law, 1965. Such plans are updated, as needed. As of the reporting date, there are various requests at different stages of deliberations pending for consideration the planning authorities. Zin-Oron area - In 2016, the District Board for the Southern District approved a detailed site plan for mining phosphates in the Zin Oron area. This plan, which covers an area of about 350 square kilometers, will permit the continued mining of phosphate located in the Zin valley and in the Oron valley for a period of 25 years or until the exhaustion of the raw material – whichever occurs first, with the possibility for extension (under the authority of the District Planning Board). Barir field - The Company is promoting a plan to mine phosphates in Barir field, located in the southern part of the South Zohar deposit in the Negev Desert. In 2015, the National Planning and Building Council (hereinafter – the National Council) approved the Policy Document regarding Mining and Quarrying of Industrial Minerals, which included a recommendation to permit phosphate mining in the South Zohar deposit and to advance a detailed National Outline Plan for the Barir field mining site. According to the recommendation of the National Council, the Government’s Housing Cabinet approved the National Outline Plan (hereinafter - NOP 14B). In 2018, the Minister of Health filed an appeal of the said approval, requiring compliance with the Ministry of Health’s recommendation to conduct a survey regarding the health impact at each site included in NOP 14B. As part of a discussion in the Housing Cabinet regarding the appeal, it was decided, with the consent of the Ministries of Health, Finance and Energy, to remove the appeal and to approve the NOP 14B, which was formally published later. In addition, it was decided to establish a team with representatives from Treasury, Health, Transportation, Environmental Protection and Energy ministries (hereinafter – The Inter-ministerial team), which will present to the Housing Cabinet a report that includes health aspects for NOP 14B. In 2018 and 2019, petitions were submitted to the Israeli Supreme Court of Justice by the municipality of Arad and by residents of Bedouin community in the "Arad Valley" against the National Council, the Government of Israel and Rotem Israel, to revoke the approval of NOP 14B and to order the National Council to discuss the NOP directives, while giving proper weight to the health risk. In 2020, the inter-ministerial team reached an outline agreement regarding the examination of the health aspects of the NOP 14B, which, according to the State, constitutes an appropriate response for the review of potential health hazards on which the petitions focus. In 2021, the Israeli Supreme Court of Justice decided to reject the petitions following a preliminary decision by the National Planning and Building Council to incorporate the main points of the outline agreement in the provisions of NOP 14B. At the end of 2021, the Housing Cabinet, approved once again the amended NOP 14B, following which the (former) Minister for Environmental Protection submitted a request for a government review of past decisions prior to promoting the Barir Detailed NOP. In accordance with the decision of the Ministry of the Interior, a deliberation of the matter should have been held by July 2022. As of the reporting date, the deliberation has not yet occurred. The Company continues its discussions with the relevant regulators to ensure the deliberation will be held as soon as possible. In addition to the procedures described above, securing the future of the phosphate mining operations at Rotem Israel depends among other things, on the following matters: • Emissions permit under the Israeli Clean Air Act (hereinafter - the Law) - In 2021, the Company's emission permit was renewed until September 2023. The permit reflects an updated outline of requirements by the Israeli Ministry of Environmental Protection (MoEP). Postponement of the execution of a limited number of projects was granted within the framework of an administrative order under Section 45 of the Law. The Company is experiencing difficulties meeting the execution schedules of a limited number of projects, and, accordingly, continues to work with the MoEP to find satisfactory solutions, while considering the uncertainty surrounding Rotem Israel's activity as far as the implementation of long-term projects is concerned. • Phosphogypsum storage - In 2021, a new Urban Building Plan was approved, the main objectives of which are to regulate areas for phosphogypsum storage reservoirs. Following the ambiguity of the guidelines regarding the calculation of the building permit fees, in April 2022, Israel’s Planning Administration stated its position that the Company should pay insignificant fees. Following Tamar Regional Council’s rejection of the position, in January 2023, the Company reached principal understandings with the Regional Council regarding the fee amounts, subject to a signed agreement. No material impact on the Company's financial results is expected. • Energy Production – As part of the Company’s efforts to ensure the continuity of energy production in Rotem Israel in accordance with the policy of the Ministry of Energy and the Ministry of Environmental Protection, in September 2022, the Company began to operate a natural gas-based steam boiler which replaced the existing energy production facility that utilized oil shale. • Finding economically feasible alternatives to continue phosphate operations in Rotem Israel – According to the Company's assessment, the estimated useful life of Rotem's phosphate rock reserves in its existing mining areas is limited to a few years. The Company is working to promote economic alternatives for future phosphate operations at Rotem Israel and to obtain required permits and approvals, including by conducting pilots to adapt various potential types of phosphate rock for the Company’s products as part of an effort to utilize and increase existing phosphate reserves. The Company estimates that it is more likely than not that it will be able to continue its phosphate operations at Rotem Israel, by obtaining the approvals and permits required to ensure its future phosphate operations within a time frame that is not expected to materially impact the Company's results. Nevertheless, there is no certainty as to the success of receiving such approvals and permits, nor is there certainty regarding future phosphate rock resources and/or by what date they will be received. Failure to obtain them, or a significant delay in obtaining them, can lead to a material impact on the Company's business, financial position and results of operations. (3) ICL Iberia – a subsidiary in Spain ICL Iberia was granted mining rights based on legislation of Spain’s Government from 1973 and the regulations accompanying this legislation. Pursuant to the special mining regulations, ICL Iberia received individual licenses for each of the 126 different sites that are relevant to current and future mining activities. Some of the licenses are valid until 2037 and the remainder are effective until 2067. (4) United Kingdom A. The mineral leases of ICL Boulby, ICL's subsidiary in the United Kingdom (hereinafter – ICL Boulby), are based on approximately 51 mineral leases and licenses for extracting various minerals, in addition to numerous easements and rights of way from private owners of land under which ICL Boulby operates, and mineral lease rights under the North Sea granted by The Crown Estates. The mineral lease rights with The Crown Estates, include provisions to explore and exploit all targeted and known polyhalite and salt mineral resources of interest to ICL Boulby. Said leases cover a total area of about 814 square kilometers (onshore leases total around 24 square kilometers and offshore leases from the Crown Estates cover around 790 square kilometers). For the future the Company only requires a small number of terrestrial mineral areas for ventilation and dewatering purposes, some of which expired in 2022. The Company is actively engaged in negotiations with approximately 18 private mineral owners in extend lease terms. Four lease agreements are currently in negotiations and an application has been approved by the Secretary of State to refer these negotiations to the High Court of Justice in London under the Working Mines Facilities Act Application of 1966 (“the Act”), which, generally, provides for a mechanism to acquire rights over land for mining and extraction. The Company believes that this demonstrates there are sufficient grounds to resolve the negotiations pursuant to the Company’s position. As for the remaining fourteen mineral leases, the Company believes that satisfactory terms will be negotiated without having to have recourse to the Act. Pending the negotiations, the Company continues to operate under the terms of the previous agreements as agreed to with the contractual partners. Subject to the renewal processes described above, all remaining lease periods, licenses, easements and rights of way are effective until 2035. In December 2021, the North York Moors Park Authority Planning Committee approved ICL Boulby's application for the continuation of polyhalite and salt production for an additional 25 years commencing 2023 (until 2048). On May 27, 2022, an official Notice was served under Regulation 63 of the Conservation of Habitats and Species Regulations 2017, which concluded that the development would not have any Likely Significant Effects on the North York Moors Special Area of Conservation and Special Protection Area. With respect to the mining royalties, ICL Boulby pays royalties of 2.3% which in 2022 amounted to $4.2 million. B. A UK subsidiary which is a part of the Growing Solutions segment (hereinafter – Everris Limited) has peat mines in the UK (Creca, Nutberry and Douglas Water). Peat is used as a component to produce professional growing media. All sites are owned by Everris Limited. The current extraction permits are granted by the local authorities and are renewed after examining the renewal applications. The extraction permits for Nutberry and Douglas Water were granted until the end of 2024, and the permit for Creca was granted until the end of 2051. (5) YPH - China Mining Concessions YPH, ICL's subsidiary in China, which is equally owned with Yunnan Phosphate Chemicals Group Corporation Ltd. ("YYTH"), holds two phosphate mining licenses that were issued in 2015 by the Division of Land and Resources of the Yunnan district in China: (1) a mining license for the Haikou Mine (hereinafter – Haikou) which the Company operates and which is valid until January 2043; and (2) a mining license for the Baitacun Mine, which is valid until April 2023. With respect to Baitacun Mine, in 2022, the Company completed a risk survey to assess the feasibility and profitability of the mining site, and it is currently working to renew its license for an additional ten years. Grant of Mining Rights to Lindu In 2016, a subsidiary of YYTH (hereinafter – YPC) issued a statement whereby in 2010 it entered into agreements with the local authority of Jinning County, Yunnan Province, and Jinning Lindu Mining Development and Construction Co. Ltd. (hereinafter - Lindu Company), according to which Lindu Company is permitted to mine up to two million tonnes of phosphate rock from a certain area measuring 0.414 square kilometers within the area of the Haikou mine (hereinafter – the Daqing Area) and to sell such phosphate rock to any third party at its own discretion. YPC has undertaken that YPH’s mining right in the Haikou mine will not be adversely affected by the above-mentioned arrangements. It was decided that YPH should conduct further communications with YPC and Lindu Company for the purpose of protecting its legal rights and to urge the parties to reach a fair, just, and reasonable solution to this issue as soon as possible. Natural Resources Royalties With respect to the mining rights, in accordance with China "Natural Resources Tax Law", YPH pays royalties of 8% on the selling price based on the market price of the rock prior to its processing. The total royalties for 2022 are about $1.5 million. Planning and Building The production process at YPH requires the Company to operate gypsum and flotation ponds that accumulate phosphogypsum fluid and other materials formed in the production processes. In 2022, the Company completed the construction of the infrastructure for the expansion of the ponds after, in April of that year, it received an official certification enabling the expansion of the ponds area, which is required as part of YPH’s ongoing operations plan. C. Contingent liabilities (1) Ecology A. In 2017, three applications for certification of claims as class actions were filed against the Company, as a result of a partial collapse of a dyke in an evaporation pond at Rotem Amfert Israel which resulted in contamination of the Ashalim Stream and its surrounding area. The claimants contend that the Company breached various provisions of environmental laws, including the provisions of the Law for Prevention of Environmental Hazards, the Water Law, provisions of the Torts Ordinance, a breach of statutory duty and negligence. Within the framework of the first application, the Court was requested to instruct the Company to rectify the harm caused as a result of its omissions in order to prevent recurrence of the damage caused as well as to grant a monetary remedy for non-pecuniary damages. The monetary remedy was not defined, however according to the claimants, the amount of the personal claim is NIS 1,000 ($311) for each resident of the State of Israel, who number approximately 8.68 million persons. Within the framework of the second application, the Court was requested to grant a monetary remedy in an amount of no less than NIS 250 million ($77 million) and concurrently, to award personal compensation in the amount of NIS 2,000 ($622) for each resident of the State of Israel, this being in respect of non-pecuniary damages. Furthermore, the Court was requested to instruct the Company to comply with the relevant laws and the rules provided thereunder. As part of the third application, the Court was requested to instruct the Company, among other things, to prepare plans for removal of the contamination, restoration of the Ashalim Stream and its surrounding area, for control and prevention of recurrence of the damage caused, to pay monetary relief to the class of injured parties, in the amount of NIS 202.5 million ($63 million), and to provide compensation by means of restoring the natural values impaired and return the area to its former condition. In May 2018, the Nature and Parks Authority (hereinafter – NPA), filed an application for certification of a class action against the Company, Rotem Amfert Israel and past officers of the Company and Rotem Amfert Israel (jointly hereinafter - the Respondents), with respect to the Ashalim incident. According to the NPA, the Respondents, jointly and/or severally, are liable for compensation due to the Ashalim incident, among other things by virtue of the Torts Ordinance and/or unjust profits and by virtue of any other law. In the Application, the Court was requested, among other things, to issue orders, the purpose of which is to take all necessary measures to prevent the recurrence of the environmental hazard, and also to cooperate with the NPA and the State's authorities in order to minimize the ecological and environmental damage in order to allow for the restoration of the nature reserve. Furthermore, the Court was requested to grant monetary relief to the public injured by the ecological and environmental damage, and to grant a monetary relief for the purpose of the restoration of the nature reserve, in the aggregate amount of NIS 397 million (about $123 million). In conjunction with the aforesaid application, the NPA filed a motion to strike the three applications mentioned above and to prefer the approval application on its behalf, as it argues that it is the most suitable to serve as the representative plaintiff in a class action in this regard, as its application is detailed and well-established as well as the special status conferred upon it under the Class Actions Law, which allows for specific benefits. In November 2018, the Company was notified that all four applicants had agreed to join efforts and manage the class actions in a joint and coordinated manner. In December 2022, following a mediation process between Rotem Israel and the Israeli Nature and Parks Authority, as well as all other applicants in the aforesaid proceedings, a settlement agreement was signed between the parties. In January 2023, the settlement agreement was submitted to the Israeli court for approval that will conclude the proceedings. According to the settlement agreement, the total amount of compensation for, among other things, the restoration of the Ashalim Stream and its surroundings, is NIS 115 million (approximately $33.5 million), including past restoration expenses, legal expenses and other expenses. In May 2018, the Company was served with a motion for discovery and pursual of documents (hereinafter – the Motion), filed with the Tel Aviv District Court, by a shareholder of the Company (hereinafter – the Movant), as a preliminary proceeding in preparation for the possible filing of an application for certification of a multiple derivative action against officers of the Company and Rotem Israel who, according to the Movant, caused the alleged damages incurred and to be incurred by the Company as a result of the Ashalim incident. In 2018, the parties reached an arrangement, according to which, the legal proceedings will be delayed until the relevant investigation's materials are provided to the Company by the investigating authority. As of the reporting date, such investigative materials have not yet been received. Considering the proceedings are in an early stage and even suspended, there is a difficulty in estimating their outcome. B. In June 2022, an unexpected flow of brine was discovered above ground at the outskirts of an alluvial fan area, which, according to initial tests by the Company, appears to have resulted from a combination of seepage from the feeder canal of ICL Dead Sea’s pumping station P-9 (hereinafter P-9) and unique ground conditions, which, according to the Company's estimation does not exceed the approved design specifications of P-9. The Company is continuously acting to rectify any resultant environmental impact to the extent required, including, at the request of the Israeli Nature and Parks Authority, implementing a project that involves the installation of sealing sheets over an approximately 2km long section of the 15km feeder canal in the area of the fan (hereinafter - the Project) which is expected to be c

Equity

Equity	12 Months Ended
Equity	Dec. 31, 2022
Equity [abstract]
Note 19 - Equity	Note 19 – Equity A. Composition: As of December 31, 2022 As of December 31, 2021 Authorized Issued and paid Authorized Issued and paid Number of ordinary shares of Israeli Shekel 1 par value (in millions) 1,485 1,314 1,485 1,312 Number of Special State shares of Israeli Shekel 1 par value 1 1 1 1 () For information regarding the amount of treasury shares, see Note 19.G. The reconciliation of the number of shares outstanding at the beginning and end of the year is as follows: Number of Outstanding Shares (in millions) As of January 1, 2021 1,305 Issuance of shares 7 As of December 31, 2021 1,312 Issuance of shares 2 As of December 31, 2022 1,314 B. Rights conferred by the shares (1) The ordinary shares grant their holders voting rights in General Meetings of the Company, the right to participate in shareholders’ meetings, the right to receive dividends and the right to a share in excess assets upon liquidation of ICL. (2) The Special State of Israel Share, is held by the State of Israel for the purpose of monitoring matters of vital interest to the State of Israel, grants special rights to make decisions, among other things, on the following matters: - Sale or transfer of company assets, which are “essential” to the State of Israel, not in the ordinary course of business . - Voluntary liquidation, change or reorganization of the organizational structure of ICL or merger (excluding mergers of entities controlled by ICL, directly or indirectly, that would not impair the rights or power of the Government, as holder of the Special State Share ). - Any acquisition or holding of 14% or more of the issued share capital of ICL . - The acquisition or holding of 25% or more of the issued share capital of ICL (including augmentation of an existing holding up to 25%), even if there was previously an understanding regarding a holding of less than 25%. - Any percentage of holding of the Company’s shares, which grants its holder the right, ability or actual possibility to appoint, directly or indirectly, such number of the Company’s directors equal to half or more of the Company’s directors appointed . During the second half of 2018, an inter-ministry team was established, headed by the Ministry of Finance, whose purpose is, among other things, to regulate the authority and supervision in respect of the Special State of Israel Share, as well as reduce the regulatory burden. In 2019, the work of this team was suspended until further notice due to the dissolution of the Knesset and lack of permanent Government. The Company is unable to estimate when or whether such team will recommence and what are the implications of this process over the Company, if any. C. Share-based payments 1. Non-marketable options Grant date Employees entitled Number of instruments (thousands) Issuance’s details Instrument terms Vesting conditions Expiration date August 6, 2014 Officers and senior employees 3,993 A n issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, as amended in June 2016 (hereinafter – the amended 2014 Equity Compensation Plan). Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. In case that on the exercise date the closing price of an ordinary share is higher than twice the exercise price (the “Share Value Cap”), the number of the exercised shares will be reduced so that the product of the exercised shares actually issued to an offeree multiplied by the share closing price will equal to the product of the number of exercised options multiplied by the Share Value Cap. 3 equal tranches: (1) one third on December 1, 2016 (2) one third on December 1, 2017 (3) one third on December 1, 2018 Two years from the vesting date. June 30, 2016 Officers and senior employees 3,035 Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date June 30, 2023 September 5, 2016 Former chairman of BOD 186 February 14, 2017 Former CEO 114 February 14, 2024 June 20, 2017 Officers and senior employees 6,868 June 20, 2024 August 2, 2017 Former chairman of BOD 165 March 6, 2018 Officers and senior employees 5,554 March 6, 2025 Grant date Employees entitled Number of instruments (thousands) Issuance’s details Instrument terms Vesting conditions Expiration date May 14, 2018 CEO 385 An issuance of non-marketable and non-transferrable options, for no consideration, under the amended 2014 Equity Compensation Plan. Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date May 14, 2025 August 20, 2018 Former chairman of BOD 403 August 20, 2025 April 15, 2019 Officers and senior manager 13,242 2 equal tranches: 5 years after the grant date June 27, 2019 CEO 3,512 May 29, 2019 Chairman of BOD 2,169 June 30, 2021 Senior employees 647 February 8, 2022 Senior employees 9,294 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date March 30, 2022 CEO 1,941 March 30, 2022 Chairman of BOD 1,055 * The options were issued upon Mr. Doppelt’s entry into office on July 1, 2019. Additional Information The options issued to the employees in Israel are covered by the provisions of Section 102 of the Israeli Income Tax Ordinance. The issuance is performed through a trustee under the Capital Gains Track. The exercise price is linked to the known CPI as of the date of payment, which is the exercise date. When the Company distributes a dividend, the exercise price is reduced on the “ex dividend” date, by the amount of the dividend per share (gross), based on the amount in NIS thereof at the effective date. The fair value of the options granted in 2014, as part of the amended 2014 Equity Compensation Plan, was estimated using the binomial model for pricing options. The fair value of all other options was estimated using the Black & Scholes model for pricing options. The parameters used in applying the models are as follows: 2014 Plan Granted 2014 Granted 2016 Granted 2017 Granted 2018 Granted 2019 Granted 2021 Granted 2022 Share price (in $) 8.2 3.9 4.5 4.4 5.4 6.8 10.0 CPI-linked exercise price (in $) 8.4 4.3 4.3 4.3 5.3 7.1 10.1 Expected volatility: First tranche 29.40% 30.51% 31.88% 28.86% 27.85% 31.70% 31.80% Second tranche 31.20% 30.51% 31.88% 28.86% 27.85% 31.70% 30.88% Third tranche 40.80% 30.51% 31.88% 28.86% - - 30.52% Expected life of options (in years): First tranche 4.3 7.0 7.0 7.0 4.4 4.4 3.2 Second tranche 5.3 7.0 7.0 7.0 4.4 4.4 3.8 Third tranche 6.3 7.0 7.0 7.0 - - 4.0 Risk-free interest rate: First tranche (0.17)% 0.01% 0.37% 0.03% (0.67)% 0.43% (1.46)% Second tranche 0.05% 0.01% 0.37% 0.03% (0.67)% 0.43% (1.29)% Third tranche 0.24 0.01% 0.37% 0.03% - - (1.21)% Fair value (in $ millions) 8.4 4.0 11.3 8.8 7.5 0.6 24.9 Weighted average grant date fair value per option (in $) 1.9 1.1 1.6 1.4 1.2 1.3 2.0 The expected volatility was determined based on the historical volatility in the Company’s share prices in the Tel-Aviv Stock Exchange. The expected life of the options was determined according to Management’s estimate of the period in which the employees will hold the options, taking into consideration their position with the Company. The risk‑free interest rate was determined based on the yield to maturity of shekel‑denominated Israeli Government debentures, with a remaining life equal or similar to the anticipated life of the option . T $12 million, $6 million and $8 million, respectively. The movement in the options are as follows: Number of options (in millions) Balance as of January 1, 2021 27 Movement in 2021: Expired during the year 1 Exercised during the year (16) Total options outstanding as of December 31, 2021 12 Movement in 2022: Granted during the year 12 Forfeited during the year (2) Exercised during the year (7) Total options outstanding as of December 31, 2022 15 Subsequent to the date of the report In February 2023, the Company’s HR & Compensation Committee and the Board of Directors, approved a new biennial equity grant for the years 2023-2024 in the form of about $461 thousand non-marketable and non-transferable options for no consideration, under the amended 2014 Equity Compensation Plan, to two senior managers. The vesting period of the options will be in three equal tranches, upon the lapse of 12 months, 24 months and 36 months from the grant date (February 14, 2023). The fair value at the grant date is about $903 thousand. The exercise prices for options outstanding at the beginning and end of each period are as follows (in US dollar): December 31, 2022 December 31, 2021 December 31, 2020 Granted in 2016 3.41 4.61 4.56 Granted in 2017 3.14 4.19 4.17 Granted in 2018 3.06 4.11 4.12 Granted in 2019 4.57 5.77 5.66 Granted in 2021 6.00 7.39 - Granted in 2022 8.91 - - The number of outstanding vested options at the end of each period and the weighted average of the exercise price for these options are as follows (): December 31, 2022 December 31, 2021 December 31, 2020 Number of options exercisable (in Millions) 5 4 11 Weighted average exercise price in Israeli Shekel 15.67 14.29 13.89 Weighted average exercise price in US Dollar 4.45 4.59 4.32 () The share price as of December 31, 2022, is NIS 25.45 and $7.23. The range of exercise prices for the options outstanding vested at the end of each period is as follows: December 31, 2022 December 31, 2021 December 31, 2020 Range of exercise price in Israeli Shekel 10.77-30.06 12.77-18.06 13.15-18.32 Range of exercise price in US Dollar 3.06-8.54 4.11-5.81 4.09-5.70 The average remaining contractual life for the outstanding vested options at the end of each period is as follows: December 31, 2022 December 31, 2021 December 31, 2020 Average remaining contractual life 3.42 2.83 3.58 2. Restricted shares Grant date Employees entitled Number of instruments (thousands) Vesting conditions () Instrument terms Additional Information Fair value at the grant date (Million) June 20, 2017 Officers and senior employees 2,211 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date An issuance for no consideration, under the amended 2014 Equity Compensation Plan. The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the approval date of the General Meeting). 10 August 2, 2017 Former chairman of BOD 53 0.3 January 10, 2018 ICL’s Directors (excluding ICL’s CEO & Chairman of the BOD) 137 0.6 March 6, 2018 Officers and senior employees 1,726 8 May 14, 2018 CEO 121 0.6 August 20, 2018 Former chairman of BOD 47 0.2 April 23, 2020 ICL’s Directors (excluding directors who are officers or directors of Israel Corporation Ltd.) 177 3 equal tranches: (1) one third on January 1, 2021 (2) one third on January 1, 2022 (3) one third on January 1,2023 The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the Grant Date (the approval date of the annual General Meeting of shareholders). 0.6 () Vesting of the Restricted Shares granted to directors would fully accelerate, if the holder ceases to serve as a director of the Company, unless he/she ceased to hold office due to those certain circumstances regarding early termination of office or imposition of enforcement measures, as set forth in Sections 231-232a and 233(2) of the Israeli Companies Law. D. D ividends distributed to the Company’s Shareholders The date of Board of Directors’ decision to distribute the dividend Actual date of distribution dividend Gross amount of the dividend distributed (in millions of $) Amount of the dividend per share (in $) February 11, 2020 March 18, 2020 23 0.02 May 10, 2020 June 17, 2020 30 0.02 July 27, 2020 September 16, 2020 36 0.03 November 10, 2020 December 16, 2020 29 0.02 Total 2020 118 0.09 February 10, 2021 March 16, 2021 34 0.03 May 5, 2021 June 16, 2021 67 0.05 July 27, 2021 September 1, 2021 68 0.05 November 3, 2021 December 15, 2021 107 0.08 Total 2021 276 0.21 February 8, 2022 March 8, 2022 169 0.13 May 10, 2022 June 15, 2022 307 0.24% July 26, 2022 September 14, 2022 376 0.29 November 8, 2022 December 14, 2022 314 0.24 Total 2022 1,166 0.9 February 14, 2023* March 15, 2023 178 0.14 (*) The record date is March 1, 2023, and the payment date is March 15, 2023. E. Cumulative translation adjustment T he translation reserve includes all translation differences arising from translation of foreign operations’ financial statements. F. Capital reserves The capital reserves include expenses for share‑based compensation to employees against a corresponding increase in equity (See item C above) and change in investment at fair value through other comprehensive income. G. Treasury shares During 2008 and 2009, 22.4 million shares were acquired by the Group under a purchase plan, for a total consideration of approximately $258 million. Total shares held by the Group are about 24.5 million.

Details of Income Statement Ite

Details of Income Statement Items	12 Months Ended
Details of Income Statement Items	Dec. 31, 2022
Details Of Income Statement [Abstract]
Note 20 - Details of Income Statement Items	Note 20 - Details of Income Statement Item s For the year ended December 31 2022 2021 2020 $ millions $ millions $ millions Sales 10,015 6,955 5,043 Cost of sales Materials consumed 3,152 2,342 1,647 Cost of labor 937 906 794 Energy and fuel 433 343 316 Depreciation and amortization 409 413 416 Other 52 340 380 4,983 4,344 3,553 For the year ended December 31 2022 2021 2020 $ millions $ millions $ millions Selling, transport and marketing expenses Land and Marine transportation 792 742 515 Cost of labor 188 171 134 Other 201 154 117 1,181 1,067 766 General and administrative expenses Cost of labor 168 166 136 Professional Services 44 44 32 Other 79 66 64 291 276 232 Research and development expenses Cost of labor 55 52 40 Other 13 12 14 68 64 54 For the year ended December 31 2022 2021 2020 $ millions $ millions $ millions Other income Profit from divestment 22 14 - Insurance Compensation 15 - - Capital gain 9 16 - Reversal of early retirement provision of employees 2 - - Past service cost - 12 11 Reversal of provision for legal claims - 11 - Reversal of Impairment of fixed assets - 9 - Other 6 1 9 Other income recorded in the income statements 54 63 20 Other expenses Provision for legal claims 17 17 - Provision for historical waste removal and site closure costs 6 14 83 Transaction costs - 8 - Impairment and disposal of assets - 9 90 Provision for early retirement and dismissal of employees - - 78 Other 7 9 5 Other expenses recorded in the income statements 30 57 256 For the year ended December 31 2022 2021 2020 $ millions $ millions $ millions Financing income and expenses Financing income: Net gain from changes in exchange rates 139 - - Financing income in relation to employee benefits 44 - - Interest income from banks and others 31 17 7 Net gain from change in fair value of derivative designated as economic hedge - 59 - Net gain from change in fair value of derivative designated as cash flow hedge - 18 54 214 94 61 Financing expenses: Net loss from change in fair value of derivative designated as economic hedge 98 - 23 Net loss from change in fair value of derivative designated as cash flow hedge 77 - - Interest expenses to banks and others 148 126 120 Financing expenses in relation to employees’ benefits 7 23 38 Banks and finance institutions commissions (mainly commission on early repayment of loans) 7 6 4 Net loss from changes in exchange rates - 79 58 Financing expenses 337 234 243 Net of borrowing costs capitalized 10 18 24 327 216 219 Net financing expenses recorded in the income statements 113 122 158

Financial Instruments and Risk

Financial Instruments and Risk Management	12 Months Ended
Financial Instruments and Risk Management	Dec. 31, 2022
Disclosure of detailed information about financial instruments [abstract]
Note 21 - Financial Instruments and Risk Management	Note 21 - Financial Instruments and Risk Management A. General The Company has extensive international operations wherein it is exposed to credit, liquidity and market risks (including currency, interest and other price risks). In order to reduce the exposure to these risks, the Company holds financial derivative instruments, (including forward transactions, SWAP transactions, and options) to reduce the exposure to foreign currency risks, commodity price risks, energy and marine transport and interest risks. Furthermore, the Company holds derivative financial instruments to hedge the exposure and changes in the cash flows. The transactions in derivatives are executed with large Israeli and non-Israeli financial institutions, and therefore Company management believes the credit risk in respect thereof is low. This Note presents information about the Company's exposure to each of the above risks, and the Company's objectives, policies and processes for measuring and managing risk. The Company regularly monitor the extent of our exposure and the rate of the hedging transactions for the various risks described below. The Company execute hedging transactions according to our hedging policy with reference to the actual developments and expectations in the various markets. B. Groups and measurement bases of financial assets and financial liabilities As of December 31, 2022 Financial assets Financial liabilities Measured at fair value through the statement of income Measured at amortized cost Measured at fair value through the statement of income Measured at amortized cost $ millions Current assets Cash and cash equivalents - 417 - - Short-term investments and deposits - 91 - - Trade receivables - 1,583 - - Other receivables - 55 - - Foreign currency derivative designated as economic hedge 3 - - - Foreign currency and interest derivative instruments designated as cash flow hedge 7 - - - Non-current assets Foreign currency and interest derivative instruments designated as cash flow hedge 19 - - - Other non-current assets - 35 - - Total financial assets 29 2,181 - - Current liabilities Short term debt - - - (512) Trade payables - - - (1,006) Other current liabilities - - - (198) Foreign currency derivative designated as economic hedge - - (28) - Foreign currency and interest derivative instruments designated as cash flow hedge - - (16) - Non-current liabilities Long term debt and debentures - - - ( 2,312) Foreign currency and interest derivative instruments designated as cash flow hedge - - (1) - Other non- current liabilities - - - (45) Total financial liabilities - - (45) (4,073) Total financial instruments, net 29 2,181 (45) (4,073) As of December 31, 2021 Financial assets Financial liabilities Measured at fair value through the statement of income Measured at amortized cost Measured at fair value through the statement of income Measured at amortized cost $ millions Current assets Cash and cash equivalents - 473 - - Short-term investments and deposits - 91 - - Trade receivables - 1,418 - - Other receivables - 45 - - Foreign currency derivative designated as economic hedge 23 - - - Marine transport derivative designated as economic hedge 2 - - - Foreign currency and interest derivative instruments designated as cash flow hedge 23 - - - Non-current assets Foreign currency and interest derivative instruments designated as cash flow hedge 97 - - - Other non-current assets - 14 - - Total financial assets 145 2,041 - - Current liabilities Short term debt - - - (577) Trade payables - - - (1,064) Other current liabilities - - - (153) Foreign currency derivative designated as economic hedge - - (3) - Non-current liabilities Long term debt and debentures - - - (2,436) Interest derivative instruments designated as economic hedge - - (7) - Other non- current liabilities - - - (49) Total financial liabilities - - (10) (4,279) Total financial instruments, net 145 2,041 (10) (4,279) C. Credit risk (1) General (a) Customer credit risks Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and it arises mainly from the Company’s receivables from customers and from other receivables as well as from investments in securities. The Company sells to a wide range and large number of customers, including customers with material credit balances. On the other hand, the Company does not have a concentration of sales to individual customers. The Company has a regular policy of ensuring the credit risk of its customers by means of purchasing credit insurance with insurance companies, other than sales to government agencies and sales in small amounts. Most of all other sales are executed only after receiving approval of coverage in the necessary amount from an insurance company or other collaterals of a similar level. Part of the Brazilian companies are using uninsured model based on self-disclosure underwriting, with local collateral structure and credit committee policy. The use of an insurance company as aforementioned ensures that the credit risk is managed professionally and objectively by an expert external party and transfers most of the credit risk to third parties. Nevertheless, the common deductible in credit insurances is 10% (even higher in a small number of cases) thus the Company is still exposed to part of the risk, out of the total In addition, the Company has an additional deductible cumulative annual amount of approximately $6 million through a wholly‑owned captive reinsurance company Most of the Company’s customers have been trading with the Company for many years and only rarely have credit losses been incurred by the Company. The financial statements include specific allowance for doubtful debts that appropriately reflect, in Management’s opinion, the credit loss in respect of accounts receivables which are considered doubtful. (b) Credit risks in respect of deposits The Company deposits its balance of liquid financial assets in bank deposits and in securities. All the deposits are with a diversified group of leading banks preferably with banks that provide loans to the Company. (2) Maximum Exposure to credit risk The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk at the reporting date was: As of December 31 Carrying amount ($ millions) 2022 2021 Cash and cash equivalents 417 473 Short term investments and deposits 91 91 Trade receivables 1,583 1,418 Other receivables 55 45 Derivatives 29 145 Other non-current assets 35 14 2,210 2,186 The maximum exposure to credit risk for trade receivables, at the reporting date by geographic region was: As of December 31 Carrying amount ($ millions) 2022 2021 Asia 317 440 Europe 457 362 South America 434 306 North America 242 193 Israel 104 95 Other 31 22 1,585 1,418 (3) Aging of debts and impairment losses The aging of trade receivables at the reporting date was: As of December 31 2022 2021 Gross Impairment Gross Impairment $ millions $ millions $ millions $ millions Not past due 1,485 (3) 1,313 (1) Past due up to 3 months 97 - 82 - Past due 3 to 12 months 10 (4) 23 (2) Past due over 12 months 1 (1) 9 (6) 1,593 (8) 1,427 (9) The movement in the allowance for doubtful accounts during the year was as follows: 2022 2021 $ millions $ millions Balance as of January 1 9 10 Additional allowance 1 (3) Reversals (2) (2) Changes due to translation differences - 4 Balance as of December 31 8 9 D. Liquidity risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company’s approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to timely meet its liabilities, under both normal and stressed conditions, without incurring unwanted losses. The Company manages the liquidity risk by holding cash balances, short-term deposits and secured bank credit facilities. The following are the contractual maturities of financial liabilities, including estimated interest payments: As of December 31, 2022 Carrying amount 12 months or less 1-2 years 3-5 years More than 5 years $ millions Non-derivative financial liabilities Short term debt (not including current maturities) 313 322 - - - Trade payables 1,006 1,006 - - - Other current liabilities 198 198 - - - Long-term debt, debentures and others 2,555 288 1,080 547 1,468 4,072 1,814 1,080 547 1,468 Financial liabilities – derivative instruments Foreign currency and interest derivative designated as economic hedge 28 28 - - - As of December 31, 2021 Carrying amount 12 months or less 1-2 years 3-5 years More than 5 years $ millions Non-derivative financial liabilities Short term debt (not including current maturities) 327 329 - - - Trade payables 1,064 1,064 - - - Other current liabilities 153 153 - - - Long-term debt, debentures and others 2,735 352 1,003 799 1,532 4,279 1,898 1,003 799 1,532 Financial liabilities – derivative instruments Foreign currency and interest derivative designated as economic hedge 10 3 - 7 - E. Market risk Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices will affect the fair value or future cash flows of a financial instrument. 1. Interest risk The Company has loans bearing variable interests and therefore its financial results and cash flows are exposed to fluctuations in the market interest rates. From time to time, the Company uses financial instruments including derivatives in order to hedge this exposure. The Company uses interest rate swap and cross currency swaps contracts mainly in order to reduce the exposure to cash flow risk in respect of changes in interest rates. As part of the global reform in interest rate benchmarks, the Libor GBP settings ceased from January 1, 2022, and replaced by SONIA (GBP) Benchmark. Most US dollar LIBOR settings will continue to be calculated using panel bank submissions until mid-2023. As of December 31, 2022, USD LIBOR continues to be used as a reference rate and in valuation of instruments with maturities that exceed the expected end date for LIBOR. the Company has USD 30 million Libor Based Debt that exceed the expected end date for LIBOR. As of December 31, 2022, we have not finalized an agreement with the banks regarding the Libor transition effects on loans and derivatives. (a) Interest Rate Profile Set forth below are details regarding the type of interest on the Company’s non-derivative interest‑bearing financial instruments As of December 31 2022 2021 $ millions $ millions Fixed rate instruments Financial assets 339 338 Financial liabilities (2,140) (2,466) (1,801) (2,128) Variable rate instruments Financial assets 38 36 Financial liabilities (696) (562) (658) (526) (b) Sensitivity analysis for fixed rate instruments Most of the Company’s instruments bearing fixed interest are not measured at fair value through the statement of income. Therefore, changes in the interest rate will not have any impact on the profit or loss in respect of changes in the value of assets and liabilities bearing fixed interest. (c) Sensitivity analysis for variable rate instruments The below analysis assumes that all other variables (except for the interest rate), in particular foreign currency rates, remain constant. As of December 31, 2022 Impact on profit (loss) Decrease of 1% in interest Decrease of 0.5% in interest Increase of 0.5% in interest Increase of 1% in interest $ millions SWAP instruments Changes in Israeli Shekel interest 23 11 (10) (19) (d) Terms of derivative financial instruments used to hedge interest risk As of December 31, 2022 Carrying amount Stated amount Maturity date Interest rate range $ millions $ millions Years % Israeli Shekel SWAP contracts from fixed ILS interest to fixed USD interest 23 462 2024-2034 2.4-4.74% As of December 31, 2021 Carrying amount Stated amount Maturity date Interest rate range $ millions $ millions Years % US Dollar SWAP contracts from variable interest to fixed interest (7) 150 2024 2.47%-2.60% Israeli Shekel SWAP contracts from fixed ILS interest to fixed USD interest 119 579 2034 2.40%-4.74% 2. Currency risk The Company is exposed to currency risk with respect to sales, purchases, assets and liabilities that are denominated in a currency other than the functional currency of the Company. The main exposure is the New Israeli Shekel, Euro, British Sterling, Chinese Yuan Brazilian Real and Turkish Lira. The Company enters foreign currency derivatives – forward exchange transactions and currency options – all in order to protect the Company from the risk that the eventual cash flows, resulting from existing assets and liabilities, and sales and purchases of goods within the framework of firm or anticipated commitments (based on a budget of up to one year), denominated in foreign currency, will be affected by changes in the exchange rates. (a) Sensitivity analysis A 10% increase at the rate of the US dollar against the following currencies would have increased (decreased) profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant. As of December 31 Impact on profit (loss) 2022 2021 $ millions $ millions Non-derivative financial instruments US Dollar/Euro (131) (80) US Dollar/Israeli Shekel 152 177 US Dollar/British Pound (1) (1) US Dollar/Japanese Yen (2) - US Dollar/Chinese Yuan 2 1 A 10% decrease of the US dollar against the above currencies as of December 31, 2022, would have the same effect but in the opposite direction. Presented hereunder is a sensitivity analysis of the Company’s foreign currency derivative instruments as of December 31, 2022. Any change in the exchange rates of the principal currencies shown below would have increased (decreased) profit and loss and equity by the amounts shown below. This analysis assumes that all other variables remain constant. As of December 31, 2022 Increase 10% Increase 5% Decrease 5% Decrease 10% $ millions US Dollar/Brazilian Real Forward transactions 10 5 (6) (12) US Dollar/Israeli Shekel Forward transactions (66) (35) 38 81 Forward transactions hedge accounting (31) (16) 18 38 Options (22) (12) 11 24 SWAP (42) (22) 25 53 US Dollar/British Pound Forward transactions (1) - - 1 Options (1) - - 1 Euro/ US Dollar Forward transactions 13 6 (8) (15) Options 4 2 (2) (5) Other Forward transactions 2 1 (1) (2) (b) Terms of derivative financial instruments used to reduce foreign currency risk As of December 31, 2022 Carrying amount Stated amount Average $ millions exchange rate Forward contracts US Dollar/Israeli Shekel (12) 746 3.4 Euro/US Dollar (4) 146 1.1 US Dollar/Brazilian Real 2 111 5.2 Euro/British Pound - (17) 1.2 US Dollar/British Pound - 11 1.2 Other (1) 35 - Forward contracts hedge accounting US Dollar/Israeli Shekel (14) 360 3.4 Currency and interest SWAPs US Dollar/Israeli Shekel 23 462 3.4 Put options US Dollar/Israeli Shekel (11) 240 3.4 Euro/US Dollar 1 47 1.1 US Dollar/Japanese Yen - 3 130.4 US Dollar/British Pound - 12 1.2 Call options US Dollar/Israeli Shekel 1 240 3.4 Euro/US Dollar (1) 47 1.1 US Dollar/Japanese Yen - 3 130.4 US Dollar/British Pound - 12 1.2 As of December 31, 2021 Carrying amount Stated amount Average $ millions exchange rate Forward contracts US Dollar/Israeli Shekel 3 515 3.2 Euro/US Dollar 4 240 1.2 US Dollar /Brazilian Real (1) 37 5.4 US Dollar/British Pound - 16 1.4 US Dollar/Chinese Yuan Renminbi 1 46 6.5 Other - 23 - Currency and interest SWAPs US Dollar/Israeli Shekel 119 579 3.7 Put options US Dollar/Israeli Shekel 14 660 3.2 Euro/US Dollar 2 57 1.2 US Dollar/Japanese Yen - 4 109.7 US Dollar/British Pound - 12 1.4 Call options US Dollar/Israeli Shekel (2) 660 3.2 Euro/US Dollar - 57 1.2 US Dollar/Japanese Yen - 4 109.7 US Dollar/British Pound - 12 1.4 (c) Linkage terms of monetary balances – in millions of dollars As of December 31, 2022 US Dollar Euro British Pound Israeli Shekel Brazilian Real Chinese Yuan Renminbi Other Total Non-derivative instruments: Cash and cash equivalents 41 17 7 1 30 306 15 417 Short term investments and deposits 84 2 - - - 2 3 91 Trade receivables 659 329 73 89 308 78 47 1,583 Other receivables 15 18 1 12 1 - 8 55 Other non-current assets 25 2 - - 7 - 1 35 Total financial assets 824 368 81 102 346 386 74 2,181 Short-term debt 161 137 18 178 7 10 1 512 Trade payables 202 229 27 372 103 69 4 1,006 Other current liabilities 49 91 1 27 15 15 - 198 Long term debt, debentures and others 1,141 659 14 453 8 34 3 2,312 Other non-current liabilities - 44 - - 1 - - 45 Total financial liabilities 1,553 1,160 60 1,030 134 128 8 4,073 Total non-derivative financial instruments, net (729) (792) 21 (928) 212 258 66 (1,892) Derivative instruments: Forward transactions - 146 11 746 111 - 17 1,031 Forward transactions hedge accounting - - - 360 - - - - Cylinder - 47 12 240 - - 3 302 SWAPS – US dollar into Israeli Shekel - - - 462 - - - 462 Total derivative instruments - 193 23 1,808 111 - 20 2,155 Net exposure (729) (599) 44 880 323 258 86 263 As of December 31, 2021 US Dollar Euro British Pound Israeli Shekel Brazilian Real Chinese Yuan Renminbi Others Total Non-derivative instruments: Cash and cash equivalents 89 23 5 3 76 263 14 473 Short term investments and deposits 86 - - - - 3 2 91 Trade receivables 684 260 41 82 222 91 38 1,418 Other receivables 2 22 1 19 1 - - 45 Other non-current assets 4 4 - - 5 - 1 14 Total financial assets 865 309 47 104 304 357 55 2,041 Short-term debt 196 92 12 184 41 52 - 577 Trade payables 210 216 28 410 103 91 6 1,064 Other current liabilities 33 73 4 18 10 15 - 153 Long term debt, debentures and others 1,161 499 21 635 51 67 2 2,436 Other non-current liabilities 1 46 - - 2 - - 49 Total financial liabilities 1,601 926 65 1,247 207 225 8 4,279 Total non-derivative financial instruments, net (736) (617) (18) (1,143) 97 132 47 (2,238) Derivative instruments: Forward transactions - 240 16 515 37 46 23 877 Cylinder - 57 12 660 - - 4 733 SWAPS – US dollar into Israeli Shekel - - - 579 - - - 579 Total derivative instruments - 297 28 1,754 37 46 27 2,189 Net exposure (736) (320) 10 611 134 178 74 (49) 3. Hedge accounting The Company is exposed to changes in the exchange rate of the shekel against the dollar in respect of principal and interest in certain debentures, loans, labor costs and other operating expenses. The Company's risk management strategy is to hedge the changes in cash flows deriving from liabilities, labor costs and other operational costs denominated in Israeli shekels by using derivatives. These exposures are hedged from time to time, according to the assessment of the exposure and inherent risks against which the Company chooses to hedge, in accordance with the Company's risk management strategy. In view of the above, the Company designated several forward contracts and options transactions for cash flow hedge and applied hedge accounting. These transactions, which include a portion of labor costs and other operational costs denominated in Israeli shekel, are intended to secure the effect of the change in the exchange rate of the dollar against the hedged portion, thereby protecting the Company's operating income from currency fluctuation. The Company applies a 1:1 hedging ratio. The main source of potential ineffectiveness in these hedging ratios is negligible schedule differences between the hedged item and the hedging instrument. As of the date of the hedge transaction, the total balance of the hedged instruments amounted to about $360 million. F. Fair value of financial instruments The carrying amounts in the books of certain financial assets and financial liabilities, including cash and cash equivalents, investments, short-term deposits and loans, receivables and other debit balances, long-term investments and receivables, short-term credit, payables and other credit balances, long-term loans bearing variable interest and other liabilities, and derivative financial instruments, correspond to or approximate their fair value. The following table details the book value and the fair value of financial instrument groups presented in the financial statements not in accordance with their fair value: As of December 31, 2022 As of December 31, 2021 Carrying amount Fair value Carrying amount Fair value $ millions $ millions Loans bearing fixed interest (1) 339 302 407 408 Debentures bearing fixed interest Marketable (2) 1,335 1,270 1,524 1,730 Non-marketable (3) 195 191 195 208 1,869 1,763 2,126 2,346 (1 ) The fair value of the Shekel, Euro, Brazilian Real and Yuan loans issued bearing fixed interest is based on calculation of the present value of the cash flows in respect of the principal and the interest and is discounted at the market interest rates on the measurement date for similar loans having similar characteristics and is classified as Level 2 in the fair value hierarchy. The average discount interest as of December 31, 2022 for the Israeli Shekel, Euro, Brazilian Real and Yuan loans was 5.2%, 4.9%, 16.3% and 4.3%, respectively (December 31, 2021 for the Israeli Shekel, Euro Brazilian Real and Yuan loans 1.5%, 1.2%, 13% and 4%, respectively). (2) The fair value of the marketable debentures is based on the quoted stock exchange price and is classified as Level 1 in the fair value hierarchy. (3) The fair value of the non‑marketable debentures is based on calculation of the present value of the cash flows in respect of the principal and the interest and is discounted at the Libor rate customary in the market for similar loans having similar characteristics and is classified as Level 2 in the fair value hierarchy. The average discount interest as of December 31, 2022, was 7% (December 31, 2021 – 2.5%). G. Hierarchy of fair value The following table presents an analysis of the financial instruments measured by fair value, using the valuation method. (See Note 4). The following levels were defined: Level 2: Observed data (directly or indirectly) not included in Level 1 above. Level 2 As of December 31, 2022 As of December 31, 2021 $ millions $ millions Derivatives designated as economic hedge, net (25) 15 Derivatives designated as cash flow hedge, net 9 120 (16) 135

Earnings per Share

Earnings per Share	12 Months Ended
Earnings per Share	Dec. 31, 2022
Notes to Consolidated Financial Statements [Abstract]
Note 22 - Earnings per Share	Note 22 - Earnings per Share Basic earnings per share Calculation of the basic earnings per share for the year ended December 31, 2022, is based on the earnings allocated to the holders of the ordinary shares divided by the weighted-average number of ordinary shares outstanding, calculated as follows: For the year ended December 31 2022 2021 2020 $ millions $ millions $ millions Earnings attributed to the shareholders of the Company 2,159 783 11 Weighted-average number of ordinary shares in thousands: For the year ended December 31 2022 2021 2020 Shares thousands Shares thousands Shares thousands Balance as of January 1 1,285,585 1,280,242 1,279,379 Shares issued during the year - 223 29 Shares vested 1,719 2,342 618 Weighted average number of ordinary shares used in computation of the basic earnings per share 1,287,304 1,282,807 1,280,026 Diluted earnings per share Calculation of the diluted earnings per share for the year ended December 31, 2022, is based on the earnings allocated to the holders of the ordinary shares divided by the weighted-average number of ordinary shares outstanding after adjustment for the number of potential diluted ordinary shares, calculated as follows: Weighted average number of ordinary shares (diluted) in thousands: For the year ended December 31 2022 2021 2020 Shares thousands Shares thousands Shares thousands Weighted average number of ordinary shares used in the computation of the basic earnings per share 1,287,304 1,282,807 1,280,026 Effect of stock options and restricted shares 2,643 4,244 247 Weighted average number of ordinary shares used in the computation of the diluted earnings per share 1,289,947 1,287,051 1,280,273 * As of December 31, 2022, the outstanding options in the amount of 7 million, representing 2.6 million shares, were included in the diluted weighted average number of ordinary shares calculation. As of December 31, 2021, all 12 million outstanding options were included. As of December 31, 2020, 27 million options, were not included since they did not have a diluting effect. The average market value of the Company’s shares, for purposes of calculating the dilutive effect of the stock options, is based on the quoted market prices for the period in which the options were outstanding.

Related and Interested Parties

Related and Interested Parties	12 Months Ended
Related and Interested Parties	Dec. 31, 2022
Related party transactions [abstract]
Note 23 - Related and Interested Parties	Note 23 - Related and Interested Parties Related parties within its meaning in IAS 24 (2009), “Related Parties Disclosure”; Interested parties within their meaning in Paragraph 1 of the definition of an “interested party” in Section 1 of the Israeli Securities Law, 1968. A. Parent company and subsidiaries Israel Corp. To the best of Israel Corp.’s knowledge, Millenium is held by Mashat (Investments) Ltd. (“ Mashat XT Investments Even though Israel Corp. holds less than 50% of the Company’s ordinary shares, it still has decisive influence at the General Meetings of the Company’s shareholders and, effectively, it has the power to appoint directors (other than the external directors) and to exert significant influence with respect to the composition of the Company’s Board of Directors. As of December 31, 2022, 73 million ordinary shares have been pledged by Israel Corporation to secure certain liabilities, almost entirely comprised of margin loans with an aggregate outstanding principal amount of $150 million. B. Benefits to key management personnel (including directors) The senior managers, in addition to their salaries, are entitled to non-cash benefits (such as vehicle, mobile etc.). The Group contributes to a post-employment defined benefit plan on their behalf. In accordance with the terms of the plan, the retirement age of senior managers is 67. Senior managers and directors also participate in the Company's incentive and equity remuneration plans (options for Company shares) (see Notes 16 and 19). The Company's key management personnel in 2022, consists of 27 individuals, of whom 11 are not employed by the company (directors). The Company's key management personnel in 2021, consisted of 22 individuals, of whom 11 were not employed by the Company (directors). Set forth below are details of the benefits for key management personnel in 2022 and 2021. For the year ended December 31 2022 2021 $ millions $ millions Short-term benefits 14 12 Post-employment benefits 1 1 Share-based payments 12 5 Total * 27 18 * To interested parties employed by the Company 7 3 * To interested parties not employed by the Company 1 1 C. Ordinary transactions that are not exceptional The Company’s Board of Directors, following the approval of the Audit Committee, decided that a transaction with related and interested parties will be considered a “negligible transaction” for public reporting purposes if all the following conditions have been met: (1) It is not an “extraordinary transaction” within the meaning thereof in the Companies Law. (2) The effect of each of the parameters listed below is less than one percent (hereinafter – the Negligibility Threshold). For every transaction or arrangement that is tested for the Negligibility Threshold, the parameters will be examined, to the extent they are relevant, on the basis of the Company's condensed or audited consolidated financial statements, as applicable, prior to the transaction, as detailed below: Acquisition of assets Assets ratio – the value of the assets in the transaction divided by total assets Sale of assets Assets ratio – the amount of the assets in the transaction divided by total assets in most recent consolidated balance sheet. Profit ratio – the profit or loss from the transaction (in absolute value) divided by the annual average of last twelve quarters profit/ loss (in absolute value). Financial liabilities Liabilities ratio – loan principle divided by the total liabilities in most recent consolidated balance sheet. Financing expenses ratio – the expected financing expenses for the specific loan divided by the gross financing expenses in most recent consolidated P&L statement. Acquisition and sale of products (except fixed assets), services, leases and production inputs Income ratio – estimated income from the transaction divided by the annual average of total income in last twelve quarterly consolidated P&L statements, or Production inputs ratio – the aggregate expenses in the transaction divided by the annual average of total expenses in last twelve quarterly consolidated P&L statements. (3) The transaction is negligible also from a qualitative point of view. For the purpose of this criteria, it shall be examined whether there are special considerations justifying reporting of the transaction, even if it does not meet the quantitative criteria described above. (4) In examining the negligibility of a transaction expected to occur in the future, among other things, the probability of the transaction occurring will be examined. D. Transactions with related and interested parties For the year ended December 31 2022 2021 2020 $ millions $ millions $ millions Sales 7 7 3 Cost of sales 13 6 3 Selling, transport and marketing expenses 15 13 7 Financing income, net - ( 2 (1) General and administrative expenses 1 1 1 Management fees to the parent company 1 1 1 (1) Until July 1, 2022, the Company and its parent company, Israel Corp., were parties to a management services agreement, which was approved by the Company’s Audit and Accounting Committee, Board of Directors and shareholders on November 9, 2020, November 11, 2020, and January 5, 2021, respectively. Under the management services agreement, Israel Corp. provided to the Company board member services and ongoing general consulting services, such as professional, financial, strategic, legal and managerial advice, for an annual management fee of $1 million plus VAT. For 2022, the Company paid Israel Corp. management fees about $500 thousands. Such amount includes the overall value of the cash and equity-based compensation for the service of the Company’s directors who are officers or directors of Israel Corp. (except for the separate compensation arrangement between the Company and the Company’s Executive Chairman of the Board, Mr. Yoav Doppelt), for the period of January-July 2022. As of July 1, 2022, the management agreement was terminated by the parties, and thereafter, directors who are officers or directors of Israel Corp. (other than Mr. Yoav Doppelt), namely Mr. Aviad Kaufman and Mr. Sagi Kabla, began to be paid the same cash compensation as paid to all other non-executive directors of the Company, namely the fixed annual fee and per meeting fees payable to directors from time to time under the regulations promulgated under the Israeli Companies Law, 1999 governing the compensation of external directors. (2) On January 30, 2020, the Company’s shareholders approved a three The Company’s directors and officers are beneficiaries of both tiers. Pursuant to the Framework Transaction, the cost of the annual premium shall not exceed a cap of $10 million for both tiers. The division of the premium amount between the Company and Israel Corp. in the joint tier is 80% to be paid by the Company and 20% by Israel Corp, and the Company’s HR & Compensation Committee and the Board of Directors have the authority to change, from time to time, the premium allocation in respect of the joint tier between the companies, according to the recommendation of the insurers and/or brokers, and provided that such changes will not exceed 25% over the entire transaction period. Deviation from these limits shall require shareholder approval. In accordance with the terms of the Framework Transaction and the Company's Compensation Policy, the Company's directors’ and officers’ liability insurance policy for 2022, was approved by the Company's authorized organs, effective as of March 2022. For 2022, the directors’ and officers’ liability insurance policy include a liability limit of $150 million for both tiers (comprised of a limit of $40 million, with an additional Side A coverage (directors and officers only) limit of $110 million). The Company is acting to renew its directors' and officers' liability insurance policy for 2023, effective as of March 2023, and will approve the renewed directors' and officers' liability insurance policy in accordance with the Israeli Companies Regulations (Relief in Transactions with Interested Parties), 5760-2000. (3) In December 2017, the Company, Oil Refineries Ltd. (a public company controlled by Israel Corp.) and OPC Energy Ltd. (a public company that is controlled indirectly by one of the Company’s controlling shareholders) signed individual agreements with Energean PLC for the supply of natural gas. Under the agreement between the Company and Energean, the Company will be entitled to acquire up to 13 BCM of natural gas over a period of 15 years, in the total amount of about $1.8 billion. For further information see Note 18. (4) In October 2020, the Company and Oil Refineries Ltd. signed individual bridge supply agreements with Tamar Reservoir for the supply of natural gas, following a process of joint negotiations with the supplier and the approval of ICL's general meeting of shareholders. For further information see Note 18. E. Balances with related and interested parties Composition: As of December 31 2022 2021 $ millions $ millions Other current assets 34 40 Other current liabilities 2 4

Group Main Entities

Group Main Entities	12 Months Ended
Group Main Entities	Dec. 31, 2022
Disclosure of subsidiaries [abstract]
Note 24 - Group Main Entities	Note 24 – Group Main Entities Ownership interest in its subsidiary and investee companies for the year ended December 31 Name of company Principal location of the company’s activity 2022 2021 ICL Israel Ltd. Israel 100.00% 100.00% Dead Sea Works Ltd. Israel 100.00% 100.00% Dead Sea Bromine Company Ltd. Israel 100.00% 100.00% Rotem Amfert Negev Ltd. Israel 100.00% 100.00% Mifalei Tovala Ltd. Israel 100.00% 100.00% Dead Sea Magnesium Ltd. Israel 100.00% 100.00% Bromine Compounds Ltd. Israel 100.00% 100.00% Fertilizers and Chemicals Ltd. Israel 100.00% 100.00% Iberpotash S.A. Spain 100.00% 100.00% Fuentes Fertilizantes S.L. Spain 100.00% 100.00% ICL Europe Coöperatief U.A. The Netherlands 100.00% 100.00% ICL Europe B.V. The Netherlands 100.00% 100.00% ICL IP Terneuzen B.V The Netherlands 100.00% 100.00% ICL Finance BV The Netherlands 100.00% 100.00% Everris International B.V. The Netherlands 100.00% 100.00% ICL Puriphos B.V. The Netherlands 100.00% 100.00% ICL-IP America Inc United States of America 100.00% 100.00% ICL Specialty Products Inc United States of America 100.00% 100.00% Everris NA, Inc. United States of America 100.00% 100.00% Growers Holdings, Inc. United States of America 100.00% 100.00% BK Giulini GmbH Germany 100.00% 100.00% ICL Holding Germany GmbH Germany 100.00% 100.00% ICL Bitterfeld GmbH Germany 100.00% 100.00% Prolactal GmbH Austria 100.00% 100.00% Cleveland Potash Ltd. United Kingdom 100.00% 100.00% Everris Ltd. United Kingdom 100.00% 100.00% ICL America do Sul Brazil 100.00% 100.00% ICL Aditivos E Ingredientes LTDA Brazil 100.00% 100.00% Qualyquímica Industria e Comercio de Produtos Quimicos Ltda Brazil 100.00% 100.00% ICL Investment Co. Ltd. China 100.00% 100.00% Yunnan Phosphate Haikou Co. Ltd. China 50.00% 50.00% ICL Asia Ltd Hong Kong 100.00% 100.00% ICL Trading (HK) Ltd. Hong Kong 100.00% 100.00% Scora S.A.S., France France 100.00% 100.00%

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
Significant Accounting Policies (Policies)	Dec. 31, 2022
Summary Of Significant Accounting Policies [Abstract]
Basis for consolidation	A. Basis for Consolidation 1. Business combinations ICL implements the acquisition method to all business combinations. The acquisition date is the date on which the acquirer obtains control over the acquiree. Control exists when ICL is exposed or has rights to variable returns from its involvement with the acquiree and it could affect those returns through its power over the acquiree. Substantive rights held by ICL and others are considered when assessing control. ICL recognizes goodwill on an acquisition according to the fair value of the consideration transferred including any amounts recognized in respect of non-controlling interest in the acquiree as well as the fair value at the acquisition date of any pre-existing equity right of ICL in the acquiree, less the net amount of the identifiable assets acquired, and the liabilities assumed. Costs associated with the acquisition that were incurred by ICL in a business combination such as advisory, legal, valuation and other professional or consulting fees, other than those associated with an issue of debt or equity instruments connected to the business combination, are expensed in the period the services are received. 2. Subsidiaries Subsidiaries are entities controlled by ICL. The financial statements of the subsidiaries are included in the consolidated financial statements from the date control commenced until the date control ceases to exist. The financial statements of subsidiaries have been changed when necessary to align them with ICL's accounting policies. 3. Non-controlling interests Non-controlling interests comprise of the subsidiary's equity that cannot be attributed, directly or indirectly, to the parent company. Profit or loss and any part of other comprehensive income are allocated to the owners of the Company and the non-controlling interests, even if the result is a negative balance of non-controlling interests. Measurement on the date of the business combination – Non‑controlling interests that are instruments that give rise to a present ownership interest and entitle the holder to a share of net assets in the event of liquidation, are measured at the date of the business combination at either fair value, or at their proportionate interest in the identifiable assets and liabilities of the acquiree, on a transaction-by-transaction basis. Transactions with non-controlling interests, while retaining control - are accounted for as equity transactions. Any difference between the consideration paid or received and the change in non‑controlling interests is included in the share of the owners of the company directly in a separate category in equity. 4. Loss of control Upon the loss of control, ICL derecognizes the assets and liabilities of the subsidiary, any non-controlling interests and the other components of equity related to the subsidiary. If ICL retains any interest in the previous subsidiary, then such interest is measured at fair value at the date that control is lost. The difference between the sum of the proceeds and fair value of the retained interest, and the derecognized balances is recognized in profit or loss as other income or other expenses. The amounts recognized in capital reserves through other comprehensive income with respect to the same subsidiary are reclassified to profit or loss or to retained earnings. 5. Transactions eliminated in consolidation Intra-group balances, transactions, unrealized income and expenses and gains and losses arising from intra-group transactions, are eliminated in preparing the consolidated financial statements. 6. Investment in associated companies and joint ventures Joint ventures are joint arrangements in which ICL has rights to the net assets of the arrangement. Associates and joint ventures are accounted for using the equity method (equity accounted investees) and are recognized initially at cost.
Foreign Currency	B. Foreign Currency 1. Transactions in foreign currency Transactions in foreign currency are translated to the functional currency based on the exchange rate in effect on the dates of the transactions. Monetary assets and liabilities denominated in foreign currency on the report date are translated into the functional currency based on the exchange rate in effect on that date. Non‑monetary items denominated in foreign currency measured at historical cost are translated using the exchange rate at the date of the transaction. 2. Foreign operations The assets and liabilities of foreign operations, including goodwill and fair value adjustments from acquisition, are translated to USD at exchange rates at the reporting date. The income and expenses of foreign operations are translated to USD at exchange rates at the dates of the transactions. Foreign currency differences are recognized in other comprehensive income and are presented in equity in the foreign currency translation reserve (hereinafter –Translation Reserve). When the foreign operation is a non-wholly owned subsidiary of the Company, then the relevant proportionate share of the foreign operation translation difference is allocated to the non-controlling interests. When a foreign operation is disposed of, the cumulative amount in the Translation Reserve is reclassified to profit or loss as a part of the capital gain or loss on disposal. Generally, foreign currency differences from a monetary item receivable from or payable to a foreign operation, including foreign operations that are subsidiaries, are recognized in profit or loss in the consolidated financial statements. Foreign exchange gains or losses arising from a monetary item receivable from or payable to a foreign operation, the settlement of which is neither planned nor likely in the foreseeable future, are considered to form part of a net investment in a foreign operation and are recognized in other comprehensive income and are presented within equity in the Translation Reserve.
Financial Instruments	C. Financial Instruments 1. Non-derivative financial assets (IFRS9) Initial recognition of financial assets: ICL initially recognizes trade receivables and debt instruments issued on the date that they are originated and for all other financial assets at the trade date in which ICL becomes a party to the contractual provisions of the instrument. A financial asset is initially measured at fair value plus direct transaction costs. Derecognition of financial assets: Derecognition of financial assets occurs when the contractual rights of ICL to the cash flows from the asset expire, or when ICL transfers the rights to receive the contractual cash flows and substantially all the risks and rewards of ownership of the financial asset. When ICL retains substantially all the said risks and rewards, it continues to recognize the financial asset. Classification of financial assets into categories and the accounting treatment of each category: Financial assets are classified at initial recognition to one of the following measurement categories: (1) amortized cost; (2) fair value through other comprehensive income – investments in debt instruments; (3) fair value through other comprehensive income – investments in equity instruments; or (4) fair value through profit or loss. The reclassification of the financial assets in subsequent periods will only occur if ICL's changes its financial debt assets business model. A financial asset is measured at amortized cost if it meets both of the following conditions and is not designated at fair value through profit or loss: (1) It is held within a business model whose objective is to hold assets so as to collect contractual cash flows; and (2) the contractual terms of the financial asset give rise to cash flows representing solely payments of principal and interest on the principal amount outstanding on specified dates. These assets are subsequently measured at amortized cost using the effective interest method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognized in profit or loss. Any gain or loss on derecognition is recognized in profit or loss. ICL has balances of trade and other receivables and deposits that are held within a business model whose objective is collecting contractual cash flows, which represent solely payments of principal and interest (for the time value and the credit risk). Accordingly, these financial assets are measured at amortized cost. Financial assets at fair value through profit or loss - are subsequently measured at fair value. Net gains or losses, including any interest income or dividend income, are recognized in profit or loss (other than certain derivatives designated as accounting hedging instruments). Investments in equity instruments at fair value through other comprehensive income - are subsequently measured at fair value. Dividends are recognized as income in profit or loss, unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognized in other comprehensive income and are never reclassified to profit or loss. 2. Non-derivative financial liabilities Non-derivative financial liabilities include bank overdrafts, loans and borrowings from banks and others, marketable debt instruments, lease liabilities, and trade and other payables. ICL initially recognizes debt securities issued on the date that they originated. All other financial liabilities are recognized initially on the trade date at which ICL becomes a party to the contractual provisions of the instrument. Subsequent to initial recognition these financial liabilities are measured at amortized cost using the effective interest method. Derecognition of the financial liabilities occur when the obligation of ICL, as specified in the agreement, expires or when it is discharged or cancelled. Change in terms of debt instruments: A substantial modification of the terms of an existing financial liability or part of it and an exchange of debt instruments having substantially different terms, between an existing borrower and lender is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability at fair value. In such cases the entire difference between the amortized cost of the original financial liability and the fair value of the new financial liability is recognized in profit or loss as financing income or expense. Substantially different terms - if the discounted present value of the cash flows according to the new terms and discounted using the original effective interest rate, is different by at least ten percent (10%) from the discounted present value of the remaining cash flows of the original financial liability. In addition to the aforesaid quantitative criterion, ICL examines, inter alia, whether there have also been changes in various economic parameters inherent in the exchanged debt instruments (e.g. linkage). In a non-substantial modification of terms (or exchange) of debt instruments, the new cash flows are discounted using the original effective interest rate, and the difference between the present value of the new financial liability and the present value of the original financial liability is recognized in profit or loss. Offset of financial instruments: Financial assets and liabilities are offset, and the net amount is presented in the statement of financial position when, and only when, ICL currently has a legal right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously. 3. Derivative financial instruments ICL holds derivative financial instruments in order to reduce exposure to foreign currency risks, marine shipping prices, and interest. Derivatives are recognized according to fair value and the changes in value are recorded in the statement of income as financing income or expense, except for derivatives used to hedge cash flows (accounting hedging). The attributable transaction costs are recorded in the statement of income as incurred. Cash flow hedges Changes in the fair value of derivatives used to hedge cash flows, in accordance with the effective portion of the hedge, are recorded through other comprehensive income directly in a hedging reserve. With respect to the non‑effective part, changes in the fair value are recognized in the statement of income. The amount accumulated in the capital reserve is reclassified and included in the statement of income in the same period as the hedged cash flows affected profit or loss under the same line item in the statement of income as the hedged item. If the hedging instrument no longer meets the criteria for hedge accounting, expires or is sold, terminated or exercised, then hedge accounting is discontinued. The cumulative gain or loss remains in other comprehensive income and is presented in the hedging reserve in equity until the forecasted transaction occurs or is no longer expected to occur and then is reclassified to the statements of income. 4. CPI-linked assets and liabilities not measured at fair value The value of index-linked financial assets and liabilities, which are not measured at fair value, is re‑measured every period in accordance with the actual increase/ decrease in the CPI. 5. Share capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares and share options are recognized as a deduction from equity, net of any tax effects. Incremental costs directly attributable to an expected issuance of an equity instrument are deducted from the equity upon the initial recognition of the equity instruments or are amortized as financing expenses in the statement of income when the issuance is no longer expected to take place. Treasury shares - when shares recognized as equity are repurchased by the Group, the amount of the consideration paid, which includes directly attributable costs, net of any tax effects, is recognized as a deduction from equity. When treasury shares are sold or reissued subsequently, the amount received is recognized as an increase in equity, and the resulting surplus on the transaction is carried to share premium, whereas a deficit on the transaction is deducted from retained earnings.
Property plant and equipment	D. Property, plant and equipment 1. Recognition and measurement Property, plant and equipment in the consolidated statements are presented at cost less accumulated depreciation and provision for impairment. The cost includes expenses that can be directly attributed to the acquisition of the asset after deducting the related amounts of government grants. The cost of assets that were self-constructed includes the cost of the materials and direct labor, as well as any additional costs that are directly attributable to bringing the asset to the required position and condition so that it will be able to function as management intended, as well as an estimate of the costs to dismantle, remove and restore, where there is an obligation for such, and capitalized borrowing costs. Gains and losses on disposal of a property, plant or equipment item are determined by comparing the proceeds from disposal of the carrying amount of the asset and are recognized net in the income statement. 2. Subsequent Costs (after initial recognition) The cost of replacing part of an item of property, plant and equipment and other subsequent costs is recognized as part of the book value of the item, if it is expected that the future economic benefit inherent therein will flow to ICL and that its cost can be reliably measured. The book value of the part that was replaced is derecognized. Routine maintenance costs are charged to the statement of income as incurred. 3. Depreciation Depreciation is a systematic allocation of the depreciable amount of an asset over its estimated useful life. The depreciable amount is the cost of the asset, or other amount substituted for cost, less its residual value. Depreciation of an item of property, plant and equipment begins when the asset is available for its intended use, that is, when it has reached the place and condition required in order that it can be used in the manner contemplated for it by Management. Depreciation is recorded in the statement of income according to the straight-line method over the estimated useful life of each significant component of the property, plant and equipment items, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. Owned land is not depreciated. The estimated useful life is as follows: In Years Buildings 15 - 30 Technical equipment and machinery (1) 5 - 33 Dikes and evaporating ponds (2) 20 - 40 Other 3 - 10 (1) Mainly 33 years (2) Mainly 40 years The Company reviews, at least at the end of every reporting year, the estimates regarding the depreciation method, useful lives and the residual value, and adjusts them if appropriate. Over the years, the Company has succeeded to extend the useful lives of part of property, plant and equipment items beyond the original estimated useful life, as a result of investments therein and other current, ongoing maintenance thereof.
Intangible Assets	E. Intangible Assets 1. Goodwill Goodwill recorded consequent to the acquisition of subsidiaries is presented at cost less accumulated impairment charges, under intangible assets. 2. Research and development Expenditures for research activities are expensed as incurred. Development expenditures are recognized as intangible asset only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and ICL has the intention and sufficient resources to complete development and to use or sell the asset. 3. Other intangible assets Other intangible assets with a defined useful life, are measured according to cost less accumulated amortization and accumulated losses from impairment. Intangible assets with indefinite useful lives are measured according to cost less accumulated losses from impairment. 4. Subsequent costs Subsequent costs are recognized as an intangible asset only when they increase the future economic benefit inherent in the asset for which they were incurred. All other costs are charged to the statement of income as incurred. 5. Amortization Amortization is a systematic allocation of the amortizable amount of an intangible asset over its useful life. The amortizable amount is the cost of the asset less its residual value. Amortization is recorded in the statement of income according to the straight-line method from the date the assets are available for use, over the estimated useful economic life of the intangible assets, except for customer relationships and geological surveys, which are amortized according to the rate of consumption of the economic benefits expected from the asset based on cash flow forecasts. Goodwill and intangible assets having an indefinite lifespan are not amortized on a systematic basis but, rather, are examined at least once a year for impairment in value. Internally generated intangible assets are not systematically amortized as long as they are not available for use, i.e. they are not yet on site or in working condition for their intended use. Accordingly, these intangible assets, such as development costs, are tested for impairment at least once a year, until such date as they are available for use. The estimated useful life is as follows: In Years Concessions and mining rights – over the remaining duration of the rights granted Trademarks 15 - 20 Technology / patents 7 - 20 Customer relationships 15 - 25 Computer applications 3 - 10 ICL periodically examines the estimated useful life of an intangible asset that is not amortized, at least once a year, in order to determine if events and circumstances continue to support the determination that the intangible asset has an indefinite life. Deferred expenses in respect of geological surveys are amortized over their useful life based on a geological estimate of the amount of the material that will be produced from the mining site. The estimates regarding the amortization method and useful life are reviewed, at a minimum, at the end of every reporting year and are adjusted where necessary. ICL assesses the useful life of the customer relationships on an ongoing basis, based on an analysis of all the relevant factors and evidence, considering the experience the Company has with respect to recurring orders and churn rates and considering the future economic benefits expected to flow to the Company from these customer relationships.
Inventories	F. Inventories Inventories are measured at the lower of cost or net realizable value. The cost of the inventories includes the costs of purchasing the inventories and bringing them to their present location and condition. In the case of work in process and finished goods, the cost includes the proportionate part of the manufacturing overhead based on normal capacity. Net realizable value is the estimated selling price in the ordinary course of business, after deduction of the estimated cost of completion and the estimated costs required to execute the sale. The cost of the inventories of raw and auxiliary materials, maintenance materials, finished goods and goods in process, is determined mainly according to the “moving average” method. If the benefit from stripping costs (costs of removing waste produced as part of a mine's mining activities during its production stage) is attributable to inventories, the Company accounts for these stripping costs as inventories. In a case where the benefit is improved access to the quarry, the Company recognizes the costs as a non‑current addition to the asset, provided the criteria presented in IFRIC 20 are met. Inventories which are expected to be sold in a period of more than 12 months from the reporting date are presented as non-current inventories, as part of non-current assets.
Capitalization of Borrowing Costs	G. Capitalization of Borrowing Costs A qualifying asset is an asset that requires a significant period of time to prepare for its intended use or sale. Specific and non-specific borrowing costs are capitalized to qualifying assets during the period required for their completion and establishment, until the time when they are ready for their intended use. Other borrowing costs are charged to "financing expenses" in the statement of income as incurred.
Impairment	H. Impairment 1. Non-derivative financial assets Provision for expected credit losses in respect of a financial asset at amortized cost, including trade receivables, is measured at an amount equal to the full lifetime of expected credit losses. Expected credit losses are a probability-weighted estimate of credit losses. With respect to other debt instruments, provision for expected credit losses is measured at an amount equal to 12-month expected credit losses, unless their credit risk has increased significantly since initial recognition. Provision for such losses in respect of a financial asset at amortized cost, is presented net of the gross book value of the asset. 2. Non-financial assets In each reporting period, an examination is made with respect to whether there are signs indicating impairment in the value of ICL’s non-financial assets, other than inventories and deferred tax assets. If such signs exist, the estimated recoverable amount of the asset is calculated. ICL conducts an annual examination, on the same date, of the recoverable amount of goodwill and intangible assets with indefinite useful lives or those that are not available for use – or more frequently if there are indications of impairment. Assets that cannot be tested individually are grouped together into the smallest group of assets that generate cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the “cash-generating unit”). The recoverable amount of an asset or a cash-generating unit is the higher of its value in use or the net selling price (fair value less cost of disposal). When determining the value in use, ICL discounts the anticipated future cash flows according to an after-tax discount rate that reflects the evaluations of the market's participants regarding the time value of money and the specific risks relating to the asset or to the cash-generating unit, in respect of which the future cash flows expected to derive from the asset or the cash-generating unit were not adjusted. Assets of the Company's headquarters and administrative facilities do not produce separate cash flows and they serve more than one cash-generating unit. Such assets are allocated to cash-generating units on a reasonable and consistent basis and are examined for impairment as part of the examination of impairment of the cash-generating units to which they are allocated. Impairment losses are recognized if the carrying amount of an asset or cash-generating unit exceeds its estimated recoverable amount and are recognized in the statement of income. For operating segments that include goodwill, an impairment loss is recognized when the book value of the operating segment exceeds its recoverable value. Impairment losses in respect of an operating segment are allocated first to reduce the carrying amount of its goodwill and then to reduce the carrying amounts of the other assets of that segment on a proportionate basis. An impairment loss is allocated between the owners of the Company and the non-controlling interests on the same basis that the profit or loss is allocated. A loss from impairment in value of goodwill recognized in previous periods is not reversible prospectively. A loss from impairment of other assets recognized in previous periods is examined in future periods to assess whether there are signs indicating that these losses have decreased or no longer exist. A loss from impairment of value is reversed if there is a change in the estimates used to determine the recoverable value, only if the book value of the asset, after reversal of the loss from impairment of value, does not exceed the book value, after deduction of depreciation or amortization, that would have been determined if the loss from impairment of value had not been recognized.
Employee Benefits	I. Employee Benefits ICL has several post-employment benefit plans. The plans are funded partly by deposits with insurance companies, financial institutions or funds managed by a trustee. The plans are classified as defined contribution plans and as defined benefit plans. 1. Defined contribution plans A post-employment benefit plan under which ICL pays fixed contributions into a separate entity and has no legal or constructive obligation to pay further amounts. ICL’s obligation to deposit in a defined contribution plan is recorded as an expense in the statement of income in the periods in which the employees provided the services. Retirement benefit plans that are not defined contribution plans: ICL’s net obligation is calculated for each plan separately, by estimating the future amount of the benefit to which an employee will be entitled as compensation for services in the current and past periods. The benefit is presented at present value after deducting the fair value of the plan's assets. The discount rate for ICL companies operating in countries having a “deep” market for high quality corporate bonds is the yield on such corporate bonds, including Israel. The discount rate for ICL companies operating in countries not having a “deep” market for high quality corporate bonds is in accordance with the yield on government bonds – the currency and redemption date of which are similar to the terms binding ICL. The calculations are performed by a qualified actuary using the projected unit credit method 2. Defined benefit plans When a net asset is created for ICL, the asset is recognized up to the net present value of the available economic benefits in the form of a refund from the plan or by a reduction in future deposits to the plan. An economic benefit in the form of a refund from the plan or a reduction in future deposits will be considered available when it can be realized in the lifetime of the plan or after settlement of the obligation. The movement in the net liability in respect of a defined benefit plan that is recognized in every accounting period in the statement of income is comprised of the following: (1) Current service costs – the increase in the present value of the liability deriving from employees’ service in the current period; (2) The net financing income (expense) is calculated by multiplying the net defined benefit liability (asset) by the discount rate used for measuring the defined benefit liability, as determined at the beginning of the annual reporting period; (3) Exchange rate differences; (4) Past service costs and plan reduction – the change in the present value of the liability in the current period as a result of a change in post-employment benefits attributed to prior periods. The difference, as of the date of the report, between the net liability at the beginning of the year plus the movement in the net liability as detailed above, and the actuarial liability less the fair value of the fund assets at the end of the year, reflects the balance of the actuarial income or expenses recognized in other comprehensive income and is recorded in retained earnings. The current interest costs and return on plan assets are recognized as expenses and interest income in the respective financing category. Costs in respect of past services are recognized immediately and without reference to whether the benefits have vested. 3. Other long-term employee benefits Some of the Company’s employees are entitled to other long-term benefits that do not relate to a post-retirement benefit plan. Actuarial gains and losses are recorded directly to the statement of income in the period in which they arise. 4. Early Retirement Pay Early retirement pay is recognized as an expense and as a liability when ICL has clearly undertaken to pay it, without any reasonable chance of cancellation, in respect of termination of employees, before they reach the customary age of retirement according to a formal, detailed plan. The benefits provided to employees upon voluntary retirement are charged when ICL proposes the plan to the employees, it is expected that the proposal will be accepted, and it is possible to reliably estimate the number of employees that will accept the proposal. If benefits are payable more than 12 months after the reporting period, then they are discounted to their present value. The discount rate is the yield at the reporting date on high-quality, index-linked corporate debentures, the denominated currency of which is the payment currency, and that have maturity dates approximating the terms of ICL’s obligations. 5. Short‑term benefits Obligations for short-term employee benefits are measured on a non-discounted basis, and the expense is recorded at the time the service is provided or upon the actual absence of the employee when the benefit is not accumulated (such as maternity leave). A provision for short-term employee benefits in respect of cash bonuses or profit-sharing plans is recognized for the amount expected to be paid, when ICL has a current legal or implied obligation and it is possible to reliably estimate the obligation. Classification of employee benefits is determined based on ICL's expectation with respect to full utilization of the benefits and not based on the date on which the employee is entitled to utilize the benefit. 6. Share-based compensation The fair value on the grant date of share-based compensation awards granted to employees is recognized as a salary expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards. The amount recognized as an expense in respect of share-based compensation awards that are conditional upon meeting vesting conditions that are service conditions and non-market performance conditions, is adjusted to reflect the number of awards that are expected to vest.
Provisions	J. Provisions A provision is recognized when ICL has a present legal or implied obligation, as the result of an event that occurred in the past, that can be reliably estimated, and when it is expected that an outflow of economic benefits will be required in order to settle the obligation. The provisions are made by means of discounting the future cash flows at a pre-tax interest rate reflecting the current market estimates of the time value of money and the risks specific to the liability, without considering the Company’s credit risk. ICL reviews its provisions in each reporting period and adjusts if necessary. In order to reflect the length of time that has elapsed, the book value of the provision is adjusted in each period and recognized as financing expenses. In rare cases where it is not possible to estimate the outcome of a potential liability, no provision is recorded in the financial statements. ICL recognizes a reimbursement asset if, and only if, it is virtually certain that the reimbursement will be received if the Company settles the obligation. The amount recognized in respect of the reimbursement does not exceed the amount of the provision. (1) Warranty A provision for warranty is recognized when the products or services, in respect of which the warranty is provided, are sold. The provision is based on historical data and on a weighting of all possible outcomes according to their probability of occurrence. (2) Provision for environmental costs ICL recognizes a provision for an existing obligation for prevention of environmental pollution and anticipated provisions for costs relating to environmental restoration stemming from past activities. Costs for preventing environmental pollution that increase the life expectancy or efficiency of a facility are capitalized to the cost of the property, plant and equipment and are depreciated according to the usual depreciation rates used by ICL. (3) Restructuring A provision for restructuring is recognized when ICL has approved a detailed and formal restructuring plan, and the restructuring either has commenced or has been announced publicly. The provision includes direct expenditures caused by the restructuring and necessary for the restructuring, and which are not associated with the continuing activities of ICL. (4) Site restoration A provision for reclamation and restoration of ICL's sites is recognized when the Company has a legal obligation which could arise, among others, from environmental regulations. (5) Legal claims A provision for legal claims is recognized when ICL has a present legal or constructive obligation as a result of an event that occurred in the past, if it is more likely than not that an outflow of economic resources will be required to settle the obligation and it can be reliably estimated.
Revenue Recognition	K. Revenue Recognition Identifying a contract ICL accounts for a contract with a customer only when the following conditions are met: (a) The parties to the contract have approved the contract and they are committed to satisfying the obligations attributable to them; (b) ICL can identify the rights of each party in relation to the goods that will be transferred; (c) ICL can identify the payment terms for the goods that will be transferred; (d) The contract has a commercial substance (i.e. the risk, timing and amount of the entity’s future cash flows are expected to change as a result of the contract); and (e) It is probable that the consideration, to which ICL is entitled to in exchange for the goods transferred to the customer, will be collected. For the purpose of clause (e) above, ICL takes into consideration its past experience with the customer, the financial stability information over the customer, the status and existence of sufficient collateral and the percentage of advances received. Identifying performance obligations ICL is a global specialty minerals and chemicals company engaged in the sale of various goods produced in its different segments of operation. ICL's contracts primarily derived from a single performance obligation to deliver the product specified in the contract. For additional information about the Company's products, see note 5 – Operating Segments. Determining the transaction price ICL's transaction price is the amount of the consideration specified in the contract with the customer, which it expects to be entitled in exchange for the goods promised to the customer, other than amounts collected for third parties. The variable considerations at ICL, which are mainly trade discounts, commercial returns and volume rebates, have no material impact on the Company's financial statements. Satisfaction of performance obligation Revenue is recognized at the point in time, when the Company transfers control over promised goods to the customer. The transfer of control over goods to a customer generally takes place upon shipment or when accepted by the customer, as provided for in the sales contract. Payment terms ICL has various payment terms which are aligned with the acceptable commercial conditions in the relevant markets. ICL's policy is to engage in agreements with payment terms not exceeding one year, and applies the practical expedient to not separate a significant financing component where the difference between the time of receiving payment and the time of transferring the goods to the customer is one year or less.
Government grants	L. Government grants Government grants are recognized initially at fair value when there is reasonable assurance that they will be received, and the Group will comply with the conditions associated with the grant. Unconditional government grants are recognized when the Group is entitled to receive them. Grants that compensate the Group for expenses incurred are presented as a deduction from the corresponding expense. Grants that compensate the Group for the cost of an asset are presented as a deduction from the related assets and are recognized in profit or loss on a systematic basis over the useful life of the asset.
Leases	M. Leases Determining whether an arrangement contains a lease On the inception date of the lease, ICL determines whether the arrangement is a lease or contains a lease, while examining if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. In its assessment of whether an arrangement conveys the right to control the use of an identified asset, ICL assesses whether it has the following two rights throughout the lease term: (a) the right to obtain substantially all the economic benefits from use of the identified asset; and (b) the right to direct the identified asset’s use. For lease contracts that contain non-lease components, such as services or maintenance, that are related to a lease component, ICL elected to account for the contract as a single lease component without separating the components. Leased assets and lease liabilities : Contracts that award ICL control over the use of a leased asset for a period of time in exchange for consideration, are accounted for as leases. Upon initial recognition ICL recognizes a liability at the present value of the balance of future lease payments, and concurrently recognizes a right-of-use asset at the same amount of the lease liability, adjusted for any prepaid or accrued lease payments, plus initial direct costs incurred in respect of the lease. Subsequent to initial recognition, the right-of-use asset is accounted for using the cost model and depreciated over the shorter of the lease term or useful life of the asset. ICL has elected to apply the practical expedient by which short-term leases of up to one year and/or leases in which the underlying asset has a low value, are recognized in profit or loss on a straight-line basis, over the lease term, without recognizing an asset and/or liability in the statement of financial position. The lease term is the non-cancellable period of the lease plus periods covered by an extension or termination option if it is reasonably certain that the lessee will or will not exercise the option, respectively. Variable lease payments that depend on an index or a rate, are initially measured using the index or rate existing at the commencement of the lease and are included in the measurement of the lease liability. When the cash flows of future lease payments change as the result of a change in an index or a rate, the balance of the liability is adjusted against the right-of-use asset. Other variable lease payments that are not included in the measurement of the lease liability are recognized in profit or loss in the period in which the event or condition that triggers payment occurs. After lease commencement, a right-of-use asset is measured on a cost basis less accumulated depreciation and accumulated impairment losses. Depreciation is calculated on a straight-line basis over the useful life or contractual lease period, whichever earlier. Sale and leaseback: ICL applies the requirements of IFRS 15 to determine whether an asset transfer is accounted for as a sale. If an asset transfer satisfies the requirements of IFRS 15 to be accounted for as a sale, ICL measures the right-of-use asset arising from the leaseback at the proportion of the previous carrying amount that relates to the right of use retained by ICL. Accordingly, ICL only recognizes the amount of gain or loss that relates to the rights transferred. If the asset transfer does not satisfy the requirements of IFRS 15 to be accounted for as a sale, the transaction is accounted for as a financing transaction. Insofar as ICL is the seller-lessee of the asset, it continues to recognize the transferred asset and recognizes a financial liability in accordance with IFRS 9, at an amount equal to the transferred proceeds.
Financing Income and Expenses	N. Financing Income and Expenses Financing income includes income from interest on amounts invested, gains from derivative financial instruments recognized in the statement of income, foreign currency gains, gains on changes in the fair value of financial assets at fair value through profit or loss and financing income recorded in relation to employee benefits. Interest income is recognized as accrued, using the effective interest method. Financing expenses include interest on loans received, securitization transaction costs, losses from derivative financial instruments, changes due to the passage of time in liabilities in respect of defined benefit plans for employees less interest income deriving from plan assets of a defined benefit plan for employees and losses from exchange rate differences. Gains and losses from exchange rate differences and derivative financial instruments are reported on a net basis. In the consolidated statements of cash flows, interest received and interest paid, are presented as part of cash flows from operating activities.
Taxes on Income	O. Taxes on Income Taxes on income (including surplus profit levy on natural resources) include current and deferred taxes, that are recognized in profit or loss, unless they relate to a business combination or are recognized directly in equity or in other comprehensive income when they relate to items recognized directly in equity or in other comprehensive income. Current tax is the expected tax payable (or receivable) on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date. Current taxes also include taxes in respect of prior years and any tax arising from dividends. Current tax assets and liabilities are offset if there is a legally enforceable right and there is intent to settle current tax liabilities and assets on a net basis. A provision for uncertain tax positions, including additional tax and interest expenses, is recognized when it is more likely than not that ICL will have to pay the obligation. Recognition of deferred taxes relates to temporary differences between the book values of the assets and liabilities for purposes of financial reporting and their value for tax purposes. The Company does not recognize deferred taxes for the following temporary differences: initial recognition of goodwill and differences deriving from investments in subsidiaries, if it is not expected that they will reverse in the foreseeable future and if ICL controls the date the provision will reverse, whether via sale or distribution of a dividend. The deferred taxes are measured according to the tax rates expected to apply to the temporary differences at the time they are realized, based on the law that was finally legislated or effectively legislated as of the date of the report. Deferred taxes in respect of intra-company transactions in the consolidated financial statements are recorded according to the tax rate applicable to the buying company. Deferred tax assets and liabilities are offset if there is a legally enforceable right and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle on a net basis. A deferred tax asset is recognized in the books when it is expected that in the future there will be taxable income against which the temporary differences can be utilized. Deferred tax assets are examined at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. ICL could become liable for additional taxes in the case of distribution of intercompany dividends between ICL's companies. These additional taxes are not included in the financial statements as ICL's companies decided not to cause distribution of a dividend that involves additional taxes to the paying company in the foreseeable future. In cases where an investee company is expected to distribute a dividend involving additional tax, the Company records a reserve for expected additional taxes.
Earnings per share	P. Earnings per share ICL presents basic and diluted earnings per share data for its ordinary share capital. The basic earnings per share are calculated by dividing the income or loss attributable to the holders of the Company’s ordinary shares by the weighted-average number of ordinary shares outstanding during the year, after adjustment in respect of treasury shares. The diluted earnings per share are determined by adjusting the income or loss attributable to the holders of the Company’s ordinary shares and the weighted-average number of ordinary shares outstanding after adjustment in respect of treasury shares and for the effect of restricted shares and options for shares granted to employees.
Transactions with controlling shareholder	Q. Transactions with controlling shareholder Assets and liabilities included in a transaction with a controlling shareholder are measured at fair value on the date of the transaction.
Non-current assets and disposal groups held for sale	R. Non-current assets and disposal groups held for sale Non-current assets (or disposal groups composed of assets and liabilities) are classified as held for sale if it is highly probable that they will be recovered primarily through a sale transaction and not through continuing use. Immediately before classification as held for sale, the assets (or components of the disposal group) are remeasured in accordance with ICL’s accounting policies. Thereafter, the assets (or components of the disposal group) are measured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on a disposal group is initially allocated to goodwill, and then to remaining assets on a pro rata basis, except that no loss is allocated to assets that are not in the scope of the measurement requirements of IFRS 5 such as: inventories, financial assets, deferred tax assets and employee benefit assets, which continue to be measured in accordance with ICL’s accounting policies. Impairment losses recognized and subsequent gains or losses on remeasurement, are recognized as profit or loss. Gains are not recognized in excess of any cumulative impairment loss. In subsequent periods, depreciable assets classified as held for sale are not depreciated on a periodic basis.
Amendments to standards and interpretations that have not yet been adopted	S. Amendments to standards and interpretations that have not yet been adopted Amendment to IAS 1, Presentation of Financial Statements: d isclosure of accounting policies ( hereinafter - the amendment) According to the amendment companies must provide disclosure of their material accounting policies rather than their significant accounting policies. Pursuant to the amendment, accounting policy information is material if, when considered with other information disclosed in the financial statements, it can be reasonably be expected t o influence decisions that the users of the financial statements make on the basis of those financial statements. The amendment to IAS 1 also clarifies that accounting policy information is expected to be material if, without it, the users of the financial statements would be unable to understand other material information in the financial statements. The amendment also clarifies that immaterial accounting policy information need not be disclosed. The amendment is applicable for reporting periods beginning on or after January 1, 2023. The Company is examining the consequences of the amendment on the financial statements with no plans for early adoption. Amendment to IAS 12, Income Taxes: d eferred t ax related to a ssets and l iabilities arising from a s ingle t r ansaction ( hereinafter - the amendment) The Amendment narrows the scope of the exemption from recognizing deferred taxes as a result of temporary differences created at the initial recognition of assets and/or liabilities, so that it does not apply to transactions that give rise to equal and off setting temporary differences. As a result, companies will need to recognize a deferred tax asset or a deferred tax liability for these temporary differences at the initial recognition of transactions that give rise to equal and offsetting temporary diffe rences, such as lease transactions and provisions for decommissioning and restoration The amendment is effective for annual periods beginning on or after January 1, 2023, by amending the opening balance of the retained earnings or adjusting a different component of equity in the period the said amendment was adopted. The Company is examining the impact of the amendment on its financial statements with no plans for early adoption.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
Significant Accounting Policies (Tables)	Dec. 31, 2022
Summary Of Significant Accounting Policies [Abstract]
Schedule of estimated useful lives of property, plant and equipment	The estimated useful life is as follows: In Years Buildings 15 - 30 Technical equipment and machinery (1) 5 - 33 Dikes and evaporating ponds (2) 20 - 40 Other 3 - 10 (1) Mainly 33 years (2) Mainly 40 years
Schedule of estimated useful lives of intangible assets	The estimated useful life is as follows: In Years Concessions and mining rights – over the remaining duration of the rights granted Trademarks 15 - 20 Technology / patents 7 - 20 Customer relationships 15 - 25 Computer applications 3 - 10

Operating Segments (Tables)

Operating Segments (Tables)	12 Months Ended
Operating Segments (Tables)	Dec. 31, 2022
Disclosure of operating segments [abstract]
Schedule of operating segment data	B. Operating segment data Industrial Products Potash Phosphate Solutions Growing Solutions Other Activities Reconciliations Consolidated $ millions For the year ended December 31, 2022 Sales to external parties 1,737 3,031 2,851 2,376 20 - 10,015 Inter-segment sales 29 282 255 46 3 (615) - Total sales 1,766 3,313 3,106 2,422 23 (615) 10,015 Segment operating income (loss) 628 1,822 777 378 (9) (87) 3,509 Other income not allocated to the segments 7 Operating income 3,516 Financing expenses, net (113) Share in earnings of equity-accounted investees 1 Income before income taxes 3,404 Depreciation and amortization 61 166 189 70 3 9 498 Capital expenditures 90 346 259 101 9 17 822 Industrial Products Potash Phosphate Solutions Growing Solutions Other Activities Reconciliations Consolidated $ millions For the year ended December 31, 2021 Sales to external parties 1,601 1,598 2,087 1,644 25 - 6,955 Inter-segment sales 16 178 167 26 3 (390) - Total sales 1,617 1,776 2,254 1,670 28 (390) 6,955 Segment operating income (loss) 435 399 294 135 (8) (61) 1,194 Other income not allocated to the segments 16 Operating income 1,210 Financing expenses, net (122) Share in earnings of equity-accounted investees 4 Income before income taxes 1,092 Depreciation amortization and impairment 65 148 207 62 2 - 484 Capital expenditures 74 270 228 74 6 17 669 Capital expenditures as part of business combination - - - 377 - - 377 Industrial Products Potash Phosphate Solutions Growing Solutions Other Activities Reconciliations Consolidated $ millions For the year ended December 31, 2020 Sales to external parties 1,242 1,091 1,663 1,016 31 - 5,043 Inter-segment sales 13 177 153 17 4 (364) - Total sales 1,255 1,268 1,816 1,033 35 (364) 5,043 Segment profit (loss) 303 121 88 17 (5) (15) 509 Other expenses not allocated to the segments (307) Operating income 202 Financing expenses, net (158) Share in earnings of equity-accounted investees 5 Income before income taxes 49 Depreciation, amortization and impairment 77 152 204 45 3 98 579 Capital expenditures 84 270 267 54 6 15 696 Capital expenditures as part of business combination - - - - 26 - 26
Schedule of sales by geographical location of the customers	C. Information based on geographical location The following table presents the distribution of ICL’s sales by geographical location of the customer: 2022 2021 2020 $ millions % of sales $ millions % of sales $ millions % of sales Brazil 2,200 22 1,178 17 447 9 China 1,495 15 1,060 15 806 16 USA 1,457 15 1,091 16 793 16 India 505 5 213 3 194 4 United Kingdom 448 4 386 6 336 7 Germany 417 4 345 5 327 6 Spain 365 4 280 4 243 5 Israel 344 3 291 4 260 5 France 305 3 270 4 238 5 Netherlands 264 3 127 2 95 2 All other 2,215 22 1,714 24 1,304 25 Total 10,015 100 6,955 100 5,043 100
Schedule of sales by geographical location of the customer by operating segments	The following table presents the distribution of the operating segments sales by geographical location of the customer: Industrial Products Potash Phosphate Solutions Growing Solutions Other Activities Reconciliations Consolidated $ millions For the year ended December 31, 2022 Europe 574 698 881 880 18 (242) 2,809 Asia 664 1,008 817 286 — (32) 2,743 South America 40 938 496 849 — (8) 2,315 North America 401 365 654 166 1 (10) 1,577 Rest of the world 87 304 258 241 4 (323) 571 Total 1,766 3,313 3,106 2,422 23 (615) 10,015 Industrial Products Potash Phosphate Solutions Growing Solutions Other Activities Reconciliations Consolidated $ millions For the year ended December 31, 2021 Europe 530 430 611 727 23 (162) 2,159 Asia 597 478 617 206 1 (23) 1,876 South America 64 467 343 436 — (5) 1,305 North America 363 209 491 127 1 (5) 1,186 Rest of the world 63 192 192 174 3 (195) 429 Total 1,617 1,776 2,254 1,670 28 (390) 6,955 Industrial Products Potash Phosphate Solutions Growing Solutions Other Activities Reconciliations Consolidated $ millions For the year ended December 31, 2020 Europe 458 376 557 561 30 (160) 1,822 Asia 405 412 477 161 1 (24) 1,432 North America 299 84 372 106 2 (4) 859 South America 40 212 210 56 - (1) 517 Rest of the world 53 184 200 149 2 (175) 413 Total 1,255 1,268 1,816 1,033 35 (364) 5,043
Schedule of sales by geographical location of the assets	For the year ended December 31 2022 2021 2020 $millions $millions $millions Israel 5,611 3,526 2,636 Europe 3,361 2,437 2,014 South America 1,994 1,095 424 Asia 1,123 861 643 North America 1,038 897 757 Other 61 56 48 13,188 8,872 6,522 Intercompany sales (3,173) (1,917) (1,479) Total 10,015 6,955 5,043
Schedule of operating income (loss) by geographical location of the assets	For the year ended December 31 2022 2021 2020 $millions $millions $millions Israel 2,668 863 105 Europe 445 7 (50) Asia 221 179 64 South America 184 95 35 North America 131 71 47 Other 5 4 4 Intercompany eliminations (138) (9) (3) Total 3,516 1,210 202
Schedule of non-current assets by geographical location of the assets	The following table present the non-current assets by geographical location of the assets () As of December 31 2022 2021 $ millions $ millions Israel 4,208 4,079 Europe 1,474 1,505 Asia 461 483 South America 407 391 North America 346 333 Other 4 5 Total 6,900 6,796 () Mainly consist of property, plant and equipment, intangible assets and non-current inventories.

Inventories (Tables)

Inventories (Tables)	12 Months Ended
Inventories (Tables)	Dec. 31, 2022
Notes to Consolidated Financial Statements [Abstract]
Schedule of inventories	As of December 31 2022 2021 $ millions $ millions Finished products 1,348 946 Raw materials 490 349 Work in progress 233 299 Spare parts 128 125 Total inventories 2,199 1,719 Of which: Non-current inventories - mainly raw materials (presented as non-current assets) 65 149 Current inventories 2,134 1,570

Prepaid expenses and other re_2

Prepaid expenses and other receivables (Tables)	12 Months Ended
Prepaid expenses and other receivables (Tables)	Dec. 31, 2022
Trade and other receivables [abstract]
Schedule of prepaid expenses and other receivables	As of December 31 2022 2021 $ millions $ millions Government institutions 111 97 Prepaid expenses 70 51 Current tax assets 53 97 Derivative instruments 10 48 Other 79 64 323 357

Investments In Subsidiaries (Ta

Investments In Subsidiaries (Tables)	12 Months Ended
Investments In Subsidiaries (Tables)	Dec. 31, 2022
Disclosure of subsidiaries [abstract]
Schedule of non-controlling interests in subsidiaries - balance Sheet	As of December 31 2022 2021 $ millions $ millions Current assets 267 231 Non-current assets 392 408 Current liabilities (145) (168) Non-current liabilities (48) (83) Equity (466) (388)
Schedule of non-controlling interests in subsidiaries - profit and Loss	For the year ended December 31 2022 2021 2020 $ millions $ millions $ millions Sales 723 528 359 Operating Income 146 105 29 Depreciation and amortization 34 38 37 Operating income before depreciation and amortization 180 143 66 Net Income 116 96 23 Total Comprehensive income 78 104 40

Other non-current assets (Table

Other non-current assets (Tables)	12 Months Ended
Other non-current assets (Tables)	Dec. 31, 2022
Other Noncurrent Assets [Abstract]
Schedule of other non-current assets	As of December 31 2022 2021 $ millions $ millions Surplus in employees' defined benefit plans (1) 97 115 Non-current inventories 65 149 Receivables from equity-accounted investees sale (2) 22 - Derivative designated as a cash flow hedge 19 97 Investments in equity-accounted investees 3 26 Other 25 16 231 403 (1) See Note 16. (2) See Note 8B(1).

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
Property, Plant and Equipment (Tables)	Dec. 31, 2022
Disclosure of detailed information about property, plant and equipment [abstract]
Schedule of property, plant and equipment	Land and buildings Technical equipment and machinery Dikes and evaporating ponds Plants under construction (1) Other Right of use asset (2) Total $ millions Cost Balance as of January 1, 2022 1,107 7,664 1,465 664 1,073 518 12,491 Additions 30 358 388 (128) 77 64 789 Disposals (15) (27) - - - (27) (69) Translation differences (36) (130) (19) (18) (6) (22) (231) Balance as of December 31, 2022 1,086 7,865 1,834 518 1,144 533 12,980 Accumulated depreciation Balance as of January 1, 2022 502 4,410 797 - 881 147 6,737 Depreciation 35 243 47 - 59 74 458 Disposals (7) (25) - - - (27) (59) Translation differences (18) (83) (15) - (4) (5) (125) Balance as of December 31, 2022 512 4,545 829 - 936 189 7,011 Depreciated balance as of December 31, 2022 574 3,320 1,005 518 208 344 5,969 (1) The additions are presented net of items for which construction has been completed and accordingly were reclassified to other categories in the “property, plant and equipment” section. (2) The total additions were recorded against lease liabilities (IFRS 16). Land and buildings Technical equipment and machinery Dikes and evaporating ponds Plants under construction (1) Other Right of use asset (2) Total $ millions Cost Balance as of January 1, 2021 880 7,419 1,441 778 1,003 496 12,017 Additions in respect of business combinations 85 20 - 9 2 9 125 Additions 193 382 51 (99) 78 37 642 Disposals (2) (44) (1) - (6) (20) (73) Exit from consolidation (9) (21) - - (1) (2) (33) Translation differences (40) (92) (26) (24) (3) (2) (187) Balance as of December 31, 2021 1,107 7,664 1,465 664 1,073 518 12,491 Accumulated depreciation Balance as of January 1, 2021 491 4,300 763 - 817 96 6,467 Depreciation 30 227 55 - 71 71 454 Reversal of impairment - (6) - - - - (6) Disposals (5) (34) - - (4) (19) (62) Exit from consolidation (3) (19) - - - - (22) Translation differences (11) (58) (21) - (3) (1) (94) Balance as of December 31, 2021 502 4,410 797 - 881 147 6,737 Depreciated balance as of December 31, 2021 605 3,254 668 664 192 371 5,754 (1) The additions are presented net of items for which construction has been completed and accordingly were reclassified to other categories in the “property, plant and equipment” section. (2) The total additions were recorded against lease liabilities (IFRS 16).

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
Intangible Assets (Tables)	Dec. 31, 2022
Notes to Consolidated Financial Statements [Abstract]
Schedule of intangible assets - composition	A. Composition Goodwill Concessions and mining rights Trademarks Technology / patents Customer relationships Computer application Others Total $ millions Cost Balance as of January 1, 2022 522 215 88 97 203 124 70 1,319 Additions - 2 - 9 - 20 2 33 Adjustment to PPA (1) 5 - - 6 (6) - - 5 Translation differences (1) (7) (4) (4) (3) (2) (3) (24) Balance as of December 31, 2022 526 210 84 108 194 142 69 1,333 Amortization Balance as of January 1, 2022 20 80 34 58 131 74 55 452 Amortization for the year - 6 2 5 15 9 3 40 Translation differences ( 1 ) (1) ( 2) ( 3) ( 2) ( 1) ( 1) ( 11) Balance as of December 31, 2022 19 85 34 60 144 82 57 481 Amortized Balance as of December 31 ,2022 507 125 50 48 50 60 12 852 (1) In July 2022, the Company completed the ADS’s Purchase Price Allocation (PPA). Goodwill Concessions and mining rights Trademarks Technology / patents Customer Computer application Others Total $ millions Cost Balance as of January 1, 2021 341 218 92 93 172 118 73 1,107 Additions in respect of business combinations 210 - 1 2 39 - - 252 Additions - - - 6 1 19 1 27 Translation differences (29) (3) (5) (4) (9) (13) (4) (67) Balance as of December 31, 2021 522 215 88 97 203 124 70 1,319 Amortization Balance as of January 1, 2021 21 74 34 55 123 76 54 437 Amortization for the year - 6 3 5 12 7 3 36 Translation differences (1) - (3) (2) (4) (9) (2) (21) Balance as of December 31, 2021 20 80 34 58 131 74 55 452 Amortized Balance as of December 31 ,2021 502 135 54 39 72 50 15 867
Schedule of total book value of intangible assets having defined and indefinite useful lives	B . Total book value of intangible assets having defined useful lives and those having indefinite useful lives are as follows: As of December 31 2022 2021 $ millions $ millions Intangible assets having a defined useful life 313 333 Intangible assets having an indefinite useful life 539 534 852 867

Impairment Testing (Tables)

Impairment Testing (Tables)	12 Months Ended
Impairment Testing (Tables)	Dec. 31, 2022
Impairment Testing [Abstract]
Schedule of intangible assets with an indefinite useful life	The carrying amounts of intangible assets with an indefinite useful life are as follows: As of December 31 2022 2021 $ millions $ millions Goodwill Phosphate Solutions 110 114 Industrial Products 90 91 Growing Solutions 271 260 Potash 20 19 Other 16 18 507 502 Trademarks 32 32 539 534

Credit from Banks and Others (T

Credit from Banks and Others (Tables)	12 Months Ended
Credit from Banks and Others (Tables)	Dec. 31, 2022
Credit From Banks And Others [Abstract]
Schedule of composition	As of December 31 2022 2021 $ millions $ millions Short-term debt From financial institutions 313 327 Current maturities of: Debentures 116 131 Long-term loans from financial institutions 15 56 Lease Liability 68 63 199 250 Total Short-Term debt 512 577 Long- term debt and debentures Long term lease liability 270 299 Loans from financial institutions 721 679 991 978 Marketable debentures 1,329 1,517 Non-marketable debentures 191 191 1,520 1,708 2,511 2,686 Less – current maturities of: Debentures 116 131 Long-term loans from financial institutions 15 56 Lease liability 68 63 199 250 Total Long- term debt and debentures 2,312 2,436
Schedule of yearly movement in credit from banks and others	As of December 31 2022 2021 $ millions $ millions Balance as of January 1 2,914 2,660 Changes from financing cash flows Additions in respect of business combination - 171 Receipt of long-term debts 1,045 1,230 Repayment of long-term debt (1,181) (1,120) Repayment of short-term credit (21) (58) Interest paid (113) (112) Receipt (payments) from transaction in derivatives 20 (17) Total net financing cash flows (250) 94 Initial recognition of lease liability 64 37 Interest expenses 148 126 Effect of changes in foreign exchange rates ( 97 (21) Change in fair value of derivatives 67 (24) Other changes (33) 42 Balance as of December 31 2,813 2,914 (*) The balance includes Short-term debt, derivatives on loans and debentures, loans and debentures and interest payables.
Schedule of information on material loans and debentures	Instrument type Loan date Original principal (millions) Currency Carrying amount ($ millions) Interest rate Principal repayment date Additional information Debentures - Series F May 2018, December 2020 693 US Dollar 714 6.38% May 2038 (3), (4) Debentures - Series E April 2016 1,569 Israeli Shekel 223 2.45% 2021- 2024 (Annual installment) Partially repaid (1), (3) Debentures (private offering) – 3 series January 2014 275 US Dollar 145 46 5.16% 5.31% January 2024 January 2026 (3), (4) Debentures - Series G January/May 2020 766 Israeli Shekel 208 2.40% 2022- 2034 (Annual installment) (1), (3) Debentures - Series D December 2014 184 US Dollar 184 4.50% December 2024 (3), (4) SLL September 2021 250 Euro 266 0.80% September 2026 (5) Loan - European Bank September 2021 25 Euro 27 0.95% June 2025 Loan-Israeli institutions November 2013 300 Israeli Shekel 40 4.74% 2015-2024 (Annual installment) Partially repaid
Schedule of credit facilities	Issuer Group of international banks European bank Date of the credit facility March 2015 December 2016 Date of credit facility termination March 2025 May 2024 The amount of the credit facility USD 1,100 million (1) USD 30 million Credit facility has been utilized Euro 330 million USD 30 million Interest rate Up to 33% use of the credit: Libor/Euribor + 0.70%. From 33% to 66% use of the credit: Libor/Euribor + 0.80% 66% or more use of the credit: Libor/Euribor + 0.95% Libor + 0.80% Loan currency type USD and Euro loans USD loans Pledges and restrictions Financial covenants - see Section D, a cross-default mechanism and a negative pledge. Financial covenants - see Section D and a negative pledge. Non-utilization fee 0.21% - (1) In July 2022, the long-term credit facility decreased by $100 million following an agreement on early termination with one of the banks, a few months prior to the official termination date. The updated total credit facility is $1,100 million. most banks signed on to continue the credit facility agreement, and from March 2023 to March 2025, the total credit facility will amount to $1,000 million.
Schedule of restrictions on the group relating to the receipt of credit	Financial Covenants (1) Financial Ratio Required under the Agreement Financial Ratio December 31, 2022 Total shareholder’s equity Equity greater than $2,000 million $5,464 million Ratio of EBITDA to the net interest expenses Equal to or greater than 3.5 39.79 Ratio of the net financial debt to EBITDA Less than 3.5 0.53 Ratio of certain subsidiaries loans to the total assets of the consolidated company Less than 10% 2.69% (1) The examination of compliance with the financial covenants is based on the Company’s consolidated financial statements. As of December 31, 2022, the Company complies with all of its financial covenants.

Other Payables (Tables)

Other Payables (Tables)	12 Months Ended
Other Payables (Tables)	Dec. 31, 2022
Trade and other payables [abstract]
Schedule of other payables	As of December 31 2022 2021 $ millions $ millions Employees 368 414 Current tax liabilities 177 183 Governmental (mainly in respect of royalties) 168 103 Accrued expenses 98 75 Derivative instruments 44 3 Income received in advance 41 33 Others 111 101 1,007 912

Taxes on Income (Tables)

Taxes on Income (Tables)	12 Months Ended
Taxes on Income (Tables)	Dec. 31, 2022
Major components of tax expense (income) [abstract]
Schedule of tax rates of subsidiaries incorporated outside of Israel	Country Tax rate Note Brazil 34% Germany 29% United States 26% (1) Netherlands 25.8% Spain 25% China 25% United Kingdom 19% (1) The tax rate is an estimated average and includes federal and states tax. Different rate may apply in each specific year, as a result of different allocation of income between the different states.
Schedule of reconciliation of changes in deferred tax liability (asset)	In respect of financial position In respect of carry forward tax losses Total Depreciable property, plant and equipment and intangible assets Inventories Provisions for employee benefits Other $millions Balance as of January 1, 2021 (439) 38 94 (7) 115 (199) Changes in 2021: Additions in respect of business combinations - 1 1 9 2 13 Amounts recorded in the statement of income 16 - 2 (14) (24) (20) Amounts recorded to a capital reserve - - (22) (1) - (23) Translation differences 2 - (2) (3) (5) (8) Balance as of December 31, 2021 (421) 39 73 (16) 88 (237) Changes in 2022: Amounts recorded in the statement of income (127) 33 4 31 35 (24) Amounts recorded to a capital reserve - - (12) 4 - (8) Translation differences 1 - (1) - (4) (4) Balance as of December 31, 2022 (547) 72 64 19 119 (273)
Schedule of deferred taxes denominated by currencies	As of December 31 2022 2021 $millions $millions Israeli Shekels (368) (327) Euro 51 84 Brazilian Real 28 13 British Pound 16 - U.S Dollar (8) (10) Other 8 3 (273) (237)
Schedule of composition of the taxes on income	For the year ended December 31 2022 2021 2020 $ millions $ millions $ millions Current taxes 869 145 70 Deferred taxes 45 22 (43) Taxes in respect of prior years 271 93 (2) 1,185 260 25
Schedule of effective income tax rate reconciliation	For the year ended December 31 2022 2021 2020 $ millions $ millions $ millions Income before taxes on income, as reported in the statements of income 3,404 1,092 49 Statutory tax rate (in Israel) 23% 23% 23% Theoretical tax expense 783 251 11 Add (less) – the tax effect of: Surplus Profit Levy tax 265 - - Reduced tax due to tax benefits (95) (64) (6) Differences deriving from additional deduction and different tax rates applicable to foreign subsidiaries 1 (10) (4) Tax on dividend 5 3 2 Deductible temporary differences and their reversal (including carryforward losses) for which deferred taxes assets were not recorded and non–deductible expenses (29) (8) 14 Taxes in respect of prior years* 271 93 (2) Differences in measurement basis (21) (8) 10 Other differences 5 3 - Taxes on income included in the income statements 1,185 260 25 * For 2022, included $275 million $188 in respect of the settlement agreement as mentioned above.
Schedule of taxes on income relating to items recorded in equity	For the year ended December 31 2022 2021 2020 $ millions $ millions $ millions Tax recorded in other comprehensive income Actuarial gains from defined benefit plan (12) (22) (6) Change in investments at fair value through other comprehensive income - (21) - Change in fair value of hedging derivatives 4 - - Taxes in respect of exchange rate differences on equity loan to a subsidiary included in translation adjustment (11) (1) (3) Total (19) (44) (9)

Employee Benefits (Tables)

Employee Benefits (Tables)	12 Months Ended
Employee Benefits (Tables)	Dec. 31, 2022
Classes of employee benefits expense [abstract]
Schedule of composition of employee benefits	Composition of employee benefits: As of December 31 2022 2021 $ millions $ millions Fair value of plan assets 432 648 Termination benefits (86) (135) Defined benefit obligation (664) (993) (318) (480)
Schedule of composition of fair value of the plan assets	Composition of fair value of the plan assets: As of December 31 2022 2021 $ millions $ millions Equity instruments With quoted market price 126 230 Without quoted market price 40 50 166 280 Debt instruments With quoted market price 232 337 Without quoted market price 10 3 242 340 Deposits with insurance companies 24 28 432 648
Schedule of movement in net defined benefit assets (liabilities)	E. Movement in net defined benefit obligation and in its components: Fair value of plan assets Defined benefit obligation Defined benefit obligation, net 2022 2021 2022 2021 2022 2021 $ millions $ millions $ millions $ millions $ millions $ millions Balance as of January 1 648 629 (993) (1,075) (345) (446) Income (costs) included in profit or loss: Current service costs - - (23) (24) (23) (24) Interest income (expenses) 12 6 (20) (14) (8) (8) Past service cost - - - 12 - 12 Effect of movements in exchange rates, net (32) 8 56 (16) 24 (8) Included in other comprehensive income: Actuarial profits (losses) deriving from changes in financial assumptions - - 230 68 230 68 Other actuarial gains (147) 17 - - (147) 17 Change with respect to translation differences, net (34) (10) 43 21 9 11 Other movements: Benefits received (paid) (20) (6) 43 35 23 29 Employer contribution 5 4 - - 5 4 Balance as of December 31 432 648 (664) (993) (232) (345)
Schedule of actuarial assumptions	Principal actuarial assumptions as of the reporting date (expressed as weighted averages): For the year ended December 31 2022 2021 2020 % % % Discount rate as of December 31 4.7 2.1 1.7 Future salary increases 3.9 3.9 3.4 Future pension increase 2.8 2.3 2.0
Schedule of sensitivity analysis	Assuming all other assumptions remain constant, the following reasonably December 2022 Decrease 10% Decrease 5% Increase 5% Increase 10% $ millions Significant actuarial assumptions Salary increases (11) (6) 6 11 Discount rate 28 14 (14) (28) Mortality table 13 6 (6) (13) The assumptions regarding the future mortality rates are based on published statistics and accepted mortality tables. H. The Effect of the plans on the Company's future cash flows The expenses recorded in respect of defined contribution plans in 2022 are $39 million The Company estimates that the expected deposits in 2023 to fund defined benefit plans are about $8 million. As of December 31, 2022, the Company estimates that the life of the defined benefit plans, based on a weighted average, is about 11 years (compared with 13.6 years in 2021). I. Long-term incentive plan (1) In February 2023, the Company’s HR & Compensation Committee and the Board of Directors approved a new biennial equity grant for the years 2023-2024 in the form of options exercisable to the Company's ordinary shares. For further information, see Note 19. (2) In November 2021, Company's HR & Compensation Committee and the Board of Directors approved a new Cash LTI plan, according to which, other senior managers will be awarded a cash incentive in 2025, the fair value of the grant as of the reporting date is about $37 million. The grant is subject to achievement of certain financial targets over the three years and can be affected by the change in share price.

Provisions (Tables)

Provisions (Tables)	12 Months Ended
Provisions (Tables)	Dec. 31, 2022
Disclosure Of Provision [Abstract]
Schedule of provisions	A. Composition and changes in the provision Site restoration and equipment dismantling (1) Legal claims Other Total $ millions Balance as of January 1, 2022 283 13 41 337 Provisions recorded during the year - 36 3 39 Provisions reversed during the year (10) (1) (1) (12) Effect of change in discount rate (18) - - (18) Payments during the year (17) (3) (1) (21) Translation differences (10) - - ( 10) Balance as of December 31, 2022 228 45 42 315 (1) Main items under 'Site restoration and equipment dismantling':

Equity (Tables)

Equity (Tables)	12 Months Ended
Equity (Tables)	Dec. 31, 2022
Equity [abstract]
Schedule of composition of equity	A. Composition: As of December 31, 2022 As of December 31, 2021 Authorized Issued and paid Authorized Issued and paid Number of ordinary shares of Israeli Shekel 1 par value (in millions) 1,485 1,314 1,485 1,312 Number of Special State shares of Israeli Shekel 1 par value 1 1 1 1 (*) For information regarding the amount of treasury shares, see Note 19.G.
Schedule of reconciliation of the number of shares outstanding	The reconciliation of the number of shares outstanding at the beginning and end of the year is as follows: Number of Outstanding Shares (in millions) As of January 1, 2021 1,305 Issuance of shares 7 As of December 31, 2021 1,312 Issuance of shares 2 As of December 31, 2022 1,314
Schedule of share-based payments to employees, non-marketable options	1. Non-marketable options Grant date Employees entitled Number of instruments (thousands) Issuance’s details Instrument terms Vesting conditions Expiration date August 6, 2014 Officers and senior employees 3,993 A n issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, as amended in June 2016 (hereinafter – the amended 2014 Equity Compensation Plan). Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. In case that on the exercise date the closing price of an ordinary share is higher than twice the exercise price (the “Share Value Cap”), the number of the exercised shares will be reduced so that the product of the exercised shares actually issued to an offeree multiplied by the share closing price will equal to the product of the number of exercised options multiplied by the Share Value Cap. 3 equal tranches: (1) one third on December 1, 2016 (2) one third on December 1, 2017 (3) one third on December 1, 2018 Two years from the vesting date. June 30, 2016 Officers and senior employees 3,035 Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date June 30, 2023 September 5, 2016 Former chairman of BOD 186 February 14, 2017 Former CEO 114 February 14, 2024 June 20, 2017 Officers and senior employees 6,868 June 20, 2024 August 2, 2017 Former chairman of BOD 165 March 6, 2018 Officers and senior employees 5,554 March 6, 2025 Grant date Employees entitled Number of instruments (thousands) Issuance’s details Instrument terms Vesting conditions Expiration date May 14, 2018 CEO 385 An issuance of non-marketable and non-transferrable options, for no consideration, under the amended 2014 Equity Compensation Plan. Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date May 14, 2025 August 20, 2018 Former chairman of BOD 403 August 20, 2025 April 15, 2019 Officers and senior manager 13,242 2 equal tranches: 5 years after the grant date June 27, 2019 CEO 3,512 May 29, 2019 * Chairman of BOD 2,169 June 30, 2021 Senior employees 647 February 8, 2022 Senior employees 9,294 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date March 30, 2022 CEO 1,941 March 30, 2022 Chairman of BOD 1,055 * The options were issued upon Mr. Doppelt’s entry into office on July 1, 2019.
Schedule of share-based payments to employees, non-marketable options, grants parameters	The fair value of the options granted in 2014, as part of the amended 2014 Equity Compensation Plan, was estimated using the binomial model for pricing options. The fair value of all other options was estimated using the Black & Scholes model for pricing options. The parameters used in applying the models are as follows: 2014 Plan Granted 2014 Granted 2016 Granted 2017 Granted 2018 Granted 2019 Granted 2021 Granted 2022 Share price (in $) 8.2 3.9 4.5 4.4 5.4 6.8 10.0 CPI-linked exercise price (in $) 8.4 4.3 4.3 4.3 5.3 7.1 10.1 Expected volatility: First tranche 29.40% 30.51% 31.88% 28.86% 27.85% 31.70% 31.80% Second tranche 31.20% 30.51% 31.88% 28.86% 27.85% 31.70% 30.88% Third tranche 40.80% 30.51% 31.88% 28.86% - - 30.52% Expected life of options (in years): First tranche 4.3 7.0 7.0 7.0 4.4 4.4 3.2 Second tranche 5.3 7.0 7.0 7.0 4.4 4.4 3.8 Third tranche 6.3 7.0 7.0 7.0 - - 4.0 Risk-free interest rate: First tranche (0.17)% 0.01% 0.37% 0.03% (0.67)% 0.43% (1.46)% Second tranche 0.05% 0.01% 0.37% 0.03% (0.67)% 0.43% (1.29)% Third tranche 0.24 0.01% 0.37% 0.03% - - (1.21)% Fair value (in $ millions) 8.4 4.0 11.3 8.8 7.5 0.6 24.9 Weighted average grant date fair value per option (in $) 1.9 1.1 1.6 1.4 1.2 1.3 2.0
Schedule of share-based payments to employees, non-marketable options, movement in the options	The movement in the options are as follows: Number of options (in millions) Balance as of January 1, 2021 27 Movement in 2021: Expired during the year 1 Exercised during the year (16) Total options outstanding as of December 31, 2021 12 Movement in 2022: Granted during the year 12 Forfeited during the year (2) Exercised during the year (7) Total options outstanding as of December 31, 2022 15
Schedule of share-based payments to employees, non-marketable options, exercise price	The exercise prices for options outstanding at the beginning and end of each period are as follows (in US dollar): December 31, 2022 December 31, 2021 December 31, 2020 Granted in 2016 3.41 4.61 4.56 Granted in 2017 3.14 4.19 4.17 Granted in 2018 3.06 4.11 4.12 Granted in 2019 4.57 5.77 5.66 Granted in 2021 6.00 7.39 - Granted in 2022 8.91 - -
Schedule of share-based payments to employees, non-marketable options, number of options vested	The number of outstanding vested options at the end of each period and the weighted average of the exercise price for these options are as follows (): December 31, 2022 December 31, 2021 December 31, 2020 Number of options exercisable (in Millions) 5 4 11 Weighted average exercise price in Israeli Shekel 15.67 14.29 13.89 Weighted average exercise price in US Dollar 4.45 4.59 4.32 () The share price as of December 31, 2022, is NIS 25.45 and $7.23.
Schedule of share-based payments to employees, non-marketable options, range of exercise prices	The range of exercise prices for the options outstanding vested at the end of each period is as follows: December 31, 2022 December 31, 2021 December 31, 2020 Range of exercise price in Israeli Shekel 10.77-30.06 12.77-18.06 13.15-18.32 Range of exercise price in US Dollar 3.06-8.54 4.11-5.81 4.09-5.70
Schedule of share-based payments to employees, non-marketable options, average remaining contractual life	The average remaining contractual life for the outstanding vested options at the end of each period is as follows: December 31, 2022 December 31, 2021 December 31, 2020 Average remaining contractual life 3.42 2.83 3.58
Schedule of share-based payments to employees, restricted shares	Grant date Employees entitled Number of instruments (thousands) Vesting conditions () Instrument terms Additional Information Fair value at the grant date (Million) June 20, 2017 Officers and senior employees 2,211 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date An issuance for no consideration, under the amended 2014 Equity Compensation Plan. The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the approval date of the General Meeting). 10 August 2, 2017 Former chairman of BOD 53 0.3 January 10, 2018 ICL’s Directors (excluding ICL’s CEO & Chairman of the BOD) 137 0.6 March 6, 2018 Officers and senior employees 1,726 8 May 14, 2018 CEO 121 0.6 August 20, 2018 Former chairman of BOD 47 0.2 April 23, 2020 ICL’s Directors (excluding directors who are officers or directors of Israel Corporation Ltd.) 177 3 equal tranches: (1) one third on January 1, 2021 (2) one third on January 1, 2022 (3) one third on January 1,2023 The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the Grant Date (the approval date of the annual General Meeting of shareholders). 0.6 () Vesting of the Restricted Shares granted to directors would fully accelerate, if the holder ceases to serve as a director of the Company, unless he/she ceased to hold office due to those certain circumstances regarding early termination of office or imposition of enforcement measures, as set forth in Sections 231-232a and 233(2) of the Israeli Companies Law.
Schedule of dividends distributed to the company's shareholders	The date of Board of Directors’ decision to distribute the dividend Actual date of distribution dividend Gross amount of the dividend distributed (in millions of $) Amount of the dividend per share (in $) February 11, 2020 March 18, 2020 23 0.02 May 10, 2020 June 17, 2020 30 0.02 July 27, 2020 September 16, 2020 36 0.03 November 10, 2020 December 16, 2020 29 0.02 Total 2020 118 0.09 February 10, 2021 March 16, 2021 34 0.03 May 5, 2021 June 16, 2021 67 0.05 July 27, 2021 September 1, 2021 68 0.05 November 3, 2021 December 15, 2021 107 0.08 Total 2021 276 0.21 February 8, 2022 March 8, 2022 169 0.13 May 10, 2022 June 15, 2022 307 0.24% July 26, 2022 September 14, 2022 376 0.29 November 8, 2022 December 14, 2022 314 0.24 Total 2022 1,166 0.9 February 14, 2023* March 15, 2023 178 0.14 (*) The record date is March 1, 2023, and the payment date is March 15, 2023.

Details of Income Statement I_2

Details of Income Statement Items (Tables)	12 Months Ended
Details of Income Statement Items (Tables)	Dec. 31, 2022
Details Of Income Statement [Abstract]
Schedule of cost of sales	For the year ended December 31 2022 2021 2020 $ millions $ millions $ millions Sales 10,015 6,955 5,043 Cost of sales Materials consumed 3,152 2,342 1,647 Cost of labor 937 906 794 Energy and fuel 433 343 316 Depreciation and amortization 409 413 416 Other 52 340 380 4,983 4,344 3,553
Schedule of expenses	For the year ended December 31 2022 2021 2020 $ millions $ millions $ millions Selling, transport and marketing expenses Land and Marine transportation 792 742 515 Cost of labor 188 171 134 Other 201 154 117 1,181 1,067 766 General and administrative expenses Cost of labor 168 166 136 Professional Services 44 44 32 Other 79 66 64 291 276 232 Research and development expenses Cost of labor 55 52 40 Other 13 12 14 68 64 54
Schedule of other income and expenses	For the year ended December 31 2022 2021 2020 $ millions $ millions $ millions Other income Profit from divestment 22 14 - Insurance Compensation 15 - - Capital gain 9 16 - Reversal of early retirement provision of employees 2 - - Past service cost - 12 11 Reversal of provision for legal claims - 11 - Reversal of Impairment of fixed assets - 9 - Other 6 1 9 Other income recorded in the income statements 54 63 20 Other expenses Provision for legal claims 17 17 - Provision for historical waste removal and site closure costs 6 14 83 Transaction costs - 8 - Impairment and disposal of assets - 9 90 Provision for early retirement and dismissal of employees - - 78 Other 7 9 5 Other expenses recorded in the income statements 30 57 256
Schedule of financing income and expenses	For the year ended December 31 2022 2021 2020 $ millions $ millions $ millions Financing income and expenses Financing income: Net gain from changes in exchange rates 139 - - Financing income in relation to employee benefits 44 - - Interest income from banks and others 31 17 7 Net gain from change in fair value of derivative designated as economic hedge - 59 - Net gain from change in fair value of derivative designated as cash flow hedge - 18 54 214 94 61 Financing expenses: Net loss from change in fair value of derivative designated as economic hedge 98 - 23 Net loss from change in fair value of derivative designated as cash flow hedge 77 - - Interest expenses to banks and others 148 126 120 Financing expenses in relation to employees’ benefits 7 23 38 Banks and finance institutions commissions (mainly commission on early repayment of loans) 7 6 4 Net loss from changes in exchange rates - 79 58 Financing expenses 337 234 243 Net of borrowing costs capitalized 10 18 24 327 216 219 Net financing expenses recorded in the income statements 113 122 158

Financial Instruments and Ris_2

Financial Instruments and Risk Management (Tables)	12 Months Ended
Financial Instruments and Risk Management (Tables)	Dec. 31, 2022
Disclosure of detailed information about financial instruments [abstract]
Schedule of groups and measurement bases of financial assets and financial liabilities	B. Groups and measurement bases of financial assets and financial liabilities As of December 31, 2022 Financial assets Financial liabilities Measured at fair value through the statement of income Measured at amortized cost Measured at fair value through the statement of income Measured at amortized cost $ millions Current assets Cash and cash equivalents - 417 - - Short-term investments and deposits - 91 - - Trade receivables - 1,583 - - Other receivables - 55 - - Foreign currency derivative designated as economic hedge 3 - - - Foreign currency and interest derivative instruments designated as cash flow hedge 7 - - - Non-current assets Foreign currency and interest derivative instruments designated as cash flow hedge 19 - - - Other non-current assets - 35 - - Total financial assets 29 2,181 - - Current liabilities Short term debt - - - (512) Trade payables - - - (1,006) Other current liabilities - - - (198) Foreign currency derivative designated as economic hedge - - (28) - Foreign currency and interest derivative instruments designated as cash flow hedge - - (16) - Non-current liabilities Long term debt and debentures - - - ( 2,312) Foreign currency and interest derivative instruments designated as cash flow hedge - - (1) - Other non- current liabilities - - - (45) Total financial liabilities - - (45) (4,073) Total financial instruments, net 29 2,181 (45) (4,073) As of December 31, 2021 Financial assets Financial liabilities Measured at fair value through the statement of income Measured at amortized cost Measured at fair value through the statement of income Measured at amortized cost $ millions Current assets Cash and cash equivalents - 473 - - Short-term investments and deposits - 91 - - Trade receivables - 1,418 - - Other receivables - 45 - - Foreign currency derivative designated as economic hedge 23 - - - Marine transport derivative designated as economic hedge 2 - - - Foreign currency and interest derivative instruments designated as cash flow hedge 23 - - - Non-current assets Foreign currency and interest derivative instruments designated as cash flow hedge 97 - - - Other non-current assets - 14 - - Total financial assets 145 2,041 - - Current liabilities Short term debt - - - (577) Trade payables - - - (1,064) Other current liabilities - - - (153) Foreign currency derivative designated as economic hedge - - (3) - Non-current liabilities Long term debt and debentures - - - (2,436) Interest derivative instruments designated as economic hedge - - (7) - Other non- current liabilities - - - (49) Total financial liabilities - - (10) (4,279) Total financial instruments, net 145 2,041 (10) (4,279)
Schedule of maximum credit exposure	(2) Maximum Exposure to credit risk The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk at the reporting date was: As of December 31 Carrying amount ($ millions) 2022 2021 Cash and cash equivalents 417 473 Short term investments and deposits 91 91 Trade receivables 1,583 1,418 Other receivables 55 45 Derivatives 29 145 Other non-current assets 35 14 2,210 2,186
Schedule of maximum credit exposure by geographical region	The maximum exposure to credit risk for trade receivables, at the reporting date by geographic region was: As of December 31 Carrying amount ($ millions) 2022 2021 Asia 317 440 Europe 457 362 South America 434 306 North America 242 193 Israel 104 95 Other 31 22 1,585 1,418
Schedule of aging of debts and impairment losses	(3) Aging of debts and impairment losses The aging of trade receivables at the reporting date was: As of December 31 2022 2021 Gross Impairment Gross Impairment $ millions $ millions $ millions $ millions Not past due 1,485 (3) 1,313 (1) Past due up to 3 months 97 - 82 - Past due 3 to 12 months 10 (4) 23 (2) Past due over 12 months 1 (1) 9 (6) 1,593 (8) 1,427 (9)
Schedule of allowance of doubtful accounts	The movement in the allowance for doubtful accounts during the year was as follows: 2022 2021 $ millions $ millions Balance as of January 1 9 10 Additional allowance 1 (3) Reversals (2) (2) Changes due to translation differences - 4 Balance as of December 31 8 9
Schedule of liquidity risk	The following are the contractual maturities of financial liabilities, including estimated interest payments: As of December 31, 2022 Carrying amount 12 months or less 1-2 years 3-5 years More than 5 years $ millions Non-derivative financial liabilities Short term debt (not including current maturities) 313 322 - - - Trade payables 1,006 1,006 - - - Other current liabilities 198 198 - - - Long-term debt, debentures and others 2,555 288 1,080 547 1,468 4,072 1,814 1,080 547 1,468 Financial liabilities – derivative instruments Foreign currency and interest derivative designated as economic hedge 28 28 - - - As of December 31, 2021 Carrying amount 12 months or less 1-2 years 3-5 years More than 5 years $ millions Non-derivative financial liabilities Short term debt (not including current maturities) 327 329 - - - Trade payables 1,064 1,064 - - - Other current liabilities 153 153 - - - Long-term debt, debentures and others 2,735 352 1,003 799 1,532 4,279 1,898 1,003 799 1,532 Financial liabilities – derivative instruments Foreign currency and interest derivative designated as economic hedge 10 3 - 7 -
Schedule of interest rate profile	(a) Interest Rate Profile Set forth below are details regarding the type of interest on the Company’s non-derivative interest‑bearing financial instruments As of December 31 2022 2021 $ millions $ millions Fixed rate instruments Financial assets 339 338 Financial liabilities (2,140) (2,466) (1,801) (2,128) Variable rate instruments Financial assets 38 36 Financial liabilities (696) (562) (658) (526)
Schedule of sensitivity analysis for variable rate instruments	(c) Sensitivity analysis for variable rate instruments The below analysis assumes that all other variables (except for the interest rate), in particular foreign currency rates, remain constant. As of December 31, 2022 Impact on profit (loss) Decrease of 1% in interest Decrease of 0.5% in interest Increase of 0.5% in interest Increase of 1% in interest $ millions SWAP instruments Changes in Israeli Shekel interest 23 11 (10) (19)
Schedule of terms of derivative financial instruments used to hedge interest risk	(d) Terms of derivative financial instruments used to hedge interest risk As of December 31, 2022 Carrying amount Stated amount Maturity date Interest rate range $ millions $ millions Years % Israeli Shekel SWAP contracts from fixed ILS interest to fixed USD interest 23 462 2024-2034 2.4-4.74% As of December 31, 2021 Carrying amount Stated amount Maturity date Interest rate range $ millions $ millions Years % US Dollar SWAP contracts from variable interest to fixed interest (7) 150 2024 2.47%-2.60% Israeli Shekel SWAP contracts from fixed ILS interest to fixed USD interest 119 579 2034 2.40%-4.74%
Schedule of sensitivity analysis non-derivative financial instruments	(a) Sensitivity analysis A 10% increase at the rate of the US dollar against the following currencies would have increased (decreased) profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant. As of December 31 Impact on profit (loss) 2022 2021 $ millions $ millions Non-derivative financial instruments US Dollar/Euro (131) (80) US Dollar/Israeli Shekel 152 177 US Dollar/British Pound (1) (1) US Dollar/Japanese Yen (2) - US Dollar/Chinese Yuan 2 1 A 10% decrease of the US dollar against the above currencies as of December 31, 2022, would have the same effect but in the opposite direction.
Schedule of market risk sensitivity analysis	Presented hereunder is a sensitivity analysis of the Company’s foreign currency derivative instruments as of December 31, 2022. Any change in the exchange rates of the principal currencies shown below would have increased (decreased) profit and loss and equity by the amounts shown below. This analysis assumes that all other variables remain constant. As of December 31, 2022 Increase 10% Increase 5% Decrease 5% Decrease 10% $ millions US Dollar/Brazilian Real Forward transactions 10 5 (6) (12) US Dollar/Israeli Shekel Forward transactions (66) (35) 38 81 Forward transactions hedge accounting (31) (16) 18 38 Options (22) (12) 11 24 SWAP (42) (22) 25 53 US Dollar/British Pound Forward transactions (1) - - 1 Options (1) - - 1 Euro/ US Dollar Forward transactions 13 6 (8) (15) Options 4 2 (2) (5) Other Forward transactions 2 1 (1) (2)
Schedule of terms of derivative financial instruments used to economically hedge foreign currency risk	(b) Terms of derivative financial instruments used to reduce foreign currency risk As of December 31, 2022 Carrying amount Stated amount Average $ millions exchange rate Forward contracts US Dollar/Israeli Shekel (12) 746 3.4 Euro/US Dollar (4) 146 1.1 US Dollar/Brazilian Real 2 111 5.2 Euro/British Pound - (17) 1.2 US Dollar/British Pound - 11 1.2 Other (1) 35 - Forward contracts hedge accounting US Dollar/Israeli Shekel (14) 360 3.4 Currency and interest SWAPs US Dollar/Israeli Shekel 23 462 3.4 Put options US Dollar/Israeli Shekel (11) 240 3.4 Euro/US Dollar 1 47 1.1 US Dollar/Japanese Yen - 3 130.4 US Dollar/British Pound - 12 1.2 Call options US Dollar/Israeli Shekel 1 240 3.4 Euro/US Dollar (1) 47 1.1 US Dollar/Japanese Yen - 3 130.4 US Dollar/British Pound - 12 1.2 As of December 31, 2021 Carrying amount Stated amount Average $ millions exchange rate Forward contracts US Dollar/Israeli Shekel 3 515 3.2 Euro/US Dollar 4 240 1.2 US Dollar /Brazilian Real (1) 37 5.4 US Dollar/British Pound - 16 1.4 US Dollar/Chinese Yuan Renminbi 1 46 6.5 Other - 23 - Currency and interest SWAPs US Dollar/Israeli Shekel 119 579 3.7 Put options US Dollar/Israeli Shekel 14 660 3.2 Euro/US Dollar 2 57 1.2 US Dollar/Japanese Yen - 4 109.7 US Dollar/British Pound - 12 1.4 Call options US Dollar/Israeli Shekel (2) 660 3.2 Euro/US Dollar - 57 1.2 US Dollar/Japanese Yen - 4 109.7 US Dollar/British Pound - 12 1.4
Schedule of linkage terms of monetary balances	(c) Linkage terms of monetary balances – in millions of dollars As of December 31, 2022 US Dollar Euro British Pound Israeli Shekel Brazilian Real Chinese Yuan Renminbi Other Total Non-derivative instruments: Cash and cash equivalents 41 17 7 1 30 306 15 417 Short term investments and deposits 84 2 - - - 2 3 91 Trade receivables 659 329 73 89 308 78 47 1,583 Other receivables 15 18 1 12 1 - 8 55 Other non-current assets 25 2 - - 7 - 1 35 Total financial assets 824 368 81 102 346 386 74 2,181 Short-term debt 161 137 18 178 7 10 1 512 Trade payables 202 229 27 372 103 69 4 1,006 Other current liabilities 49 91 1 27 15 15 - 198 Long term debt, debentures and others 1,141 659 14 453 8 34 3 2,312 Other non-current liabilities - 44 - - 1 - - 45 Total financial liabilities 1,553 1,160 60 1,030 134 128 8 4,073 Total non-derivative financial instruments, net (729) (792) 21 (928) 212 258 66 (1,892) Derivative instruments: Forward transactions - 146 11 746 111 - 17 1,031 Forward transactions hedge accounting - - - 360 - - - - Cylinder - 47 12 240 - - 3 302 SWAPS – US dollar into Israeli Shekel - - - 462 - - - 462 Total derivative instruments - 193 23 1,808 111 - 20 2,155 Net exposure (729) (599) 44 880 323 258 86 263 As of December 31, 2021 US Dollar Euro British Pound Israeli Shekel Brazilian Real Chinese Yuan Renminbi Others Total Non-derivative instruments: Cash and cash equivalents 89 23 5 3 76 263 14 473 Short term investments and deposits 86 - - - - 3 2 91 Trade receivables 684 260 41 82 222 91 38 1,418 Other receivables 2 22 1 19 1 - - 45 Other non-current assets 4 4 - - 5 - 1 14 Total financial assets 865 309 47 104 304 357 55 2,041 Short-term debt 196 92 12 184 41 52 - 577 Trade payables 210 216 28 410 103 91 6 1,064 Other current liabilities 33 73 4 18 10 15 - 153 Long term debt, debentures and others 1,161 499 21 635 51 67 2 2,436 Other non-current liabilities 1 46 - - 2 - - 49 Total financial liabilities 1,601 926 65 1,247 207 225 8 4,279 Total non-derivative financial instruments, net (736) (617) (18) (1,143) 97 132 47 (2,238) Derivative instruments: Forward transactions - 240 16 515 37 46 23 877 Cylinder - 57 12 660 - - 4 733 SWAPS – US dollar into Israeli Shekel - - - 579 - - - 579 Total derivative instruments - 297 28 1,754 37 46 27 2,189 Net exposure (736) (320) 10 611 134 178 74 (49)
Schedule of fair value of financial instruments	The following table details the book value and the fair value of financial instrument groups presented in the financial statements not in accordance with their fair value: As of December 31, 2022 As of December 31, 2021 Carrying amount Fair value Carrying amount Fair value $ millions $ millions Loans bearing fixed interest (1) 339 302 407 408 Debentures bearing fixed interest Marketable (2) 1,335 1,270 1,524 1,730 Non-marketable (3) 195 191 195 208 1,869 1,763 2,126 2,346 (1 ) The fair value of the Shekel, Euro, Brazilian Real and Yuan loans issued bearing fixed interest is based on calculation of the present value of the cash flows in respect of the principal and the interest and is discounted at the market interest rates on the measurement date for similar loans having similar characteristics and is classified as Level 2 in the fair value hierarchy. The average discount interest as of December 31, 2022 for the Israeli Shekel, Euro, Brazilian Real and Yuan loans was 5.2%, 4.9%, 16.3% and 4.3%, respectively (December 31, 2021 for the Israeli Shekel, Euro Brazilian Real and Yuan loans 1.5%, 1.2%, 13% and 4%, respectively). (2) The fair value of the marketable debentures is based on the quoted stock exchange price and is classified as Level 1 in the fair value hierarchy. (3) The fair value of the non‑marketable debentures is based on calculation of the present value of the cash flows in respect of the principal and the interest and is discounted at the Libor rate customary in the market for similar loans having similar characteristics and is classified as Level 2 in the fair value hierarchy. The average discount interest as of December 31, 2022, was 7% (December 31, 2021 – 2.5%).
Schedule of hierarchy of fair value	The following levels were defined: Level 2: Observed data (directly or indirectly) not included in Level 1 above. Level 2 As of December 31, 2022 As of December 31, 2021 $ millions $ millions Derivatives designated as economic hedge, net (25) 15 Derivatives designated as cash flow hedge, net 9 120 (16) 135

Earnings per Share (Tables)

Earnings per Share (Tables)	12 Months Ended
Earnings per Share (Tables)	Dec. 31, 2022
Notes to Consolidated Financial Statements [Abstract]
Schedule of basic earnings per share	Calculation of the basic earnings per share for the year ended December 31, 2022, is based on the earnings allocated to the holders of the ordinary shares divided by the weighted-average number of ordinary shares outstanding, calculated as follows: For the year ended December 31 2022 2021 2020 $ millions $ millions $ millions Earnings attributed to the shareholders of the Company 2,159 783 11
Schedule of weighted average number of ordinary shares	Weighted-average number of ordinary shares in thousands: For the year ended December 31 2022 2021 2020 Shares thousands Shares thousands Shares thousands Balance as of January 1 1,285,585 1,280,242 1,279,379 Shares issued during the year - 223 29 Shares vested 1,719 2,342 618 Weighted average number of ordinary shares used in computation of the basic earnings per share 1,287,304 1,282,807 1,280,026
Schedule of weighted average number of ordinary shares diluted	Weighted average number of ordinary shares (diluted) in thousands: For the year ended December 31 2022 2021 2020 Shares thousands Shares thousands Shares thousands Weighted average number of ordinary shares used in the computation of the basic earnings per share 1,287,304 1,282,807 1,280,026 Effect of stock options and restricted shares 2,643 4,244 247 Weighted average number of ordinary shares used in the computation of the diluted earnings per share 1,289,947 1,287,051 1,280,273 * As of December 31, 2022, the outstanding options in the amount of 7 million, representing 2.6 million shares, were included in the diluted weighted average number of ordinary shares calculation. As of December 31, 2021, all 12 million outstanding options were included. As of December 31, 2020, 27 million options, were not included since they did not have a diluting effect.

Related and Interested Parties

Related and Interested Parties (Tables)	12 Months Ended
Related and Interested Parties (Tables)	Dec. 31, 2022
Related party transactions [abstract]
Schedule of benefits to key management personnel	For the year ended December 31 2022 2021 $ millions $ millions Short-term benefits 14 12 Post-employment benefits 1 1 Share-based payments 12 5 Total * 27 18 * To interested parties employed by the Company 7 3 * To interested parties not employed by the Company 1 1
Schedule of transactions with related and interested parties	For the year ended December 31 2022 2021 2020 $ millions $ millions $ millions Sales 7 7 3 Cost of sales 13 6 3 Selling, transport and marketing expenses 15 13 7 Financing income, net - ( 2 (1) General and administrative expenses 1 1 1 Management fees to the parent company 1 1 1
Schedule of balances with interested parties	As of December 31 2022 2021 $ millions $ millions Other current assets 34 40 Other current liabilities 2 4

Group Main Entities (Tables)

Group Main Entities (Tables)	12 Months Ended
Group Main Entities (Tables)	Dec. 31, 2022
Disclosure of subsidiaries [abstract]
Schedule of composition of group	Ownership interest in its subsidiary and investee companies for the year ended December 31 Name of company Principal location of the company’s activity 2022 2021 ICL Israel Ltd. Israel 100.00% 100.00% Dead Sea Works Ltd. Israel 100.00% 100.00% Dead Sea Bromine Company Ltd. Israel 100.00% 100.00% Rotem Amfert Negev Ltd. Israel 100.00% 100.00% Mifalei Tovala Ltd. Israel 100.00% 100.00% Dead Sea Magnesium Ltd. Israel 100.00% 100.00% Bromine Compounds Ltd. Israel 100.00% 100.00% Fertilizers and Chemicals Ltd. Israel 100.00% 100.00% Iberpotash S.A. Spain 100.00% 100.00% Fuentes Fertilizantes S.L. Spain 100.00% 100.00% ICL Europe Coöperatief U.A. The Netherlands 100.00% 100.00% ICL Europe B.V. The Netherlands 100.00% 100.00% ICL IP Terneuzen B.V The Netherlands 100.00% 100.00% ICL Finance BV The Netherlands 100.00% 100.00% Everris International B.V. The Netherlands 100.00% 100.00% ICL Puriphos B.V. The Netherlands 100.00% 100.00% ICL-IP America Inc United States of America 100.00% 100.00% ICL Specialty Products Inc United States of America 100.00% 100.00% Everris NA, Inc. United States of America 100.00% 100.00% Growers Holdings, Inc. United States of America 100.00% 100.00% BK Giulini GmbH Germany 100.00% 100.00% ICL Holding Germany GmbH Germany 100.00% 100.00% ICL Bitterfeld GmbH Germany 100.00% 100.00% Prolactal GmbH Austria 100.00% 100.00% Cleveland Potash Ltd. United Kingdom 100.00% 100.00% Everris Ltd. United Kingdom 100.00% 100.00% ICL America do Sul Brazil 100.00% 100.00% ICL Aditivos E Ingredientes LTDA Brazil 100.00% 100.00% Qualyquímica Industria e Comercio de Produtos Quimicos Ltda Brazil 100.00% 100.00% ICL Investment Co. Ltd. China 100.00% 100.00% Yunnan Phosphate Haikou Co. Ltd. China 50.00% 50.00% ICL Asia Ltd Hong Kong 100.00% 100.00% ICL Trading (HK) Ltd. Hong Kong 100.00% 100.00% Scora S.A.S., France France 100.00% 100.00%

Significant Accounting Polici_4

Significant Accounting Policies (Schedule of Estimated Useful LIves of Property, Plant and Equipment) (Details)	12 Months Ended
	Dec. 31, 2022
Buildings [Member] \| Minimum [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Life Depreciation in Years	15 years
Buildings [Member] \| Maximum [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Life Depreciation in Years	30 years
Technical equipment and machinery [Member] \| Minimum [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Life Depreciation in Years	5 years	[1]
Technical equipment and machinery [Member] \| Maximum [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Life Depreciation in Years	33 years	[1]
Dikes and evaporating ponds [Member] \| Minimum [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Life Depreciation in Years	20 years	[2]
Dikes and evaporating ponds [Member] \| Maximum [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Life Depreciation in Years	40 years	[2]
Other [Member] \| Minimum [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Life Depreciation in Years	3 years
Other [Member] \| Maximum [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Life Depreciation in Years	10 years

[1]Mainly 33 years[2]Mainly 40 years

Significant Accounting Polici_5

Significant Accounting Policies (Schedule of Estimated Useful LIves of Intangible Assets) (Details)	12 Months Ended
	Dec. 31, 2022
Trademarks [Member] \| Minimum [Member]
Intangible assets [Line Items]
Estimated Useful Life Amortization in Years	15 years
Trademarks [Member] \| Maximum [Member]
Intangible assets [Line Items]
Estimated Useful Life Amortization in Years	20 years
Technology / patents [Member] \| Minimum [Member]
Intangible assets [Line Items]
Estimated Useful Life Amortization in Years	7 years
Technology / patents [Member] \| Maximum [Member]
Intangible assets [Line Items]
Estimated Useful Life Amortization in Years	20 years
Customer relationships [Member] \| Minimum [Member]
Intangible assets [Line Items]
Estimated Useful Life Amortization in Years	15 years
Customer relationships [Member] \| Maximum [Member]
Intangible assets [Line Items]
Estimated Useful Life Amortization in Years	25 years
Computer applications [Member] \| Minimum [Member]
Intangible assets [Line Items]
Estimated Useful Life Amortization in Years	3 years
Computer applications [Member] \| Maximum [Member]
Intangible assets [Line Items]
Estimated Useful Life Amortization in Years	10 years

Operating Segments (Operating S

Operating Segments (Operating Segment Data) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Sales [Abstract]
Sales to external parties	$ 10,015	$ 6,955	$ 5,043
Inter-segment sales	0	0	0
Total sales	10,015	6,955	5,043
Operating income (loss) [Abstract]
Segment operating income (loss)	3,509	1,194	509
Other income not allocated to the segments	7	16	(307)
Operating income	3,516	1,210	202
Financing expenses, net	(113)	(122)	(158)
Share in earnings of equity-accounted investees	1	4	5
Income before income taxes	3,404	1,092	49
Depreciation and amortization	498	484	579
Capital expenditures	822	669	696
Capital expenditures as part of business combination		377	26
Industrial Products [Member]
Sales [Abstract]
Sales to external parties	1,737	1,601	1,242
Inter-segment sales	29	16	13
Total sales	1,766	1,617	1,255
Operating income (loss) [Abstract]
Segment operating income (loss)	628	435	303
Depreciation and amortization	61	65	77
Capital expenditures	90	74	84
Capital expenditures as part of business combination		0	0
Potash [Member]
Sales [Abstract]
Sales to external parties	3,031	1,598	1,091
Inter-segment sales	282	178	177
Total sales	3,313	1,776	1,268
Operating income (loss) [Abstract]
Segment operating income (loss)	1,822	399	121
Depreciation and amortization	166	148	152
Capital expenditures	346	270	270
Capital expenditures as part of business combination		0	0
Phosphate Solutions [Member]
Sales [Abstract]
Sales to external parties	2,851	2,087	1,663
Inter-segment sales	255	167	153
Total sales	3,106	2,254	1,816
Operating income (loss) [Abstract]
Segment operating income (loss)	777	294	88
Depreciation and amortization	189	207	204
Capital expenditures	259	228	267
Capital expenditures as part of business combination		0	0
Growing Solutions [Member]
Sales [Abstract]
Sales to external parties	2,376	1,644	1,016
Inter-segment sales	46	26	17
Total sales	2,422	1,670	1,033
Operating income (loss) [Abstract]
Segment operating income (loss)	378	135	17
Depreciation and amortization	70	62	45
Capital expenditures	101	74	54
Capital expenditures as part of business combination		377	0
Other Activities [Member]
Sales [Abstract]
Sales to external parties	20	25	31
Inter-segment sales	3	3	4
Total sales	23	28	35
Operating income (loss) [Abstract]
Segment operating income (loss)	(9)	(8)	(5)
Depreciation and amortization	3	2	3
Capital expenditures	9	6	6
Capital expenditures as part of business combination		0	26
Reconciliations [Member]
Sales [Abstract]
Sales to external parties	0	0	0
Inter-segment sales	(615)	(390)	(364)
Total sales	(615)	(390)	(364)
Operating income (loss) [Abstract]
Segment operating income (loss)	(87)	(61)	(15)
Depreciation and amortization	9	0	98
Capital expenditures	$ 17	17	15
Capital expenditures as part of business combination		$ 0	$ 0

Operating Segments (Sales by Ge

Operating Segments (Sales by Geographical Location of the Customer) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of geographical areas [Line Items]
Sales	$ 10,015	$ 6,955	$ 5,043
% of sales	100%	100%	100%
Brazil [Member]
Disclosure of geographical areas [Line Items]
Sales	$ 2,200	$ 1,178	$ 447
% of sales	22%	17%	9%
China [Member]
Disclosure of geographical areas [Line Items]
Sales	$ 1,495	$ 1,060	$ 806
% of sales	15%	15%	16%
USA [Member]
Disclosure of geographical areas [Line Items]
Sales	$ 1,457	$ 1,091	$ 793
% of sales	15%	16%	16%
India [Member]
Disclosure of geographical areas [Line Items]
Sales	$ 505	$ 213	$ 194
% of sales	5%	3%	4%
United Kingdom [Member]
Disclosure of geographical areas [Line Items]
Sales	$ 448	$ 386	$ 336
% of sales	4%	6%	7%
Germany [Member]
Disclosure of geographical areas [Line Items]
Sales	$ 417	$ 345	$ 327
% of sales	4%	5%	6%
Spain [Member]
Disclosure of geographical areas [Line Items]
Sales	$ 365	$ 280	$ 243
% of sales	4%	4%	5%
Israel [Member]
Disclosure of geographical areas [Line Items]
Sales	$ 344	$ 291	$ 260
% of sales	3%	4%	5%
France [Member]
Disclosure of geographical areas [Line Items]
Sales	$ 305	$ 270	$ 238
% of sales	3%	4%	5%
Netherlands [Member]
Disclosure of geographical areas [Line Items]
Sales	$ 264	$ 127	$ 95
% of sales	3%	2%	2%
All others [Member]
Disclosure of geographical areas [Line Items]
Sales	$ 2,215	$ 1,714	$ 1,304
% of sales	22%	24%	25%

Operating Segments (Sales by _2

Operating Segments (Sales by geographical location of the customer by Operating Segments) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of geographical areas [Line Items]
Sales	$ 10,015	$ 6,955	$ 5,043
Europe [Member]
Disclosure of geographical areas [Line Items]
Sales	2,809	2,159	1,822
Asia [Member]
Disclosure of geographical areas [Line Items]
Sales	2,743	1,876	1,432
South America [Member]
Disclosure of geographical areas [Line Items]
Sales	2,315	1,305	517
North America [Member]
Disclosure of geographical areas [Line Items]
Sales	1,577	1,186	859
Rest of the world [Member]
Disclosure of geographical areas [Line Items]
Sales	571	429	413
Industrial Products [Member]
Disclosure of geographical areas [Line Items]
Sales	1,766	1,617	1,255
Industrial Products [Member] \| Europe [Member]
Disclosure of geographical areas [Line Items]
Sales	574	530	458
Industrial Products [Member] \| Asia [Member]
Disclosure of geographical areas [Line Items]
Sales	664	597	405
Industrial Products [Member] \| South America [Member]
Disclosure of geographical areas [Line Items]
Sales	40	64	40
Industrial Products [Member] \| North America [Member]
Disclosure of geographical areas [Line Items]
Sales	401	363	299
Industrial Products [Member] \| Rest of the world [Member]
Disclosure of geographical areas [Line Items]
Sales	87	63	53
Potash [Member]
Disclosure of geographical areas [Line Items]
Sales	3,313	1,776	1,268
Potash [Member] \| Europe [Member]
Disclosure of geographical areas [Line Items]
Sales	698	430	376
Potash [Member] \| Asia [Member]
Disclosure of geographical areas [Line Items]
Sales	1,008	478	412
Potash [Member] \| South America [Member]
Disclosure of geographical areas [Line Items]
Sales	938	467	212
Potash [Member] \| North America [Member]
Disclosure of geographical areas [Line Items]
Sales	365	209	84
Potash [Member] \| Rest of the world [Member]
Disclosure of geographical areas [Line Items]
Sales	304	192	184
Phosphate Solutions [Member]
Disclosure of geographical areas [Line Items]
Sales	3,106	2,254	1,816
Phosphate Solutions [Member] \| Europe [Member]
Disclosure of geographical areas [Line Items]
Sales	881	611	557
Phosphate Solutions [Member] \| Asia [Member]
Disclosure of geographical areas [Line Items]
Sales	817	617	477
Phosphate Solutions [Member] \| South America [Member]
Disclosure of geographical areas [Line Items]
Sales	496	343	210
Phosphate Solutions [Member] \| North America [Member]
Disclosure of geographical areas [Line Items]
Sales	654	491	372
Phosphate Solutions [Member] \| Rest of the world [Member]
Disclosure of geographical areas [Line Items]
Sales	258	192	200
Growing Solutions [Member]
Disclosure of geographical areas [Line Items]
Sales	2,422	1,670	1,033
Growing Solutions [Member] \| Europe [Member]
Disclosure of geographical areas [Line Items]
Sales	880	727	561
Growing Solutions [Member] \| Asia [Member]
Disclosure of geographical areas [Line Items]
Sales	286	206	161
Growing Solutions [Member] \| South America [Member]
Disclosure of geographical areas [Line Items]
Sales	849	436	56
Growing Solutions [Member] \| North America [Member]
Disclosure of geographical areas [Line Items]
Sales	166	127	106
Growing Solutions [Member] \| Rest of the world [Member]
Disclosure of geographical areas [Line Items]
Sales	241	174	149
Other activities [Member]
Disclosure of geographical areas [Line Items]
Sales	23	28	35
Other activities [Member] \| Europe [Member]
Disclosure of geographical areas [Line Items]
Sales	18	23	30
Other activities [Member] \| Asia [Member]
Disclosure of geographical areas [Line Items]
Sales	0	1	1
Other activities [Member] \| South America [Member]
Disclosure of geographical areas [Line Items]
Sales	0	0	0
Other activities [Member] \| North America [Member]
Disclosure of geographical areas [Line Items]
Sales	1	1	2
Other activities [Member] \| Rest of the world [Member]
Disclosure of geographical areas [Line Items]
Sales	4	3	2
Reconciliations [Member]
Disclosure of geographical areas [Line Items]
Sales	(615)	(390)	(364)
Reconciliations [Member] \| Europe [Member]
Disclosure of geographical areas [Line Items]
Sales	(242)	(162)	(160)
Reconciliations [Member] \| Asia [Member]
Disclosure of geographical areas [Line Items]
Sales	(32)	(23)	(24)
Reconciliations [Member] \| South America [Member]
Disclosure of geographical areas [Line Items]
Sales	(8)	(5)	(1)
Reconciliations [Member] \| North America [Member]
Disclosure of geographical areas [Line Items]
Sales	(10)	(5)	(4)
Reconciliations [Member] \| Rest of the world [Member]
Disclosure of geographical areas [Line Items]
Sales	$ (323)	$ (195)	$ (175)

Operating Segments (Sales by _3

Operating Segments (Sales by Geographical Location of the Assets) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of geographical areas [Line Items]
Sales	$ 10,015	$ 6,955	$ 5,043
Israel [Member] \| Assets [Member]
Disclosure of geographical areas [Line Items]
Sales	5,611	3,526	2,636
Europe [Member]
Disclosure of geographical areas [Line Items]
Sales	2,809	2,159	1,822
Europe [Member] \| Assets [Member]
Disclosure of geographical areas [Line Items]
Sales	3,361	2,437	2,014
South America [Member]
Disclosure of geographical areas [Line Items]
Sales	2,315	1,305	517
South America [Member] \| Assets [Member]
Disclosure of geographical areas [Line Items]
Sales	1,994	1,095	424
Asia [Member]
Disclosure of geographical areas [Line Items]
Sales	2,743	1,876	1,432
Asia [Member] \| Assets [Member]
Disclosure of geographical areas [Line Items]
Sales	1,123	861	643
North America [Member]
Disclosure of geographical areas [Line Items]
Sales	1,577	1,186	859
North America [Member] \| Assets [Member]
Disclosure of geographical areas [Line Items]
Sales	1,038	897	757
Others [Member]
Disclosure of geographical areas [Line Items]
Sales	571	429	413
Others [Member] \| Assets [Member]
Disclosure of geographical areas [Line Items]
Sales	61	56	48
Subtotal [Member] \| Assets [Member]
Disclosure of geographical areas [Line Items]
Sales	13,188	8,872	6,522
Intercompany sales [Member] \| Assets [Member]
Disclosure of geographical areas [Line Items]
Sales	$ (3,173)	$ (1,917)	$ (1,479)

Operating Segments (Operating I

Operating Segments (Operating Income-Loss by Geographical Location of the Assets) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of geographical areas [Line Items]
Operating income	$ 3,516	$ 1,210	$ 202
Israel [Member]
Disclosure of geographical areas [Line Items]
Operating income	2,668	863	105
Europe [Member]
Disclosure of geographical areas [Line Items]
Operating income	445	7	(50)
Asia [Member]
Disclosure of geographical areas [Line Items]
Operating income	221	179	64
South America [Member]
Disclosure of geographical areas [Line Items]
Operating income	184	95	35
North America [Member]
Disclosure of geographical areas [Line Items]
Operating income	131	71	47
Others [Member]
Disclosure of geographical areas [Line Items]
Operating income	5	4	4
Intercompany eliminations [Member]
Disclosure of geographical areas [Line Items]
Operating income	$ (138)	$ (9)	$ (3)

Operating Segments (Non Current

Operating Segments (Non Current Assets by Geographical Location of the Assets) (Details) - USD ($) $ in Millions		Dec. 31, 2022	Dec. 31, 2021
Disclosure of geographical areas [Line Items]
Non-current assets	[1]	$ 6,900	$ 6,796
Israel [Member]
Disclosure of geographical areas [Line Items]
Non-current assets	[1]	4,208	4,079
Europe [Member]
Disclosure of geographical areas [Line Items]
Non-current assets	[1]	1,474	1,505
Asia [Member]
Disclosure of geographical areas [Line Items]
Non-current assets	[1]	461	483
South America [Member]
Disclosure of geographical areas [Line Items]
Non-current assets	[1]	407	391
North America [Member]
Disclosure of geographical areas [Line Items]
Non-current assets	[1]	346	333
Other [Member]
Disclosure of geographical areas [Line Items]
Non-current assets	[1]	$ 4	$ 5

[1]Mainly consist of property, plant and equipment, intangible assets and non-current inventories.

Inventories (Information) (Deta

Inventories (Information) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Classes of current inventories [abstract]
Finished products	$ 1,348	$ 946
Raw materials	490	349
Work in progress	233	299
Spare parts	128	125
Total inventories	2,199	1,719
Non-current inventories - mainly raw materials (presented as non-current assets)	65	149
Current inventories	$ 2,134	$ 1,570

Prepaid expenses and other re_3

Prepaid expenses and other receivables (information) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Trade and other receivables [abstract]
Government institutions	$ 111	$ 97
Prepaid expenses	70	51
Current tax assets	53	97
Derivative instruments	10	48
Other	79	64
Total other receivables	$ 323	$ 357

Investments in Subsidiaries (Na

Investments in Subsidiaries (Narratives) (Details) $ in Millions	1 Months Ended	12 Months Ended
	Jan. 31, 2022 USD ($)	Feb. 03, 2023 USD ($)	Dec. 31, 2022 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021
Disclosure of detailed information about business combination [line items]
Percentage of acquisition of business			25%
Total consideration			$ 258
Description of take or pay agreement			Company engaged in a long-term take-or-pay supply agreement for all the vacuum salt produced at ICL Iberia.
Novetide Ltd [Member]
Disclosure of detailed information about business combination [line items]
Percentage of shares sell	50
Consideration, equity method				$ 33
Sales consideration				$ 8
Capital gain	$ 22
Nobian’s Holding [Member]
Disclosure of detailed information about business combination [line items]
Percentage of acquisition of business					51%
Percentage of shares sell		100
Total consideration		$ 13

Investments in Subsidiaries (No

Investments in Subsidiaries (Non-Controlling Interests in Subsidiaries - Balance Sheet) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Investments in subsidiaries and investee companies [Line Items]
Current assets	$ 4,548,000	$ 3,909,000
Non-current assets	7,202,000	7,171,000
Current liabilities	(2,606,000)	(2,612,000)
Non-current liabilities	(3,431,000)	(3,732,000)
Equity	(5,713,000)	(4,736,000)	$ (4,088,000)	$ (4,061,000)
Non-controlling interests [Member]
Investments in subsidiaries and investee companies [Line Items]
Current assets	267	231
Non-current assets	392	408
Current liabilities	(145)	(168)
Non-current liabilities	(48)	(83)
Equity	$ (466)	$ (388)

Investments in Subsidiaries (_2

Investments in Subsidiaries (Non-Controlling Interests in Subsidiaries - Profit and Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Investments in subsidiaries and investee companies [Line Items]
Sales	$ 10,015	$ 6,955	$ 5,043
Operating Income	3,516	1,210	202
Depreciation and amortization	498	484	579
Net Income	2,219	832	24
Total Comprehensive income	2,130	921	138
Non-controlling interests [Member]
Investments in subsidiaries and investee companies [Line Items]
Sales	723	528	359
Operating Income	146	105	29
Depreciation and amortization	34	38	37
Operating income before depreciation and amortization	180	143	66
Net Income	116	96	23
Total Comprehensive income	$ 78	$ 104	$ 40

Other non-current assets (Infor

Other non-current assets (Information) (Details) - USD ($) $ in Millions		Dec. 31, 2022	Dec. 31, 2021
Other Noncurrent Assets [Abstract]
Surplus in employees' defined benefit plans	[1]	$ 97	$ 115
Non-current inventories		65	149
Receivables from equity-accounted investees sale	[2]	22	0
Derivative designated as a cash flow hedge		19	97
Investments in equity-accounted investees		3	26
Other		25	16
Total other non-current assets		$ 231	$ 403

[1]See Note 16.[2]See Note 8B(1).

Property, Plant and Equipment_2

Property, Plant and Equipment (Information) (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year		$ 5,754
Reversal of impairment		0	$ 9		$ 0
Balance at end of year		5,969	5,754
Depreciated balance at end of year		5,969	5,754
Gross [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year		12,491	12,017
Additions in respect of business combinations			125
Additions		789	642
Disposals		(69)	(73)
Exit from consolidation			(33)
Translation differences		(231)	(187)
Balance at end of year		12,980	12,491		12,017
Depreciated balance at end of year		12,980	12,491		12,017
Accumulated depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year		(6,737)	(6,467)
Depreciation		(458)	(454)
Reversal of impairment			6
Disposals		59	62
Exit from consolidation			22
Translation differences		125	94
Balance at end of year		(7,011)	(6,737)		(6,467)
Depreciated balance at end of year		(7,011)	(6,737)		(6,467)
Land and buildings [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year		605
Balance at end of year		574	605
Depreciated balance at end of year		574	605
Land and buildings [Member] \| Gross [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year		1,107	880
Additions in respect of business combinations			85
Additions		30	193
Disposals		(15)	(2)
Exit from consolidation			(9)
Translation differences		(36)	(40)
Balance at end of year		1,086	1,107		880
Depreciated balance at end of year		1,086	1,107		880
Land and buildings [Member] \| Accumulated depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year		(502)	(491)
Depreciation		(35)	(30)
Reversal of impairment			0
Disposals		7	5
Exit from consolidation			3
Translation differences		18	11
Balance at end of year		(512)	(502)		(491)
Depreciated balance at end of year		(512)	(502)		(491)
Technical equipment and machinery [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year		3,254
Balance at end of year		3,320	3,254
Depreciated balance at end of year		3,320	3,254
Technical equipment and machinery [Member] \| Gross [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year		7,664	7,419
Additions in respect of business combinations			20
Additions		358	382
Disposals		(27)	(44)
Exit from consolidation			(21)
Translation differences		(130)	(92)
Balance at end of year		7,865	7,664		7,419
Depreciated balance at end of year		7,865	7,664		7,419
Technical equipment and machinery [Member] \| Accumulated depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year		(4,410)	(4,300)
Depreciation		(243)	(227)
Reversal of impairment			6
Disposals		25	34
Exit from consolidation			19
Translation differences		83	58
Balance at end of year		(4,545)	(4,410)		(4,300)
Depreciated balance at end of year		(4,545)	(4,410)		(4,300)
Dikes and evaporating ponds [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year		668
Balance at end of year		1,005	668
Depreciated balance at end of year		1,005	668
Dikes and evaporating ponds [Member] \| Gross [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year		1,465	1,441
Additions in respect of business combinations			0
Additions		388	51
Disposals		0	(1)
Exit from consolidation			0
Translation differences		(19)	(26)
Balance at end of year		1,834	1,465		1,441
Depreciated balance at end of year		1,834	1,465		1,441
Dikes and evaporating ponds [Member] \| Accumulated depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year		(797)	(763)
Depreciation		(47)	(55)
Reversal of impairment			0
Disposals		0	0
Exit from consolidation			0
Translation differences		15	21
Balance at end of year		(829)	(797)		(763)
Depreciated balance at end of year		(829)	(797)		(763)
Plants under construction [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year	[1]	664
Balance at end of year	[1]	518	664
Depreciated balance at end of year	[1]	518	664
Plants under construction [Member] \| Gross [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year	[1]	664	778
Additions in respect of business combinations	[1]		(9)
Additions	[1]	(128)	(99)
Disposals	[1]	0	0
Exit from consolidation	[1]		0
Translation differences	[1]	(18)	(24)
Balance at end of year	[1]	518	664		778
Depreciated balance at end of year	[1]	518	664		778
Plants under construction [Member] \| Accumulated depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year	[1]	0	0
Depreciation	[1]	0	0
Reversal of impairment	[1]		0
Disposals	[1]	0	0
Exit from consolidation	[1]		0
Translation differences	[1]	0	0
Balance at end of year	[1]	0	0		0
Depreciated balance at end of year	[1]	0	0		0
Other [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year		192
Balance at end of year		208	192
Depreciated balance at end of year		208	192
Other [Member] \| Gross [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year		1,073	1,003
Additions in respect of business combinations			2
Additions		77	78
Disposals		0	(6)
Exit from consolidation			(1)
Translation differences		(6)	(3)
Balance at end of year		1,144	1,073		1,003
Depreciated balance at end of year		1,144	1,073		1,003
Other [Member] \| Accumulated depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year		(881)	(817)
Depreciation		(59)	(71)
Reversal of impairment			0
Disposals		0	4
Exit from consolidation			0
Translation differences		4	3
Balance at end of year		(936)	(881)		(817)
Depreciated balance at end of year		(936)	(881)		(817)
Right of use assets [member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year	[2]	371
Balance at end of year		344	371	[2]
Depreciated balance at end of year		344	371	[2]
Right of use assets [member] \| Gross [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year	[2]	518	496
Additions in respect of business combinations	[2]		9
Additions	[2]	64	37
Disposals	[2]	(27)	(20)
Exit from consolidation	[2]		(2)
Translation differences	[2]	(22)	(2)
Balance at end of year	[2]	533	518		496
Depreciated balance at end of year	[2]	533	518		496
Right of use assets [member] \| Accumulated depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year	[2]	(147)	(96)
Depreciation	[2]	(74)	(71)
Reversal of impairment			0
Disposals	[2]	27	19
Exit from consolidation	[2]		0
Translation differences	[2]	5	1
Balance at end of year	[2]	(189)	(147)		(96)
Depreciated balance at end of year	[2]	$ (189)	$ (147)		$ (96)

[1]The additions are presented net of items for which construction has been completed and accordingly were reclassified to other categories in the “property, plant and equipment” section.[2]The total additions were recorded against lease liabilities (IFRS 16).

Intangible Assets (Composition)

Intangible Assets (Composition) (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Balance at beginning of period		$ 867
Balance at end of period		852	$ 867
Gross [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Balance at beginning of period		1,319	1,107
Additions in respect of business combinations			252
Additions		33	27
Adjustment to PPA	[1]	5
Translation differences		(24)	(67)
Balance at end of period		1,333	1,319
Accumulated impairment [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Balance at beginning of period		(452)	(437)
Amortization for the year		(40)	(36)
Translation differences		11	21
Balance at end of period		(481)	(452)
Goodwill [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Balance at beginning of period		502
Balance at end of period		507	502
Goodwill [Member] \| Gross [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Balance at beginning of period		522	341
Additions in respect of business combinations			210
Additions		0	0
Adjustment to PPA	[1]	5
Translation differences		(1)	(29)
Balance at end of period		526	522
Goodwill [Member] \| Accumulated impairment [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Balance at beginning of period		(20)	(21)
Amortization for the year		0	0
Translation differences		1	1
Balance at end of period		(19)	(20)
Concessions and mining rights [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Balance at beginning of period		135
Balance at end of period		125	135
Concessions and mining rights [Member] \| Gross [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Balance at beginning of period		215	218
Additions in respect of business combinations			0
Additions		2	0
Adjustment to PPA	[1]	0
Translation differences		(7)	(3)
Balance at end of period		210	215
Concessions and mining rights [Member] \| Accumulated impairment [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Balance at beginning of period		(80)	(74)
Amortization for the year		(6)	(6)
Translation differences		1	0
Balance at end of period		(85)	(80)
Trademarks [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Balance at beginning of period		54
Balance at end of period		50	54
Trademarks [Member] \| Gross [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Balance at beginning of period		88	92
Additions in respect of business combinations			1
Additions		0	0
Adjustment to PPA	[1]	0
Translation differences		(4)	(5)
Balance at end of period		84	88
Trademarks [Member] \| Accumulated impairment [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Balance at beginning of period		(34)	(34)
Amortization for the year		(2)	(3)
Translation differences		2	3
Balance at end of period		(34)	(34)
Technology / patents [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Balance at beginning of period		39
Balance at end of period		48	39
Technology / patents [Member] \| Gross [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Balance at beginning of period		97	93
Additions in respect of business combinations			2
Additions		9	6
Adjustment to PPA	[1]	6
Translation differences		(4)	(4)
Balance at end of period		108	97
Technology / patents [Member] \| Accumulated impairment [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Balance at beginning of period		(58)	(55)
Amortization for the year		(5)	(5)
Translation differences		3	2
Balance at end of period		(60)	(58)
Customer relationships [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Balance at beginning of period		72
Balance at end of period		50	72
Customer relationships [Member] \| Gross [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Balance at beginning of period		203	172
Additions in respect of business combinations			39
Additions		0	1
Adjustment to PPA	[1]	(6)
Translation differences		(3)	(9)
Balance at end of period		194	203
Customer relationships [Member] \| Accumulated impairment [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Balance at beginning of period		(131)	(123)
Amortization for the year		(15)	(12)
Translation differences		2	4
Balance at end of period		(144)	(131)
Computer application [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Balance at beginning of period		50
Balance at end of period		60	50
Computer application [Member] \| Gross [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Balance at beginning of period		124	118
Additions in respect of business combinations			0
Additions		20	19
Adjustment to PPA	[1]	0
Translation differences		(2)	(13)
Balance at end of period		142	124
Computer application [Member] \| Accumulated impairment [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Balance at beginning of period		(74)	(76)
Amortization for the year		(9)	(7)
Translation differences		1	9
Balance at end of period		(82)	(74)
Other Intangible Assets [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Balance at beginning of period		15
Balance at end of period		12	15
Other Intangible Assets [Member] \| Gross [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Balance at beginning of period		70	73
Additions in respect of business combinations			0
Additions		2	1
Adjustment to PPA	[1]	0
Translation differences		(3)	(4)
Balance at end of period		69	70
Other Intangible Assets [Member] \| Accumulated impairment [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Balance at beginning of period		(55)	(54)
Amortization for the year		(3)	(3)
Translation differences		1	2
Balance at end of period		$ (57)	$ (55)

[1]In July 2022, the Company completed the ADS’s Purchase Price Allocation (PPA).

Intangible Assets (Total Book V

Intangible Assets (Total Book Value of Intangible Assets ) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Intangible assets and goodwill [abstract]
Intangible assets having a defined useful life	$ 313	$ 333
Intangible assets having an indefinite useful life	539	534
Total intangible assets	$ 852	$ 867

Impairment Testing (Narratives)

Impairment Testing (Narratives) (Details)	Dec. 31, 2022
Impairment Testing [Abstract]
After-tax discount rate used in calculation of the recoverable amount of the operating segments (nominal)	10.40%
Long-term growth rate	2.60%

Impairment Testing (Carrying Am

Impairment Testing (Carrying Amounts of Intangible Assets) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Intangible assets having an indefinite useful life [Line Items]
Intangible assets having an indefinite useful life	$ 539	$ 534
Goodwill [Member]
Intangible assets having an indefinite useful life [Line Items]
Intangible assets having an indefinite useful life	507	502
Trademarks [Member]
Intangible assets having an indefinite useful life [Line Items]
Intangible assets having an indefinite useful life	32	32
Phosphate Solutions [Member] \| Goodwill [Member]
Intangible assets having an indefinite useful life [Line Items]
Intangible assets having an indefinite useful life	110	114
Industrial Products [Member] \| Goodwill [Member]
Intangible assets having an indefinite useful life [Line Items]
Intangible assets having an indefinite useful life	90	91
Growing Solutions [Member] \| Goodwill [Member]
Intangible assets having an indefinite useful life [Line Items]
Intangible assets having an indefinite useful life	271	260
Potash [Member] \| Goodwill [Member]
Intangible assets having an indefinite useful life [Line Items]
Intangible assets having an indefinite useful life	20	19
Other [Member] \| Goodwill [Member]
Intangible assets having an indefinite useful life [Line Items]
Intangible assets having an indefinite useful life	$ 16	$ 18

Credit from Banks and Others (N

Credit from Banks and Others (Narratives) (Details) ₪ in Millions, R$ in Millions, $ in Millions	1 Months Ended				12 Months Ended
	Apr. 30, 2022 BRL (R$)	Apr. 30, 2022 USD ($)	Mar. 31, 2022 ILS (₪)	Mar. 31, 2022 USD ($)	Dec. 31, 2022 ILS (₪)	Dec. 31, 2022 USD ($)	Jul. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Borrowings From Banks And Others [Line Items]
Total guarantees the Company provided including to an associated Company						$ 127		$ 93
Limit guarantees and indemnities to third parties up to an agreed amount						550
Utilization of the securitization facility						$ 233		$ 180
Net debt to EBITDA under securitization agreements						4.75
Percentage of direct and indirect scope of sustainability performance targets					25%	25%
Amount of securitization agreements with committed value						$ 300
Amount of securitization agreements with uncommitted value						$ 100
Percentage of voting rights						25%
Increased (decreased) revolving credit facility capacity							$ (100)
Revolving credit facility							1,100
Total expected credit facility from all banks							$ 1,000
Private Placement Bond [Member]
Borrowings From Banks And Others [Line Items]
Repayments of bonds					₪ 15	$ 4
Series E Bond [Member]
Borrowings From Banks And Others [Line Items]
Repayments of bonds			₪ 392	$ 123
MUFG Bank [Member]
Borrowings From Banks And Others [Line Items]
Repayments of bonds \| R$	R$ 180
Terminate credit facility	R$ 230	$ 48

Credit from Banks and Others (C

Credit from Banks and Others (Composition) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Short-term debt
From financial institutions	$ 313	$ 327
Current maturities of: Debentures	116	131
Long-term loans from financial institutions	15	56
Lease liability	68	63
Total current maturities of short-term debt	199	250
Total short-term debt	512	577
Long- term debt and debentures
Long term lease liability	270	299
Loans from financial institutions	721	679
Total long- term debt and debentures	991	978
Marketable debentures	1,329	1,517
Non-marketable Debentures	191	191
Total Marketable Debentures	1,520	1,708
Total Long Term Debt And Marketable Debentures	2,511	2,686
Less – current maturities of: Debentures	116	131
Long-term loans from financial institutions	15	56
Lease liability	68	63
Total current maturities of short-term debt	199	250
Long-term debt, debentures and others	$ 2,312	$ 2,436

Credit from Banks and Others (Y

Credit from Banks and Others (Yearly movement in Credit from Banks and Others) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Credit From Banks And Others [Abstract]
Balance as at January 1	$ 2,914	$ 2,660
Changes from financing cash flows
Additions in respect of business combination	0	171
Receipt of long-term debts	1,045	1,230	$ 1,175
Repayment of long-term debt	(1,181)	(1,120)
Repayment of short-term credit	(21)	(58)
Interest paid	(113)	(112)
Receipt (payments) from transaction in derivatives	20	17
Total net financing cash flows	(250)	94
Initial recognition of lease liability	64	37
Interest expenses	148	126
Effect of changes in foreign exchange rates	(97)	(21)
Change in fair value of derivatives	67	(24)
Other changes	(33)	42
Balance as at December 31	$ 2,813	$ 2,914	$ 2,660

Credit from Banks and Others (I

Credit from Banks and Others (Information on Material Loans and Debentures) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Debentures Series F [Member] \| May 2018, December 2020 [Member] \| US Dollar [Member]
Disclosure of material loans and debentures [Line Items]
Original amount	$ 693
Carrying amount	$ 714
Interest rate	6.38%
Principal repayment date	May 2038
Debentures Series E [Member] \| April 2016 [Member] \| Israel, New Shekels
Disclosure of material loans and debentures [Line Items]
Original amount	$ 1,569
Carrying amount	$ 223
Interest rate	2.45%
Principal repayment date	2021- 2024 (Annual installment)
Debentures (private offering) - 3 series [Member] \| January 2014 [Member] \| US Dollar [Member]
Disclosure of material loans and debentures [Line Items]
Original amount	$ 275
Carrying amount	$ 145
Interest rate	5.16% 5.31%
Principal repayment date	January 2024 January 2026
Debentures (private offering) - 3 series [Member] \| January 2014 [Member] \| US Dollar [Member]
Disclosure of material loans and debentures [Line Items]
Carrying amount	$ 46
Debentures Series G [Member] \| January/May 2020 [Member] \| Israel, New Shekels
Disclosure of material loans and debentures [Line Items]
Original amount	766
Carrying amount	$ 208
Interest rate	2.40%
Principal repayment date	2022- 2034 (Annual installment)
Debentures Series D [Member] \| December 2014 [Member] \| US Dollar [Member]
Disclosure of material loans and debentures [Line Items]
Original amount	$ 184
Carrying amount	$ 184
Interest rate	4.50%
Principal repayment date	December 2024
Sustainability linked loan (SLL) [Member] \| September 2021 [Member] \| Euro Member Countries, Euro
Disclosure of material loans and debentures [Line Items]
Original amount	$ 250
Carrying amount	$ 266
Interest rate	0.80
Principal repayment date	September 2026
Loan from European Bank [Member] \| September 2021 [Member] \| GBP [Member]
Disclosure of material loans and debentures [Line Items]
Original amount	$ 25
Carrying amount	$ 27
Interest rate	0.95%
Principal repayment date	June 2025
Loan-Israeli Institutions [Member] \| November 2013 [Member] \| Israel, New Shekels
Disclosure of material loans and debentures [Line Items]
Original amount	$ 300
Carrying amount	$ 40
Interest rate	4.74%
Principal repayment date	2015-2024 (Annual installment)

Credit from Banks and Others _2

Credit from Banks and Others (Credit Facilities) (Details)	12 Months Ended
Credit from Banks and Others (Credit Facilities) (Details)	Dec. 31, 2022
Group Of International Banks [Member]
Disclosure of material loans and debentures [Line Items]
Date of the credit facility	March 2015
Date of credit facility termination	March 2025
The amount of the credit facility	USD 1,100 million	[1]
Credit facility has been utilized	Euro 330 million
Interest rate	Up to 33% use of the credit: Libor/Euribor + 0.70%. From 33% to 66% use of the credit: Libor/Euribor + 0.80% 66% or more use of the credit: Libor/Euribor + 0.95%
Loan currency type	USD and Euro loans
Pledges and restrictions	Financial covenants - see Section D, a cross-default mechanism and a negative pledge.
Non-utilization fee	0.21%
European bank [Member]
Disclosure of material loans and debentures [Line Items]
Date of the credit facility	December 2016
Date of credit facility termination	May 2024
The amount of the credit facility	USD 30 million
Credit facility has been utilized	USD 30 million
Interest rate	Libor + 0.80%
Loan currency type	USD loans
Pledges and restrictions	Financial covenants - see Section D and a negative pledge.
Non-utilization fee	0%

[1]In July 2022, the long-term credit facility decreased by $100 million following an agreement on early termination with one of the banks, a few months prior to the official termination date. The updated total credit facility is $1,100 million. most banks signed on to continue the credit facility agreement, and from March 2023 to March 2025, the total credit facility will amount to $1,000 million.

Credit from Banks and Others (R

Credit from Banks and Others (Restrictions on the Group Relating to the Receipt of Credit) (Details) $ in Millions	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Credit From Banks And Others [Abstract]
Financial covenants total shareholder's greater than $2,000 million	$ 5,464	$ 4,527
Financial Covenant: Ratio of the EBITDA to the net interest expenses equal to or greater than 3.5	39.79
Financial Covenant: Ratio of the net financial debt to EBITDA less than 3.5	0.53
Financial Covenant: Ratio of certain subsidiaries loans to the total assets of the consolidated company less than 10%	2.69%

Other Payables (Information) (D

Other Payables (Information) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Trade and other payables [abstract]
Employees	$ 368	$ 414
Current tax liabilities	177	183
Governmental (mainly in respect of royalties)	168	103
Accrued expenses	98	75
Derivative instruments	44	3
Income received in advance	41	33
Others	111	101
Other payables	$ 1,007	$ 912

Taxes on Income (Narratives) (D

Taxes on Income (Narratives) (Details) ₪ in Millions	3 Months Ended	12 Months Ended
Taxes on Income (Narratives) (Details) ₪ in Millions	Jun. 30, 2022 USD ($)	Dec. 31, 2022 ILS (₪)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020	Dec. 31, 2008	Dec. 31, 2022 USD ($)
Deferred income taxes [Line Items]
Income tax rate		23%	23%	23%	23%
Tax provision \| ₪		₪ 47
Unreleased trapped earnings amount		₪ 950	$ 270,000,000
Carryforward tax losses of subsidiaries for which deferred taxes recorded				$ 286,000,000			$ 384,000,000
Carryforward tax losses for which deferred taxes were not recorded				338,000,000			$ 109,000,000
Capital losses for which deferred taxes were not recorded			$ 142,000,000	$ 161,000,000
Royalty percentage for resources produced from the quarries		5%	5%
Amount of magnesium charge DSW per tone			$ 100
Percentage of revenue generates from bromine compounds sales		12%	12%
Percentage of revenue generates from downstream phosphate products sales		12%	12%
Amount of tax expenses for prior years	$ 188,000,000
Amount of interest and linkage net of corporate income tax	$ 124,000,000
Demand for payment of surplus profit levy by Israeli Tax Authority			$ 77,000,000
IRELAND [Member]
Deferred income taxes [Line Items]
Reduced tax rate percentage						11.50%
Israel [Member] \| Preferred Enterprises Located In Development Area [Member]
Deferred income taxes [Line Items]
Income tax rate		7.50%	7.50%
Israel [Member] \| Preferred Enterprises Located In Rest Of Country [Member]
Deferred income taxes [Line Items]
Income tax rate		16%	16%

Taxes on Income (Tax rates of s

Taxes on Income (Tax rates of subsidiaries outside Israel) (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Deferred income taxes [Line Items]
Tax rate	23%	23%	23%
Brazil [Member]
Deferred income taxes [Line Items]
Tax rate	34%
Germany [Member]
Deferred income taxes [Line Items]
Tax rate	29%
United States [Member]
Deferred income taxes [Line Items]
Tax rate	1%
Additional information for tax rate	The tax rate is an estimated average and includes federal and states tax. Different rate may apply in each specific year, as a result of different allocation of income between the different states.
Netherlands [Member]
Deferred income taxes [Line Items]
Tax rate	25.80%
Spain [Member]
Deferred income taxes [Line Items]
Tax rate	25%
China [Member]
Deferred income taxes [Line Items]
Tax rate	25%
United Kingdom [Member]
Deferred income taxes [Line Items]
Tax rate	19%

Taxes on Income (Deferred incom

Taxes on Income (Deferred income taxes) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Deferred income taxes [Line Items]
Balance as at the begining of the year	$ (237)	$ (199)
Additions in respect of business combinations		13
Amounts recorded in the statement of income	(24)	(20)
Amounts recorded to a capital reserve	(8)	(23)
Translation differences	(4)	(8)
Balance as at the end of the year	(273)	(237)
Depreciable property, plant and equipment and intangible assets [Member]
Deferred income taxes [Line Items]
Balance as at the begining of the year	(421)	(439)
Additions in respect of business combinations		0
Amounts recorded in the statement of income	(127)	16
Amounts recorded to a capital reserve	0	0
Translation differences	1	2
Balance as at the end of the year	(547)	(421)
Inventories [Member]
Deferred income taxes [Line Items]
Balance as at the begining of the year	39	38
Amounts recorded in the statement of income	33	0
Amounts recorded to a capital reserve	0	0
Translation differences	0	0
Balance as at the end of the year	72	39
Provisions for employee benefits [Member]
Deferred income taxes [Line Items]
Balance as at the begining of the year	73	94
Additions in respect of business combinations		1
Amounts recorded in the statement of income	4	2
Amounts recorded to a capital reserve	(12)	(22)
Translation differences	(1)	(2)
Balance as at the end of the year	64	73
Other [Member]
Deferred income taxes [Line Items]
Balance as at the begining of the year	(16)	(7)
Additions in respect of business combinations		9
Amounts recorded in the statement of income	31	(14)
Amounts recorded to a capital reserve	4	(1)
Translation differences	0	(3)
Balance as at the end of the year	19	(16)
In respect of carry forward tax losses [Member]
Deferred income taxes [Line Items]
Balance as at the begining of the year	88	115
Additions in respect of business combinations		2
Amounts recorded in the statement of income	35	(24)
Amounts recorded to a capital reserve	0	0
Translation differences	(4)	(5)
Balance as at the end of the year	$ 119	$ 88

Taxes on Income (Deferred Taxes

Taxes on Income (Deferred Taxes by Currency) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Deferred income taxes [Line Items]
Deferred income taxes	$ (273)	$ (237)	$ (199)
Euro Member Countries, Euro
Deferred income taxes [Line Items]
Deferred income taxes	51	84
Brazilian Real [Member]
Deferred income taxes [Line Items]
Deferred income taxes	28	13
British Pound [Member]
Deferred income taxes [Line Items]
Deferred income taxes	16	0
US Dollar [Member]
Deferred income taxes [Line Items]
Deferred income taxes	(8)	(10)
Israel, New Shekels
Deferred income taxes [Line Items]
Deferred income taxes	(368)	(327)
Other [Member]
Deferred income taxes [Line Items]
Deferred income taxes	$ 8	$ 3

Taxes on Income (Composition) (

Taxes on Income (Composition) (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Major components of tax expense (income) [abstract]
Current taxes		$ 869	$ 145	$ 70
Deferred taxes		45	22	(43)
Taxes in respect of prior years	[1]	271	93	(2)
Income taxes		$ 1,185	$ 260	$ 25

[1]For 2022, included $275 million relating to Surplus Profit Levy, of which $188 in respect of the settlement agreement as mentioned above.

Taxes on Income (Theoretical Ta

Taxes on Income (Theoretical Tax) (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Major components of tax expense (income) [abstract]
Income before income taxes, as reported in the statements of income		$ 3,404	$ 1,092	$ 49
Statutory tax rate (in Israel)		23%	23%	23%
Theoretical tax expense		$ 783	$ 251	$ 11
Add (less) - the tax effect of:
Surplus Profit Levy Tax		265	0	0
Reduced tax due to tax benefits		(95)	(64)	(6)
Differences deriving from additional deduction and different tax rates applicable to foreign subsidiaries		1	(10)	(4)
Tax on dividend		5	3	2
Deductible temporary differences (including carryforward losses) for which deferred taxes assets were not recorded and non-deductible expenses		(29)	(8)	14
Taxes in respect of prior years	[1]	271	93	(2)
Differences in measurement basis		(21)	(8)	10
Other Differences		5	3	0
Taxes on income included in the income statements		1,185	$ 260	$ 25
Tax expense including surplus profit levy		275
Tax expense including surplus profit levy in settlement agreement		$ 188

[1]For 2022, included $275 million relating to Surplus Profit Levy, of which $188 in respect of the settlement agreement as mentioned above.

Taxes on Income (Items Recorded

Taxes on Income (Items Recorded in Equity) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Major components of tax expense (income) [abstract]
Actuarial gains from defined benefit plan	$ (12)	$ (22)	$ (6)
Change in investments at fair value through other comprehensive income	0	(21)	0
Change in fair value of hedging derivatives	4	0	0
Taxes in respect of exchange rate differences on equity loan to a subsidiary included in translation adjustment	(11)	(1)	(3)
Tax recorded in other comprehensive income	$ (19)	$ (44)	$ (9)

Employee Benefits (Narratives)

Employee Benefits (Narratives) (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Nov. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of pension and early retirement plan		Some of the Company’s employees in and outside of Israel have defined benefit pension plans for their retirement, which are controlled by the Company. Generally, according to the terms of the plans, as stated, the employees are entitled to receive pension payments based on, among other things, their number of years of service (in certain cases up to 70% of their last base salary) or computed, in certain cases, based on a fixed salary. Some employees of a subsidiary in Israel are entitled to early retirement if they meet certain conditions, including age and seniority at the time of retirement.
Actual return (loss) on plan assets		$ (135)	$ 23	$ 14
Expenses recorded in respect of defined contribution plans		39	$ 43	$ 39
The Company's estimate of deposits expected in funded defined benefit plans for 2019		$ 8
Life of defined benefit plans		11 years	13 years 7 months 6 days
Year 2024 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Cash incentive to senior managers subject to compliance with certain financial targets	$ 37

Employee Benefits (Composition

Employee Benefits (Composition of Employee Benefits) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Classes of employee benefits expense [abstract]
Fair value of plan assets	$ 432	$ 648
Termination benefits	(86)	(135)
Defined benefit obligation	(664)	(993)
Total Employee benefits	$ (318)	$ (480)

Employee Benefits (Compositio_2

Employee Benefits (Composition of Fair Value of the Plan Assets) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Levels of fair value hierarchy [Line Items]
Equity instruments	$ 166	$ 280
Debt instruments	242	340
Deposits with insurance companies	24	28
Fair value of plan assets	432	648
With quoted market price [Member]
Levels of fair value hierarchy [Line Items]
Equity instruments	126	230
Debt instruments	232	337
Without quoted market price [Member]
Levels of fair value hierarchy [Line Items]
Equity instruments	40	50
Debt instruments	$ 10	$ 3

Employee Benefits (Movement in

Employee Benefits (Movement in Net Defined Benefit Assets Liabilities and in their Components) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Movement in net defined benefit assets (liabilities) [Line Items]
Balance as at the begining of the year	$ 648
Other movements [Abstract]
Balance as at the end of the year	432	$ 648
Fair value of plan assets [Member]
Movement in net defined benefit assets (liabilities) [Line Items]
Balance as at the begining of the year	648	629
Income (costs) included in profit or loss [Abstract]
Current service costs	0	0
Interest income (expenses)	12	6
Past service cost	0	0
Effect of movements in exchange rates, net	(32)	8
Included in other comprehensive income [Abstract]
Actuarial profits (losses) deriving from changes in financial assumptions	0	0
Other actuarial gains	(147)	17
Change with respect to translation differences ,net	(34)	(10)
Other movements [Abstract]
Benefits received (paid)	(20)	(6)
Employer contribution	5	4
Balance as at the end of the year	432	648
Defined benefit obligation [Member]
Movement in net defined benefit assets (liabilities) [Line Items]
Balance as at the begining of the year	(993)	(1,075)
Income (costs) included in profit or loss [Abstract]
Current service costs	(23)	(24)
Interest income (expenses)	(20)	(14)
Past service cost	0	12
Effect of movements in exchange rates, net	56	(16)
Included in other comprehensive income [Abstract]
Actuarial profits (losses) deriving from changes in financial assumptions	230	68
Other actuarial gains	0
Change with respect to translation differences ,net	43	21
Other movements [Abstract]
Benefits received (paid)	43	35
Employer contribution	0	0
Balance as at the end of the year	(664)	(993)
Defined benefit obligation, net [Member]
Movement in net defined benefit assets (liabilities) [Line Items]
Balance as at the begining of the year	(345)	(446)
Income (costs) included in profit or loss [Abstract]
Current service costs	(23)	(24)
Interest income (expenses)	(8)	(8)
Past service cost	0	12
Effect of movements in exchange rates, net	24	(8)
Included in other comprehensive income [Abstract]
Actuarial profits (losses) deriving from changes in financial assumptions	230	68
Other actuarial gains	(147)	17
Change with respect to translation differences ,net	9	11
Other movements [Abstract]
Benefits received (paid)	23	29
Employer contribution	5	4
Balance as at the end of the year	$ (232)	$ (345)

Employee Benefits (Actuarial As

Employee Benefits (Actuarial Assumptions) (Details)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Discount rate as at the end of the year [Member]
Actuarial assumptions [Line Items]
Principal actuarial assumptions	4.70%	2.10%	1.70%
Future salary increases [Member]
Actuarial assumptions [Line Items]
Principal actuarial assumptions	3.90%	3.90%	3.40%
Future pension increase [Member]
Actuarial assumptions [Line Items]
Principal actuarial assumptions	2.80%	2.30%	2%

Employee Benefits (Sensitivity

Employee Benefits (Sensitivity Analysis) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Actuarial assumptions [Line Items]
Defined benefit obligation	$ 664	$ 993
Salary increase [Member] \| Decrease 10% [Member]
Actuarial assumptions [Line Items]
Defined benefit obligation	(11)
Salary increase [Member] \| Decrease 5% [Member]
Actuarial assumptions [Line Items]
Defined benefit obligation	(6)
Salary increase [Member] \| Increase 5% [Member]
Actuarial assumptions [Line Items]
Defined benefit obligation	6
Salary increase [Member] \| Increase 10% [Member]
Actuarial assumptions [Line Items]
Defined benefit obligation	11
Discount rate [Member] \| Decrease 10% [Member]
Actuarial assumptions [Line Items]
Defined benefit obligation	28
Discount rate [Member] \| Decrease 5% [Member]
Actuarial assumptions [Line Items]
Defined benefit obligation	14
Discount rate [Member] \| Increase 5% [Member]
Actuarial assumptions [Line Items]
Defined benefit obligation	(14)
Discount rate [Member] \| Increase 10% [Member]
Actuarial assumptions [Line Items]
Defined benefit obligation	(28)
Mortality table [Member] \| Decrease 10% [Member]
Actuarial assumptions [Line Items]
Defined benefit obligation	13
Mortality table [Member] \| Decrease 5% [Member]
Actuarial assumptions [Line Items]
Defined benefit obligation	6
Mortality table [Member] \| Increase 5% [Member]
Actuarial assumptions [Line Items]
Defined benefit obligation	(6)
Mortality table [Member] \| Increase 10% [Member]
Actuarial assumptions [Line Items]
Defined benefit obligation	$ (13)

Provisions (Narratives) (Detail

Provisions (Narratives) (Details) $ in Millions	12 Months Ended
Provisions (Narratives) (Details) $ in Millions	Dec. 31, 2022 USD ($)
Suria And Sallent Sites, Spain [Member]
Disclosure of other provisions [line items]
Amount of provision for the closure and restoration for the Salltent site	$ 74
Period used for estimating the cost of closure and restoration for the Salltent site	50 years
Rotem Amfert Israel [Member]
Disclosure of other provisions [line items]
Amount of provision for the closure and restoration for the Salltent site	$ 75
Bromine Israel [Member]
Disclosure of other provisions [line items]
Amount of provision for the closure and restoration for the Salltent site	$ 27

Provisions (Information) (Detai

Provisions (Information) (Details) $ in Millions	12 Months Ended
Provisions (Information) (Details) $ in Millions	Dec. 31, 2022 USD ($)
Disclosure of other provisions [line items]
Balance at the beginning of the year	$ 337
Provisions recorded during the year	39
Provisions reversed during the period	(12)
Effect of change in discount rate	18
Payments during the period	(21)
Translation differences	(10)
Balance at the end of the year	315
Site restoration and equipmen dismantling [Member]
Disclosure of other provisions [line items]
Balance at the beginning of the year	283	[1]
Provisions recorded during the year	0	[1]
Provisions reversed during the period	(10)	[1]
Effect of change in discount rate	18	[1]
Payments during the period	(17)	[1]
Translation differences	(10)	[1]
Balance at the end of the year	228	[1]
Legal claims [Member]
Disclosure of other provisions [line items]
Balance at the beginning of the year	13
Provisions recorded during the year	36
Provisions reversed during the period	(1)
Effect of change in discount rate	0
Payments during the period	(3)
Translation differences	0
Balance at the end of the year	45
Other [Member]
Disclosure of other provisions [line items]
Balance at the beginning of the year	41
Provisions recorded during the year	3
Provisions reversed during the period	(1)
Effect of change in discount rate	0
Payments during the period	(1)
Translation differences	0
Balance at the end of the year	$ 42

[1] Main items under 'Site restoration and equipment dismantling':

Commitments, Concessions and _2

Commitments, Concessions and Contingent Liabilities (Narratives) (Details) ₪ / shares in Units, Numberofpersons in Thousands	1 Months Ended		12 Months Ended
	Oct. 31, 2020 ₪ / shares	Jun. 30, 2020 USD ($)	Dec. 31, 2022 ILS (₪) Numberofpersons	Dec. 31, 2022 USD ($) Numberofpersons	Dec. 31, 2017 USD ($)	Dec. 31, 2016	Dec. 31, 2022 USD ($)
Capital commitments [abstract]
Contractual commitments for acquisition of raw materials and energy							$ 2,600,000,000
Contractual commitments for acquisition of Property, Plant and Equipment							684,000,000
Project cost to be paid throughout construction and operation period				$ 110,000,000
Expected extension of construction period			4 years	4 years
Expected extension of operation period			25 years	25 years
Total amount of new natural gas agreement with Energean					$ 2,000,000,000
Year of supply of natural gas					15 years
Price of gas supply obtained from Energean \| ₪ / shares	₪ 4
Rotem's existing obligations to rehabilitate its mining and plants areas				$ 19,000,000
Amount of alleged damages for dialogue meeting to be held before pursuing legal action				$ 27,000,000
Period of mining of phosphate or until exhaustion of raw material whichever occurs first						25 years
Long term lease agreement with a third party of office building		15 years
Extension term lease agreement with third party of office building		10 years
Annual rent on long-term lease agreement		$ 3,000,000
Indemnification payable for directors and officers limit							300,000,000
Consolidated Depreciation Expenses Relating To Assets In Concession Area							108,000,000
Dsw Rate Of Royalties Payment			5%	5%
Royalty rate for production of phosphates			0.05	0.05
Total royalties				$ 1,500,000
Claimed remedies for an application for a class action on alleged environmental hazards to Zin stream			₪ 3,000,000,000				933,000,000
Remedy relating aquifer and Bokek stream restoration - application for certification of a claim as class action							24,000,000
Remedy relating dyke collapse - first class action for 8.68 million persons			₪ 1,000				311
Number of persons involved in salt harvesting project \| Numberofpersons			8,680	8,680
Remedy relating dyke collapse - second class action			₪ 250,000,000				77,000,000
Award personal compensation			2,000				622
Remedy relating dyke collapse - third class action			202,500,000				63,000,000
Remedy relating dyke collapse - Nature and Parks Authority			397,000,000				123,000,000
Amount transferred to NPA \| ₪			3,000,000
A class action claim relating air pollution in Haifa Bay			₪ 13,400,000,000				4,200,000,000
The company's part in financing of the coastline defenses			39.50%	39.50%
The company's part in financing of the Salt Harvesting project			80%	80%
The government's part in financing of the Salt Harvesting project			20%	20%
Maximum government's share in financing of the Salt Harvesting project \| ₪			₪ 1,400,000,000
ICL's damages lawsuit against IBM							300,000,000
IBM counterclaim			170,000,000				53,000,000
Amount of damages alleged by group incurred respondents			133,000,000	$ 40,000,000
Amount Of additional damages alleged by group incurred respondents			57,000,000	17,000,000
Maximal damage for Hamonization for application for certification of a claim as class action			426,000,000				121,000,000
Minimal damage for Hamonization for application for certification of a claim as class action			26,000,000				8,000,000
Compensation in application for certification of a claim as class action regarding alleged monopolistic exploitation - difference test			56,000,000				17,000,000
Compensation in application for certification of a claim as class action regarding alleged monopolistic exploitation - comparison test			73,000,000				$ 23,000,000
Compensation amount for restoration expenses, legal expenses and other expenses			₪ 115,000,000	$ 33,500,000
Percentage of mining royalties			2.30%	2.30%
Royalty payment				$ 4,200,000
Estimated public compensation			₪ 1,400,000,000	$ 435,000,000

Equity (Narratives) (Details)

Equity (Narratives) (Details) $ / shares in Units, $ in Thousands, shares in Millions	1 Months Ended	12 Months Ended
	Feb. 28, 2023 USD ($)	Dec. 31, 2022 USD ($) ₪ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Equity [abstract]
Percentage of acquisition of issued share capital			14%
Percentage of acquisition of augmentation of issued share capital			25%
Percentage of acquisition of augmentation of existing holding up to			25%
Percentage of acquisition of augmentation of existing holding less than			25%
Number of non-marketable and non-transferable options granted	$ 461
Fair value non-marketable and non-transferable options granted	$ 903
Weighted average share price \| (per share)		₪ 25.45	$ 7.23
Number of shares acquired by subsidiaries or associates under purchase plan \| shares			22.4
Total consideration		₪ 258,000	$ 258,000
Expenses from Equity Compensation Plans			$ 12,000	$ 6,000	$ 8,000
Total shares held by the company and it's subsidiaries \| shares		24.5	24.5

Equity (Composition) (Details)

Equity (Composition) (Details) - shares shares in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Number of Ordinary shares of Israeli Shekel 1 par value (in millions) [Member]
Disclosure of classes of share capital [Line Items]
Number of shares authorized	1,485	1,485
Number of shares issued and paid	1,314	1,312	1,305
Number of Special State shares of Israeli Shekel 1 par value [Member]
Disclosure of classes of share capital [Line Items]
Number of shares authorized	1	1
Number of shares issued and paid	1	1

Equity (Reconciliation of the N

Equity (Reconciliation of the Number of Shares Outstanding) (Details) - Number of Ordinary shares of Israeli Shekel 1 par value (in millions) [Member] - shares shares in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of classes of share capital [Line Items]
Balance as at Start of Period	1,312	1,305
Issuance of shares	2	7
Balance as at End of Period	1,314	1,312

Equity (Share-based Payments to

Equity (Share-based Payments to Employees, Non-marketable Options) (Details) - Non-marketable options [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2022 shares
Officers and senior employees [Member] \| August 6, 2014 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments (thousands)	3,993
Issuance's details	A
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. In case that on the exercise date the closing price of an ordinary share is higher than twice the exercise price (the “Share Value Cap”), the number of the exercised shares will be reduced so that the product of the exercised shares actually issued to an offeree multiplied by the share closing price will equal to the product of the number of exercised options multiplied by the Share Value Cap.
Vesting conditions	3 equal tranches: (1) one third on December 1, 2016 (2) one third on December 1, 2017 (3) one third on December 1, 2018
Expiration date	Two years from the vesting date.
Officers and senior employees [Member] \| June 30, 2016 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments (thousands)	3,035
Issuance's details	A
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Expiration date	June 30, 2023
Officers and senior employees [Member] \| June 20, 2017 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments (thousands)	6,868
Issuance's details	A
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Expiration date	June 20, 2024
Officers and senior employees [Member] \| March 6, 2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments (thousands)	5,554
Issuance's details	A
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Expiration date	March 6, 2025
Former chairman of BOD [Member] \| September 5, 2016 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments (thousands)	186
Issuance's details	A
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Expiration date	June 30, 2023
Former chairman of BOD [Member] \| August 2, 2017 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments (thousands)	165
Issuance's details	A
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Expiration date	June 20, 2024
Former chairman of BOD [Member] \| August 20, 2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments (thousands)	403
Issuance's details	An issuance of non-marketable and non-transferrable options, for no consideration, under the amended 2014 Equity Compensation Plan.
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Expiration date	August 20, 2025
Former CEO [Member] \| February 14, 2017 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments (thousands)	114
Issuance's details	A
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Expiration date	February 14, 2024
CEO [Member] \| May 14, 2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments (thousands)	385
Issuance's details	An issuance of non-marketable and non-transferrable options, for no consideration, under the amended 2014 Equity Compensation Plan.	[1]
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Expiration date	May 14, 2025
CEO [Member] \| June 27, 2019 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments (thousands)	3,512
Issuance's details	An issuance of non-marketable and non-transferrable options, for no consideration, under the amended 2014 Equity Compensation Plan.
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	2 equal tranches:(1) half at the end of 24 months after the grant date.(2) half at the end of 36 months after the grant date.
Expiration date	5 years after the grant date
CEO [Member] \| March 30, 2022 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments (thousands)	1,941
Issuance's details	An issuance of non-marketable and non-transferrable options, for no consideration, under the amended 2014 Equity Compensation Plan.
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Expiration date	5 years after the grant date
Officers and senior manager [Member] \| April 15, 2019 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments (thousands)	13,242
Issuance's details	An issuance of non-marketable and non-transferrable options, for no consideration, under the amended 2014 Equity Compensation Plan.
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	2 equal tranches:(1) half at the end of 24 months after the grant date.(2) half at the end of 36 months after the grant date.
Expiration date	5 years after the grant date
Chairman BOD [Member] \| May 29, 2019 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments (thousands)	2,169	[1]
Issuance's details	An issuance of non-marketable and non-transferrable options, for no consideration, under the amended 2014 Equity Compensation Plan.	[1]
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.	[1]
Vesting conditions	2 equal tranches:(1) half at the end of 24 months after the grant date.(2) half at the end of 36 months after the grant date.	[1]
Expiration date	5 years after the grant date	[1]
Chairman BOD [Member] \| March 30, 2022 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments (thousands)	1,055
Issuance's details	An issuance of non-marketable and non-transferrable options, for no consideration, under the amended 2014 Equity Compensation Plan.
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Expiration date	5 years after the grant date
Senior Employees [Member] \| June 30, 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments (thousands)	647
Issuance's details	An issuance of non-marketable and non-transferrable options, for no consideration, under the amended 2014 Equity Compensation Plan.
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	2 equal tranches:(1) half at the end of 24 months after the grant date.(2) half at the end of 36 months after the grant date.
Expiration date	5 years after the grant date
Senior Employees [Member] \| February 8, 2022 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments (thousands)	9,294
Issuance's details	An issuance of non-marketable and non-transferrable options, for no consideration, under the amended 2014 Equity Compensation Plan.
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Expiration date	5 years after the grant date

[1]The options were issued upon Mr. Doppelt's entry into office on July 1, 2019.

Equity (Share-based Payments _2

Equity (Share-based Payments to Employees, Non-marketable Options, Grants Parameters) (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) yr $ / shares
Granted 2014 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in $) \| $ / shares	$ 8.2
CPI-linked exercise price (in $) \| $	$ 8.4
Fair value \| $	$ 8,400,000
Weighted average grant date fair value per option (in $) \| $ / shares	$ 1.9
Granted 2016 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in $) \| $ / shares	$ 3.9
CPI-linked exercise price (in $) \| $	$ 4.3
Fair value \| $	$ 4,000,000
Weighted average grant date fair value per option (in $) \| $ / shares	$ 1.1
Granted 2017 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in $) \| $ / shares	$ 4.5
CPI-linked exercise price (in $) \| $	$ 4.3
Fair value \| $	$ 11,300,000
Weighted average grant date fair value per option (in $) \| $ / shares	$ 1.6
Granted 2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in $) \| $ / shares	$ 4.4
CPI-linked exercise price (in $) \| $	$ 4.3
Fair value \| $	$ 8,800,000
Weighted average grant date fair value per option (in $) \| $ / shares	$ 1.4
Granted 2019 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in $) \| $ / shares	$ 5.4
CPI-linked exercise price (in $) \| $	$ 5.3
Fair value \| $	$ 7,500,000
Weighted average grant date fair value per option (in $) \| $ / shares	$ 1.2
Granted 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in $) \| $ / shares	$ 6.8
CPI-linked exercise price (in $) \| $	$ 7.1
Fair value \| $	$ 600,000
Weighted average grant date fair value per option (in $) \| $ / shares	$ 1.3
Granted 2022 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in $) \| $ / shares	$ 10
CPI-linked exercise price (in $) \| $	$ 10.1
Fair value \| $	$ 24,900,000
Weighted average grant date fair value per option (in $) \| $ / shares	$ 2
First tranche [Member] \| Granted 2014 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	29.40%
Expected life of options (in years)	4.3
Risk-free interest rate	(0.17%)
First tranche [Member] \| Granted 2016 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	30.51%
Expected life of options (in years)	7
Risk-free interest rate	0.01%
First tranche [Member] \| Granted 2017 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	31.88%
Expected life of options (in years)	7
Risk-free interest rate	0.37%
First tranche [Member] \| Granted 2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	28.86%
Expected life of options (in years)	7
Risk-free interest rate	0.03%
First tranche [Member] \| Granted 2019 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	27.85%
Expected life of options (in years)	4.4
Risk-free interest rate	(0.67%)
First tranche [Member] \| Granted 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	31.70%
Expected life of options (in years)	4.4
Risk-free interest rate	0.43%
First tranche [Member] \| Granted 2022 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	31.80%
Expected life of options (in years)	3.2
Risk-free interest rate	(1.46%)
Second tranche [Member] \| Granted 2014 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	31.20%
Expected life of options (in years)	5.3
Risk-free interest rate	0.05%
Second tranche [Member] \| Granted 2016 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	30.51%
Expected life of options (in years)	7
Risk-free interest rate	0.01%
Second tranche [Member] \| Granted 2017 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	31.88%
Expected life of options (in years)	7
Risk-free interest rate	0.37%
Second tranche [Member] \| Granted 2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	28.86%
Expected life of options (in years)	7
Risk-free interest rate	0.03%
Second tranche [Member] \| Granted 2019 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	27.85%
Expected life of options (in years)	4.4
Risk-free interest rate	(0.67%)
Second tranche [Member] \| Granted 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	31.70%
Expected life of options (in years)	4.4
Risk-free interest rate	0.43%
Second tranche [Member] \| Granted 2022 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	30.88%
Expected life of options (in years)	3.8
Risk-free interest rate	(1.29%)
Third tranche [Member] \| Granted 2014 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	40.80%
Expected life of options (in years)	6.3
Risk-free interest rate	0.24%
Third tranche [Member] \| Granted 2016 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	30.51%
Expected life of options (in years)	7
Risk-free interest rate	0.01%
Third tranche [Member] \| Granted 2017 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	31.88%
Expected life of options (in years)	7
Risk-free interest rate	0.37%
Third tranche [Member] \| Granted 2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	28.86%
Expected life of options (in years)	7
Risk-free interest rate	0.03%
Third tranche [Member] \| Granted 2019 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	0%
Expected life of options (in years)	0
Risk-free interest rate	0%
Third tranche [Member] \| Granted 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	0%
Expected life of options (in years)	0
Risk-free interest rate	0%
Third tranche [Member] \| Granted 2022 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	30.52%
Expected life of options (in years)	4
Risk-free interest rate	(1.21%)

Equity (Share-based Payments _3

Equity (Share-based Payments to Employees, Non-marketable Options, Movement) (Details) - Non-marketable options [Member] - Share Share in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Balance as at start of year	12	27
Granted during the year	12
Expired during the year		1
Forfeited during the year	(2)
Exercised during the year	(7)	(16)
Balance as at end of year	15	12

Equity (Share-based Payments _4

Equity (Share-based Payments to Employees, Non-marketable Options, Exercise Price) (Details) - $ / shares	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Granted in 2016 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price for options outstanding	$ 3.41	$ 4.61	$ 4.56
Granted in 2017 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price for options outstanding	3.14	4.19	4.17
Granted in 2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price for options outstanding	3.06	4.11	4.12
Granted in 2019 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price for options outstanding	4.57	5.77	5.66
Granted in 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price for options outstanding	6	7.39	0
Granted in 2022 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price for options outstanding	$ 8.91	$ 0	$ 0

Equity (Share-based Payments _5

Equity (Share-based Payments to Employees, Non-marketable Options, Number of Options Vested) (Details) $ in Millions		Dec. 31, 2022 USD ($) ₪ / shares	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2021 USD ($) ₪ / shares	Dec. 31, 2021 USD ($) $ / shares	Dec. 31, 2020 USD ($) ₪ / shares	Dec. 31, 2020 USD ($) $ / shares
Equity [abstract]
Number of options exercisable (In Millions)	[1]	5	5	4	4	11	11
Weighted average exercise price \| (per share)	[1]	₪ 15.67	$ 4.45	₪ 14.29	$ 4.59	₪ 13.89	$ 4.32

[1]The share price as of December 31, 2022, is NIS 25.45 and $7.23.

Equity (Share-based Payments _6

Equity (Share-based Payments to Employees, Non-marketable Options, Range of Exercise Prices) (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Range of exercise price in Israeli Shekel	10.77-30.06	12.77-18.06	13.15-18.32
Range of exercise price in US Dollar	3.06-8.54	4.11-5.81	4.09-5.70

Equity (Share-based Payments _7

Equity (Share-based Payments to Employees, Non-marketable Options, Average Remaining Contractual Life) (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Average remaining contractual life	3 years 5 months 1 day	2 years 9 months 29 days	3 years 6 months 29 days

Equity (Share-based Payments _8

Equity (Share-based Payments to Employees, Restricted Shares) (Details) - Restricted shares [Member] shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) shares
Officers and senior employees [Member] \| June 20, 2017 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments (thousands) \| shares	2,211
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date	[1]
Instrument terms	An issuance for no consideration, under the amended 2014 Equity Compensation Plan.
Additional information	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the approval date of the General Meeting).
Fair value at the grant date (Million) \| $	$ 10
Officers and senior employees [Member] \| March 6, 2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments (thousands) \| shares	1,726
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Instrument terms	An issuance for no consideration, under the amended 2014 Equity Compensation Plan.
Additional information	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the approval date of the General Meeting).
Fair value at the grant date (Million) \| $	$ 8
ICLs Directors (excluding ICLs CEO and Chairman of the BOD) [Member] \| January 10, 2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments (thousands) \| shares	137
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Instrument terms	An issuance for no consideration, under the amended 2014 Equity Compensation Plan.
Additional information	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the approval date of the General Meeting).
Fair value at the grant date (Million) \| $	$ 0.6
ICLs Directors (excluding directors who are officers or directors of Israel Corporation Ltd.) [Member] \| April 23, 2020 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments (thousands) \| shares	177
Vesting conditions	3 equal tranches: (1) one third on January 1, 2021 (2) one third on January 1, 2022 (3) one third on January 1,2023	[1]
Instrument terms	An issuance for no consideration, under the amended 2014 Equity Compensation Plan.
Additional information	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the Grant Date (the approval date of the annual General Meeting of shareholders).
Fair value at the grant date (Million) \| $	$ 0.6
Former Chairman B O D [Member] \| August 2, 2017 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments (thousands) \| shares	53
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Instrument terms	An issuance for no consideration, under the amended 2014 Equity Compensation Plan.
Additional information	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the approval date of the General Meeting).
Fair value at the grant date (Million) \| $	$ 0.3
Former Chairman B O D [Member] \| August 20, 2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments (thousands) \| shares	47
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Instrument terms	An issuance for no consideration, under the amended 2014 Equity Compensation Plan.
Additional information	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the approval date of the General Meeting).
Fair value at the grant date (Million) \| $	$ 0.2
CEO [Member] \| May 14, 2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments (thousands) \| shares	121
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Instrument terms	An issuance for no consideration, under the amended 2014 Equity Compensation Plan.
Additional information	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the approval date of the General Meeting).
Fair value at the grant date (Million) \| $	$ 0.6

[1]Vesting of the Restricted Shares would be fully accelerated if the holder ceases to serve as a director of the Company, unless he/she ceased to hold office due to those certain circumstances regarding early termination of office or imposition of enforcement measures, as set forth in Sections 231-232a and 233(2) of the Israeli Companies Law.

Equity (Dividends Distributed t

Equity (Dividends Distributed to the Company's Shareholders) (Details) - USD ($) $ / shares in Units, $ in Millions		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Gross amount of the dividend distributed (in millions of $)		$ 1,166	$ 276	$ 118
Amount of the dividend per share (in $)		$ 0.9	$ 0.21	$ 0.09
February 11, 2020 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Actual date of distribution of the dividend				Mar. 18, 2020
Gross amount of the dividend distributed (in millions of $)				$ 23
Amount of the dividend per share (in $)				$ 0.02
May 10, 2020 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Actual date of distribution of the dividend				Jun. 17, 2020
Gross amount of the dividend distributed (in millions of $)				$ 30
Amount of the dividend per share (in $)				$ 0.02
July 27, 2020 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Actual date of distribution of the dividend				Sep. 16, 2020
Gross amount of the dividend distributed (in millions of $)				$ 36
Amount of the dividend per share (in $)				$ 0.03
November 10, 2020 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Actual date of distribution of the dividend				Dec. 16, 2020
Gross amount of the dividend distributed (in millions of $)				$ 29
Amount of the dividend per share (in $)				$ 0.02
February 10, 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Actual date of distribution of the dividend			Mar. 16, 2021
Gross amount of the dividend distributed (in millions of $)			$ 34
Amount of the dividend per share (in $)			$ 0.03
May 5, 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Actual date of distribution of the dividend			Jun. 16, 2021
Gross amount of the dividend distributed (in millions of $)			$ 67
Amount of the dividend per share (in $)			$ 0.05
July 27, 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Actual date of distribution of the dividend			Sep. 01, 2021
Gross amount of the dividend distributed (in millions of $)			$ 68
Amount of the dividend per share (in $)			$ 0.05
November 3, 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Actual date of distribution of the dividend			Dec. 15, 2021
Gross amount of the dividend distributed (in millions of $)			$ 107
Amount of the dividend per share (in $)			$ 0.08
February 8, 2022 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Actual date of distribution of the dividend		Mar. 08, 2022
Gross amount of the dividend distributed (in millions of $)		$ 169
Amount of the dividend per share (in $)		$ 0.13
May 10, 2022 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Actual date of distribution of the dividend		Jun. 15, 2022
Gross amount of the dividend distributed (in millions of $)		$ 307
Amount of the dividend per share (in $)		$ 0.24
July 26, 2022 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Actual date of distribution of the dividend		Sep. 14, 2022
Gross amount of the dividend distributed (in millions of $)		$ 376
Amount of the dividend per share (in $)		$ 0.29
November 8, 2022 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Actual date of distribution of the dividend		Dec. 14, 2022
Gross amount of the dividend distributed (in millions of $)		$ 314
Amount of the dividend per share (in $)		$ 0.24
February 14, 2023 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Actual date of distribution of the dividend	[1]	Mar. 15, 2023
Gross amount of the dividend distributed (in millions of $)	[1]	$ 178
Amount of the dividend per share (in $)	[1]	$ 0.14

[1]The record date is March 1, 2023, and the payment date is March 15, 2023.

Details of Income Statement I_3

Details of Income Statement Items (Sales) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Details Of Income Statement [Abstract]
Sales	$ 10,015	$ 6,955	$ 5,043
Cost of sales
Materials consumed	3,152	2,342	1,647
Cost of labor	937	906	794
Energy and fuel	433	343	316
Depreciation and amortization	409	413	416
Other	52	340	380
Cost of sales	$ 4,983	$ 4,344	$ 3,553

Details of Income Statement I_4

Details of Income Statement Items (Expenses) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Selling, transport and marketing expenses
Land and marine transportation	$ 792	$ 742	$ 515
Cost of labor	188	171	134
Other	201	154	117
Selling, transport and marketing expenses	1,181	1,067	766
General and administrative expenses
Cost of labor	168	166	136
Professional Services	44	44	32
Other	79	66	64
General and administrative expenses	291	276	232
Research and development expenses
Cost of labor	55	52	40
Other	13	12	14
Research and development expenses	$ 68	$ 64	$ 54

Details of Income Statement I_5

Details of Income Statement Items (Other Income and Expenses) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Other income and expenses [Abstract]
Profit from divestment	$ 22	$ 14	$ 0
Insurance Compensation	15	0	0
Capital gain	9	16	0
Reversal of early retirement provision of employees	2	0	0
Past service cost	0	12	11
Reversal of provision for legal claims	0	11	0
Reversal of Impairment of fixed assets	0	9	0
Other	6	1	9
Other income recorded in the income statements	54	63	20
Provision for legal claims	17	17	0
Provision for historical waste removal and site closure costs	6	14	83
Transaction costs	0	8	0
Impairment and disposal of assets	0	9	90
Provision for early retirement and dismissal of employees	0	0	78
Other	7	9	5
Other expenses recorded in the income statements	$ 30	$ 57	$ 256

Details of Income Statement I_6

Details of Income Statement Items (Financing Income and Expenses) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Financing income:
Net gain from changes in exchange rates	$ 139	$ 0	$ 0
Financing income in relation to employee benefits	44	0	0
Interest income from banks and others	31	17	7
Net gain from change in fair value of derivative designated as economic hedge	0	59	0
Net gain from change in fair value of derivative designated as cash flow hedge	0	18	54
Finance income	214	94	61
Financing expenses:
Net loss from change in fair value of derivative designated as economic hedge	98	0	23
Net loss from change in fair value of derivative designated as cash flow hedge	77	0	0
Interest expenses to banks and others	148	126	120
Financing expenses in relation to employees' benefits	7	23	38
Banks and finance institutions commissions (mainly commission on early repayment of loans)	7	6	4
Net loss from changes in exchange rates	0	79	58
Financing expenses	337	234	243
Net of borrowing costs capitalized	10	18	24
Finance expenses	327	216	219
Net financing expenses recorded in the income statements	$ 113	$ 122	$ 158

Financial Instruments and Ris_3

Financial Instruments and Risk Management (Narratives) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Disclosure of risk management strategy related to hedge accounting [Line Items]
Amount annual additional deductible cumulative	$ 6	$ 6
LIBOR-based debt mature after the expected end date	$ 30	$ 30
Hedging ratio	1:1
Hedged instruments amount	360	360
Average interest discount on debenture		7%	2.50%
Israel, New Shekels
Disclosure of risk management strategy related to hedge accounting [Line Items]
Average interest discount on loan		5.20%	1.50%
Euro Member Countries, Euro
Disclosure of risk management strategy related to hedge accounting [Line Items]
Average interest discount on loan		4.90%	1.20%
Brazil, Brazil Real
Disclosure of risk management strategy related to hedge accounting [Line Items]
Average interest discount on loan		16.30%	13%
China, Yuan Renminbi
Disclosure of risk management strategy related to hedge accounting [Line Items]
Average interest discount on loan		4.30%	4%

Financial Instruments and Ris_4

Financial Instruments and Risk Management (Groups and Measurement Bases of Financial Assets and Financial Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of financial instruments [Line Items]
Cash and cash equivalents	$ 417	$ 473	$ 214	$ 95
Short-term investments and deposits	91	91
Other receivables	323	357
Other non-current asset	231	403
Short term debt	(512)	(577)
Trade payables	(1,006)	(1,064)
Other current liabilities	(1,007)	(912)
Long term debt and debentures	(2,312)	(2,436)
Other non- current liabilities	(60)	(70)
Financial assets measured at fair value through the statement of income [Member]
Disclosure of financial instruments [Line Items]
Cash and cash equivalents	0	0
Short-term investments and deposits	0	0
Trade receivables	0	0
Other receivables	0	0
Foreign currency derivative designated as economic hedge	3	23
Marine transport derivative designated as economic hedge		2
Foreign currency and interest derivative instruments designated as cash flow hedge Current assets	7	23
Foreign currency and interest derivative instruments designated as cash flow hedge Non-current assets	19	97
Other non-current asset	0	0
Total financial assets	29	145
Short term debt	0	0
Trade payables	0	0
Other current liabilities	0	0
Foreign currency derivative designated as economic hedge Current Liabilities	0	0
Interest derivative instruments designated as economic hedge	0
Long term debt and debentures	0	0
Foreign currency and interest derivative instruments designated as cash flow hedge Non Current Liabilities	0	0
Other non- current liabilities	0	0
Total financial liabilities	0	0
Total financial instruments, net	29	145
Measured at amortized cost [Member]
Disclosure of financial instruments [Line Items]
Cash and cash equivalents	417	473
Short-term investments and deposits	91	91
Trade receivables	1,583	1,418
Other receivables	55	45
Foreign currency derivative designated as economic hedge	0	0
Marine transport derivative designated as economic hedge		0
Foreign currency and interest derivative instruments designated as cash flow hedge Current assets	0	0
Foreign currency and interest derivative instruments designated as cash flow hedge Non-current assets	0	0
Other non-current asset	35	14
Total financial assets	2,181	2,041
Short term debt	0	0
Trade payables	0	0
Other current liabilities	0	0
Foreign currency derivative designated as economic hedge Current Liabilities	0	0
Interest derivative instruments designated as economic hedge	0
Long term debt and debentures	0	0
Foreign currency and interest derivative instruments designated as cash flow hedge Non Current Liabilities	0	0
Other non- current liabilities	0	0
Total financial liabilities	0	0
Total financial instruments, net	2,181	2,041
Financial liabilities measured at fair value through the statement of income [Member]
Disclosure of financial instruments [Line Items]
Cash and cash equivalents	0	0
Short-term investments and deposits	0	0
Trade receivables	0	0
Other receivables	0	0
Foreign currency derivative designated as economic hedge	0	0
Marine transport derivative designated as economic hedge		0
Foreign currency and interest derivative instruments designated as cash flow hedge Current assets	0	0
Foreign currency and interest derivative instruments designated as cash flow hedge Non-current assets	0	0
Other non-current asset	0	0
Total financial assets	0	0
Short term debt	0	0
Trade payables	0	0
Other current liabilities	0	0
Foreign currency derivative designated as economic hedge Current Liabilities	(28)	(3)
Interest derivative instruments designated as economic hedge	(16)
Long term debt and debentures	0	0
Foreign currency and interest derivative instruments designated as cash flow hedge Non Current Liabilities	(1)	(7)
Other non- current liabilities	0	0
Total financial liabilities	(45)	(10)
Total financial instruments, net	(45)	(10)
Measured at amortized cost [Member]
Disclosure of financial instruments [Line Items]
Cash and cash equivalents	0	0
Short-term investments and deposits	0	0
Trade receivables	0	0
Other receivables	0	0
Foreign currency derivative designated as economic hedge	0	0
Marine transport derivative designated as economic hedge		0
Foreign currency and interest derivative instruments designated as cash flow hedge Current assets	0	0
Foreign currency and interest derivative instruments designated as cash flow hedge Non-current assets	0	0
Other non-current asset	0	0
Total financial assets	0	0
Short term debt	(512)	(577)
Trade payables	(1,006)	(1,064)
Other current liabilities	(198)	(153)
Foreign currency derivative designated as economic hedge Current Liabilities	0	0
Interest derivative instruments designated as economic hedge	0
Long term debt and debentures	(2,312)	(2,436)
Foreign currency and interest derivative instruments designated as cash flow hedge Non Current Liabilities	0	0
Other non- current liabilities	(45)	(49)
Total financial liabilities	(4,073)	(4,279)
Total financial instruments, net	$ (4,073)	$ (4,279)

Financial Instruments and Ris_5

Financial Instruments and Risk Management (Credit Risk - Maximum Exposure to Credit Risk) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Maximum Exposure to credit risk Financial assets [Line Items]
Carrying amount	$ 2,210	$ 2,186
Cash and cash equivalents [Member]
Maximum Exposure to credit risk Financial assets [Line Items]
Carrying amount	417	473
Short term investments and deposits [Member]
Maximum Exposure to credit risk Financial assets [Line Items]
Carrying amount	91	91
Trade receivables [Member]
Maximum Exposure to credit risk Financial assets [Line Items]
Carrying amount	1,583	1,418
Other receivables [Member]
Maximum Exposure to credit risk Financial assets [Line Items]
Carrying amount	55	45
Derivatives [Member]
Maximum Exposure to credit risk Financial assets [Line Items]
Carrying amount	29	145
Other non-current assets [Member]
Maximum Exposure to credit risk Financial assets [Line Items]
Carrying amount	$ 35	$ 14

Financial Instruments and Ris_6

Financial Instruments and Risk Management (Credit Risk - Maximum Exposure to Credit Risk for Trade Receivables by Geographic Region) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Disclosure of financial instruments [Line Items]
Maximum exposure to credit risk of loans or receivables	$ 1,585	$ 1,418
Asia [Member]
Disclosure of financial instruments [Line Items]
Maximum exposure to credit risk of loans or receivables	317	440
Europe [Member]
Disclosure of financial instruments [Line Items]
Maximum exposure to credit risk of loans or receivables	457	362
South America [Member]
Disclosure of financial instruments [Line Items]
Maximum exposure to credit risk of loans or receivables	434	306
North America [Member]
Disclosure of financial instruments [Line Items]
Maximum exposure to credit risk of loans or receivables	242	193
Israel [Member]
Disclosure of financial instruments [Line Items]
Maximum exposure to credit risk of loans or receivables	104	95
Others [Member]
Disclosure of financial instruments [Line Items]
Maximum exposure to credit risk of loans or receivables	$ 31	$ 22

Financial Instruments and Ris_7

Financial Instruments and Risk Management (Credit Risk - Aging of Trade Receivables) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Gross [Member]
Disclosure of financial instruments [Line Items]
Trade receivables	$ 1,593	$ 1,427
Gross [Member] \| Not past due [Member]
Disclosure of financial instruments [Line Items]
Trade receivables	1,485	1,313
Gross [Member] \| Past due up to 3 months [Member]
Disclosure of financial instruments [Line Items]
Trade receivables	97	82
Gross [Member] \| Past due 3 to 12 months [Member]
Disclosure of financial instruments [Line Items]
Trade receivables	10	23
Gross [Member] \| Past due over 12 months [Member]
Disclosure of financial instruments [Line Items]
Trade receivables	1	9
Accumulated impairment [member]
Disclosure of financial instruments [Line Items]
Trade receivables	(8)	(9)
Accumulated impairment [member] \| Not past due [Member]
Disclosure of financial instruments [Line Items]
Trade receivables	(3)	(1)
Accumulated impairment [member] \| Past due up to 3 months [Member]
Disclosure of financial instruments [Line Items]
Trade receivables	0	0
Accumulated impairment [member] \| Past due 3 to 12 months [Member]
Disclosure of financial instruments [Line Items]
Trade receivables	(4)	(2)
Accumulated impairment [member] \| Past due over 12 months [Member]
Disclosure of financial instruments [Line Items]
Trade receivables	$ (1)	$ (6)

Financial Instruments and Ris_8

Financial Instruments and Risk Management (Credit Risk - Movement in the Allowance of Doubtful Accounts during the Year) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about financial instruments [abstract]
Balance at start of period	$ 9	$ 10
Additional allowance	1	(3)
Reversals	(2)	(2)
Change due to translation differences	0	4
Balance at end of period	$ 8	$ 9

Financial Instruments and Ris_9

Financial Instruments and Risk Management (Liquidity Risk) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Disclosure of risk management strategy related to hedge accounting [Line Items]
Short term debt (not including current maturities)	$ 512	$ 577
Trade payables	1,006	1,064
Other current liabilities	1,007	912
Long-term debt, debentures and others	2,312	2,436
Not past due [Member] \| Non-derivative instruments [Member]
Disclosure of risk management strategy related to hedge accounting [Line Items]
Short term debt (not including current maturities)	313	327
Trade payables	1,006	1,064
Other current liabilities	198	153
Long-term debt, debentures and others	2,555	2,735
Non-derivatives financial liabilities	4,072	4,279
Not past due [Member] \| Foreign currency and interest derivative designated as economic hedge [Member] \| Derivative instruments [Member]
Disclosure of risk management strategy related to hedge accounting [Line Items]
Derivatives financial liabilities	28	10
12 months or less [Member] \| Non-derivative instruments [Member]
Disclosure of risk management strategy related to hedge accounting [Line Items]
Short term debt (not including current maturities)	322	329
Trade payables	1,006	1,064
Other current liabilities	198	153
Long-term debt, debentures and others	288	352
Non-derivatives financial liabilities	1,814	1,898
12 months or less [Member] \| Foreign currency and interest derivative designated as economic hedge [Member] \| Derivative instruments [Member]
Disclosure of risk management strategy related to hedge accounting [Line Items]
Derivatives financial liabilities	28	3
Second year [Member] \| Non-derivative instruments [Member]
Disclosure of risk management strategy related to hedge accounting [Line Items]
Short term debt (not including current maturities)	0	0
Trade payables	0	0
Other current liabilities	0	0
Long-term debt, debentures and others	1,080	1,003
Non-derivatives financial liabilities	1,080	1,003
Second year [Member] \| Foreign currency and interest derivative designated as economic hedge [Member] \| Derivative instruments [Member]
Disclosure of risk management strategy related to hedge accounting [Line Items]
Derivatives financial liabilities	0	0
3-5 years [Member] \| Non-derivative instruments [Member]
Disclosure of risk management strategy related to hedge accounting [Line Items]
Short term debt (not including current maturities)	0	0
Trade payables	0	0
Other current liabilities	0	0
Long-term debt, debentures and others	547	799
Non-derivatives financial liabilities	547	799
3-5 years [Member] \| Foreign currency and interest derivative designated as economic hedge [Member] \| Derivative instruments [Member]
Disclosure of risk management strategy related to hedge accounting [Line Items]
Derivatives financial liabilities	0	7
Sixth year and thereafter [Member] \| Non-derivative instruments [Member]
Disclosure of risk management strategy related to hedge accounting [Line Items]
Short term debt (not including current maturities)	0	0
Trade payables	0	0
Other current liabilities	0	0
Long-term debt, debentures and others	1,468	1,532
Non-derivatives financial liabilities	1,468	1,532
Sixth year and thereafter [Member] \| Foreign currency and interest derivative designated as economic hedge [Member] \| Derivative instruments [Member]
Disclosure of risk management strategy related to hedge accounting [Line Items]
Derivatives financial liabilities	$ 0	$ 0

Financial Instruments and Ri_10

Financial Instruments and Risk Management (Market Risk - Interest Rate Profile) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Fixed rate instruments [Member]
Disclosure of financial instruments by type of interest rate [Line Items]
Financial assets	$ 339	$ 338
Financial liabilities	(2,140)	(2,466)
Total financial instruments, net	(1,801)	(2,128)
Variable rate instruments [Member]
Disclosure of financial instruments by type of interest rate [Line Items]
Financial assets	38	36
Financial liabilities	(696)	(562)
Total financial instruments, net	$ (658)	$ (526)

Financial Instruments and Ri_11

Financial Instruments and Risk Management (Market Risk - Sensitivity Analysis for Variable Rate Instruments) (Details) - Swap contract [Member] - Changes In Israeli Shekel Interest [Member] $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Decrease 1% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	$ 23
Decrease 0.5% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	11
Increase 0.5% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	(10)
Increase 1% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	$ (19)

Financial Instruments and Ri_12

Financial Instruments and Risk Management (Market Risk - Terms of Derivative Financial Instruments Used to Hedge Interest Risk) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
SWAP contracts from variable interest to fixed interest [Member]
Disclosure of detailed information about hedges [Line Items]
Carrying amount (fair value)		$ (7)
Stated amount		$ 150
Maturity date (in years)		2024
Interest rate range		2.47%-2.60%
SWAP contracts from fixed ILS interest to fixed USD interest [Member]
Disclosure of detailed information about hedges [Line Items]
Carrying amount (fair value)	$ 23	$ 119
Stated amount	$ 462	$ 579
Maturity date (in years)	2024-2034	2034
Interest rate range	2.4-4.74	2.40%-4.74%

Financial Instruments and Ri_13

Financial Instruments and Risk Management (Market risk - Sensitivity Analysis Non-derivative Financial Instruments) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Euro/US Dollar [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	$ (131)	$ (80)
US Dollar/Israeli Shekel [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	152	177
US Dollar/British Pound [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	(1)	(1)
US Dollar/Japanese Yen [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	(2)	0
US Dollar/Chinese Yuan Renminbi [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	$ 2	$ 1

Financial Instruments and Ri_14

Financial Instruments and Risk Management (Market risk - Sensitivity Analysis) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Euro/US Dollar [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	$ (131)	$ (80)
US Dollar/British Pound [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	(1)	(1)
US Dollar/Israeli Shekel [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	152	177
US Dollar/Japanese Yen [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	(2)	0
US Dollar/Chinese Yuan Renminbi [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	2	$ 1
Option contract [Member] \| Euro/US Dollar [Member] \| Increase 10% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	4
Option contract [Member] \| Euro/US Dollar [Member] \| Increase 5% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	2
Option contract [Member] \| Euro/US Dollar [Member] \| Decrease 5% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	(2)
Option contract [Member] \| Euro/US Dollar [Member] \| Decrease 10% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	(5)
Option contract [Member] \| US Dollar/British Pound [Member] \| Increase 10% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	(1)
Option contract [Member] \| US Dollar/British Pound [Member] \| Increase 5% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	0
Option contract [Member] \| US Dollar/British Pound [Member] \| Decrease 5% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	0
Option contract [Member] \| US Dollar/British Pound [Member] \| Decrease 10% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	1
Option contract [Member] \| US Dollar/Israeli Shekel [Member] \| Increase 10% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	(22)
Option contract [Member] \| US Dollar/Israeli Shekel [Member] \| Increase 5% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	(12)
Option contract [Member] \| US Dollar/Israeli Shekel [Member] \| Decrease 5% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	11
Option contract [Member] \| US Dollar/Israeli Shekel [Member] \| Decrease 10% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	24
Swap contract [Member] \| US Dollar/Israeli Shekel [Member] \| Increase 10% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	(42)
Swap contract [Member] \| US Dollar/Israeli Shekel [Member] \| Increase 5% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	(22)
Swap contract [Member] \| US Dollar/Israeli Shekel [Member] \| Decrease 5% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	25
Swap contract [Member] \| US Dollar/Israeli Shekel [Member] \| Decrease 10% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	53
Forward contracts [Member] \| Euro/US Dollar [Member] \| Increase 10% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	13
Forward contracts [Member] \| Euro/US Dollar [Member] \| Increase 5% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	6
Forward contracts [Member] \| Euro/US Dollar [Member] \| Decrease 5% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	(8)
Forward contracts [Member] \| Euro/US Dollar [Member] \| Decrease 10% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	(15)
Forward contracts [Member] \| US Dollar/British Pound [Member] \| Increase 10% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	(1)
Forward contracts [Member] \| US Dollar/British Pound [Member] \| Increase 5% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	0
Forward contracts [Member] \| US Dollar/British Pound [Member] \| Decrease 5% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	0
Forward contracts [Member] \| US Dollar/British Pound [Member] \| Decrease 10% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	1
Forward contracts [Member] \| US Dollar/Israeli Shekel [Member] \| Increase 10% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	(66)
Forward contracts [Member] \| US Dollar/Israeli Shekel [Member] \| Increase 5% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	(35)
Forward contracts [Member] \| US Dollar/Israeli Shekel [Member] \| Decrease 5% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	38
Forward contracts [Member] \| US Dollar/Israeli Shekel [Member] \| Decrease 10% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	81
Forward contracts [Member] \| Other [Member] \| Increase 10% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	2
Forward contracts [Member] \| Other [Member] \| Increase 5% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	1
Forward contracts [Member] \| Other [Member] \| Decrease 5% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	(1)
Forward contracts [Member] \| Other [Member] \| Decrease 10% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	(2)
Forward contracts [Member] \| US Dollar/Brazilian Real risk [Member] \| Increase 10% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	10
Forward contracts [Member] \| US Dollar/Brazilian Real risk [Member] \| Increase 5% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	5
Forward contracts [Member] \| US Dollar/Brazilian Real risk [Member] \| Decrease 5% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	(6)
Forward contracts [Member] \| US Dollar/Brazilian Real risk [Member] \| Decrease 10% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	(12)
Forward Transactions Hedge Accounting [Member] \| US Dollar/Israeli Shekel [Member] \| Increase 10% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	(31)
Forward Transactions Hedge Accounting [Member] \| US Dollar/Israeli Shekel [Member] \| Increase 5% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	(16)
Forward Transactions Hedge Accounting [Member] \| US Dollar/Israeli Shekel [Member] \| Decrease 5% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	18
Forward Transactions Hedge Accounting [Member] \| US Dollar/Israeli Shekel [Member] \| Decrease 10% [Member]
Disclosure of financial instruments [Line Items]
Impact on profit (loss)	$ 38

Financial Instruments and Ri_15

Financial Instruments and Risk Management (Market risk - Terms of Derivative Financial Instruments Used to Economically Hedge Foreign Currency Risk) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Put options [Member] \| Euro/U.S Dollar [Member]
Disclosure of detailed information about hedges [Line Items]
Carrying amount	$ 1	$ 2
Stated amount	$ 47	$ 57
Average exchange rate	1.1	1.2
Put options [Member] \| US Dollar/British Pound [Member]
Disclosure of detailed information about hedges [Line Items]
Carrying amount	$ 0	$ 0
Stated amount	$ 12	$ 12
Average exchange rate	1.2	1.4
Put options [Member] \| US Dollar/Israeli Shekel [Member]
Disclosure of detailed information about hedges [Line Items]
Carrying amount	$ (11)	$ 14
Stated amount	$ 240	$ 660
Average exchange rate	3.4	3.2
Put options [Member] \| US Dollar/Japanese Yen [Member]
Disclosure of detailed information about hedges [Line Items]
Carrying amount	$ 0	$ 0
Stated amount	$ 3	$ 4
Average exchange rate	130.4	109.7
Call options [Member] \| Euro/U.S Dollar [Member]
Disclosure of detailed information about hedges [Line Items]
Carrying amount	$ (1)	$ 0
Stated amount	$ 47	$ 57
Average exchange rate	1.1	1.2
Call options [Member] \| US Dollar/British Pound [Member]
Disclosure of detailed information about hedges [Line Items]
Carrying amount	$ 0	$ 0
Stated amount	$ 12	$ 12
Average exchange rate	1.2	1.4
Call options [Member] \| US Dollar/Israeli Shekel [Member]
Disclosure of detailed information about hedges [Line Items]
Carrying amount	$ 1	$ (2)
Stated amount	$ 240	$ 660
Average exchange rate	3.4	3.2
Call options [Member] \| US Dollar/Japanese Yen [Member]
Disclosure of detailed information about hedges [Line Items]
Carrying amount	$ 0	$ 0
Stated amount	$ 3	$ 4
Average exchange rate	130.4	109.7
Swap contract [Member] \| US Dollar/Israeli Shekel [Member]
Disclosure of detailed information about hedges [Line Items]
Carrying amount	$ 23	$ 119
Stated amount	$ 462	$ 579
Average exchange rate	3.4	3.7
SWAP contracts from variable interest to fixed interest [Member]
Disclosure of detailed information about hedges [Line Items]
Carrying amount		$ (7)
Stated amount		150
SWAP contracts from fixed ILS interest to fixed USD interest [Member]
Disclosure of detailed information about hedges [Line Items]
Carrying amount	$ 23	119
Stated amount	462	579
Forward contracts [Member] \| Euro/U.S Dollar [Member]
Disclosure of detailed information about hedges [Line Items]
Carrying amount	(4)	4
Stated amount	$ 146	$ 240
Average exchange rate	1.1	1.2
Forward contracts [Member] \| Euro/British Pound [Member]
Disclosure of detailed information about hedges [Line Items]
Carrying amount	$ 0
Stated amount	$ (17)
Average exchange rate	1.2
Forward contracts [Member] \| US Dollar/British Pound [Member]
Disclosure of detailed information about hedges [Line Items]
Carrying amount	$ 0	$ 0
Stated amount	$ 11	$ 16
Average exchange rate	1.2	1.4
Forward contracts [Member] \| US Dollar/Israeli Shekel [Member]
Disclosure of detailed information about hedges [Line Items]
Carrying amount	$ (12)	$ 3
Stated amount	$ 746	$ 515
Average exchange rate	3.4	3.2
Forward contracts [Member] \| US Dollar/Chinese Yuan Renminbi [Member]
Disclosure of detailed information about hedges [Line Items]
Carrying amount		$ 1
Stated amount		$ 46
Average exchange rate		6.5
Forward contracts [Member] \| US Dollar/Brazilian Real risk [Member]
Disclosure of detailed information about hedges [Line Items]
Carrying amount	$ 2	$ (1)
Stated amount	$ 111	$ 37
Average exchange rate	5.2	5.4
Forward contracts [Member] \| Other [Member]
Disclosure of detailed information about hedges [Line Items]
Carrying amount	$ (1)	$ 0
Stated amount	$ 35	$ 23
Average exchange rate	0	0
Forward Transactions Hedge Accounting [Member] \| US Dollar/Israeli Shekel [Member]
Disclosure of detailed information about hedges [Line Items]
Carrying amount	$ (14)
Stated amount	$ 360
Average exchange rate	3.4

Financial Instruments and Ri_16

Financial Instruments and Risk Management (Market risk - Linkage Terms of Monetary Balances) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	$ 263	$ (49)
Total financial assets [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	2,181	2,041
Cash and cash equivalents [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	417	473
Short term investments and deposits [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	91	91
Trade receivables [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	1,583	1,418
Other receivables [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	55	45
Other non-current assets [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	35	14
Total financial liabilities [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	4,073	4,279
Short-term debt [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	512	577
Trade payables [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	1,006	1,064
Other current liabilities [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	198	153
Long term debt, debentures and others [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	2,312	2,436
Other non-current liabilities [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	45	49
US Dollar risk[Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	(729)	(736)
US Dollar risk[Member] \| Total financial assets [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	824	865
US Dollar risk[Member] \| Cash and cash equivalents [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	41	89
US Dollar risk[Member] \| Short term investments and deposits [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	84	86
US Dollar risk[Member] \| Trade receivables [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	659	684
US Dollar risk[Member] \| Other receivables [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	15	2
US Dollar risk[Member] \| Other non-current assets [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	25	4
US Dollar risk[Member] \| Total financial liabilities [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	1,553	1,601
US Dollar risk[Member] \| Short-term debt [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	161	196
US Dollar risk[Member] \| Trade payables [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	202	210
US Dollar risk[Member] \| Other current liabilities [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	49	33
US Dollar risk[Member] \| Long term debt, debentures and others [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	1,141	1,161
US Dollar risk[Member] \| Other non-current liabilities [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	1
Euro Currency Risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	(599)	(320)
Euro Currency Risk [Member] \| Total financial assets [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	368	309
Euro Currency Risk [Member] \| Cash and cash equivalents [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	17	23
Euro Currency Risk [Member] \| Short term investments and deposits [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	2	0
Euro Currency Risk [Member] \| Trade receivables [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	329	260
Euro Currency Risk [Member] \| Other receivables [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	18	22
Euro Currency Risk [Member] \| Other non-current assets [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	2	4
Euro Currency Risk [Member] \| Total financial liabilities [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	1,160	926
Euro Currency Risk [Member] \| Short-term debt [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	137	92
Euro Currency Risk [Member] \| Trade payables [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	229	216
Euro Currency Risk [Member] \| Other current liabilities [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	91	73
Euro Currency Risk [Member] \| Long term debt, debentures and others [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	659	499
Euro Currency Risk [Member] \| Other non-current liabilities [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	44	46
British Pound risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	44	10
British Pound risk [Member] \| Total financial assets [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	81	47
British Pound risk [Member] \| Cash and cash equivalents [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	7	5
British Pound risk [Member] \| Short term investments and deposits [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	0
British Pound risk [Member] \| Trade receivables [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	73	41
British Pound risk [Member] \| Other receivables [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	1	1
British Pound risk [Member] \| Other non-current assets [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	0
British Pound risk [Member] \| Total financial liabilities [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	60	65
British Pound risk [Member] \| Short-term debt [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	18	12
British Pound risk [Member] \| Trade payables [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	27	28
British Pound risk [Member] \| Other current liabilities [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	1	4
British Pound risk [Member] \| Long term debt, debentures and others [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	14	21
British Pound risk [Member] \| Other non-current liabilities [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	0
Israeli Shekel risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	880	611
Israeli Shekel risk [Member] \| Total financial assets [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	102	104
Israeli Shekel risk [Member] \| Cash and cash equivalents [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	1	3
Israeli Shekel risk [Member] \| Short term investments and deposits [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	0
Israeli Shekel risk [Member] \| Trade receivables [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	89	82
Israeli Shekel risk [Member] \| Other receivables [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	12	19
Israeli Shekel risk [Member] \| Other non-current assets [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	0
Israeli Shekel risk [Member] \| Total financial liabilities [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	1,030	1,247
Israeli Shekel risk [Member] \| Short-term debt [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	178	184
Israeli Shekel risk [Member] \| Trade payables [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	372	410
Israeli Shekel risk [Member] \| Other current liabilities [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	27	18
Israeli Shekel risk [Member] \| Long term debt, debentures and others [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	453	635
Israeli Shekel risk [Member] \| Other non-current liabilities [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	0
Chinese Yuan Renminbi risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	258	178
Chinese Yuan Renminbi risk [Member] \| Total financial assets [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	386	357
Chinese Yuan Renminbi risk [Member] \| Cash and cash equivalents [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	306	263
Chinese Yuan Renminbi risk [Member] \| Short term investments and deposits [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	2	3
Chinese Yuan Renminbi risk [Member] \| Trade receivables [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	78	91
Chinese Yuan Renminbi risk [Member] \| Other receivables [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	0
Chinese Yuan Renminbi risk [Member] \| Other non-current assets [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	0
Chinese Yuan Renminbi risk [Member] \| Total financial liabilities [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	128	225
Chinese Yuan Renminbi risk [Member] \| Short-term debt [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	10	52
Chinese Yuan Renminbi risk [Member] \| Trade payables [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	69	91
Chinese Yuan Renminbi risk [Member] \| Other current liabilities [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	15	15
Chinese Yuan Renminbi risk [Member] \| Long term debt, debentures and others [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	34	67
Chinese Yuan Renminbi risk [Member] \| Other non-current liabilities [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	0
Brazilian Real risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	323	134
Brazilian Real risk [Member] \| Total financial assets [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	346	304
Brazilian Real risk [Member] \| Cash and cash equivalents [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	30	76
Brazilian Real risk [Member] \| Short term investments and deposits [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	0
Brazilian Real risk [Member] \| Trade receivables [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	308	222
Brazilian Real risk [Member] \| Other receivables [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	1	1
Brazilian Real risk [Member] \| Other non-current assets [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	7	5
Brazilian Real risk [Member] \| Total financial liabilities [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	134	207
Brazilian Real risk [Member] \| Short-term debt [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	7	41
Brazilian Real risk [Member] \| Trade payables [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	103	103
Brazilian Real risk [Member] \| Other current liabilities [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	15	10
Brazilian Real risk [Member] \| Long term debt, debentures and others [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	8	51
Brazilian Real risk [Member] \| Other non-current liabilities [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	1	2
Other [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	86	74
Other [Member] \| Total financial assets [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	74	55
Other [Member] \| Cash and cash equivalents [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	15	14
Other [Member] \| Short term investments and deposits [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	3	2
Other [Member] \| Trade receivables [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	47	38
Other [Member] \| Other receivables [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	8	0
Other [Member] \| Other non-current assets [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	1	1
Other [Member] \| Total financial liabilities [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	8	8
Other [Member] \| Short-term debt [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	1	0
Other [Member] \| Trade payables [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	4	6
Other [Member] \| Other current liabilities [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	0
Other [Member] \| Long term debt, debentures and others [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	3	2
Other [Member] \| Other non-current liabilities [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	0
Non-derivative instruments [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	(1,892)	(2,238)
Non-derivative instruments [Member] \| US Dollar risk[Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	(729)	(736)
Non-derivative instruments [Member] \| Euro Currency Risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	(792)	(617)
Non-derivative instruments [Member] \| British Pound risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	21	(18)
Non-derivative instruments [Member] \| Israeli Shekel risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	(928)	(1,143)
Non-derivative instruments [Member] \| Chinese Yuan Renminbi risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	258	132
Non-derivative instruments [Member] \| Brazilian Real risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	212	97
Non-derivative instruments [Member] \| Other [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	66	47
Derivative instruments [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	2,155	2,189
Derivative instruments [Member] \| US Dollar risk[Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	0
Derivative instruments [Member] \| Euro Currency Risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	193	297
Derivative instruments [Member] \| British Pound risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	23	28
Derivative instruments [Member] \| Israeli Shekel risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	1,808	1,754
Derivative instruments [Member] \| Chinese Yuan Renminbi risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	46
Derivative instruments [Member] \| Brazilian Real risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	111	37
Derivative instruments [Member] \| Other [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	20	27
SWAP USD into ILS [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	462	579
SWAP USD into ILS [Member] \| US Dollar risk[Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	0
SWAP USD into ILS [Member] \| Euro Currency Risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	0
SWAP USD into ILS [Member] \| British Pound risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	0
SWAP USD into ILS [Member] \| Israeli Shekel risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	462	579
SWAP USD into ILS [Member] \| Chinese Yuan Renminbi risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	0
SWAP USD into ILS [Member] \| Brazilian Real risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	0
SWAP USD into ILS [Member] \| Other [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	0
Cylinder instruments [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	302	733
Cylinder instruments [Member] \| US Dollar risk[Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	0
Cylinder instruments [Member] \| Euro Currency Risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	47	57
Cylinder instruments [Member] \| British Pound risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	12	12
Cylinder instruments [Member] \| Israeli Shekel risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	240	660
Cylinder instruments [Member] \| Chinese Yuan Renminbi risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	0
Cylinder instruments [Member] \| Brazilian Real risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	0
Cylinder instruments [Member] \| Other [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	3	4
Forward Transactions Hedge Accounting [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0
Forward Transactions Hedge Accounting [Member] \| Euro Currency Risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0
Forward Transactions Hedge Accounting [Member] \| British Pound risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0
Forward Transactions Hedge Accounting [Member] \| Israeli Shekel risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	360
Forward Transactions Hedge Accounting [Member] \| Chinese Yuan Renminbi risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0
Forward Transactions Hedge Accounting [Member] \| Brazilian Real risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0
Forward Transactions Hedge Accounting [Member] \| Other [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0
Forward contracts [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	1,031	877
Forward contracts [Member] \| US Dollar risk[Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	0
Forward contracts [Member] \| Euro Currency Risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	146	240
Forward contracts [Member] \| British Pound risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	11	16
Forward contracts [Member] \| Israeli Shekel risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	746	515
Forward contracts [Member] \| Chinese Yuan Renminbi risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	0	46
Forward contracts [Member] \| Brazilian Real risk [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	111	37
Forward contracts [Member] \| Other [Member]
Disclosure of financial instruments [Line Items]
Exposure on monetary balances	$ 17	$ 23

Financial Instruments and Ri_17

Financial Instruments and Risk Management (Fair Value of Financial Instruments) (Details) - USD ($) $ in Millions		Dec. 31, 2022	Dec. 31, 2021
Carrying amount [Member]
Disclosure of financial instruments [Line Items]
Loans bearing fixed interest	[1]	$ 339	$ 407
Notes and debentures issued		1,869	2,126
Carrying amount [Member] \| Marketable [Member]
Disclosure of financial instruments [Line Items]
Notes and debentures issued	[2]	1,335	1,524
Carrying amount [Member] \| Non marketable [Member]
Disclosure of financial instruments [Line Items]
Notes and debentures issued	[3]	195	195
Fair value [Member]
Disclosure of financial instruments [Line Items]
Loans bearing fixed interest	[1]	302	408
Notes and debentures issued		1,763	2,346
Fair value [Member] \| Marketable [Member]
Disclosure of financial instruments [Line Items]
Notes and debentures issued	[2]	1,270	1,730
Fair value [Member] \| Non marketable [Member]
Disclosure of financial instruments [Line Items]
Notes and debentures issued	[3]	$ 191	$ 208

[1]The fair value of the Shekel, Euro, and Yuan loans issued bearing fixed interest is based on calculation of the present value of the cash flows in respect of the principal and the interest and is discounted at the market interest rates on the measurement date for similar loans having similar characteristics and is classified as Level 2 in the fair value hierarchy. The average discount interest as of December 31, 2020 for the Shekel, Euro and Yuan loans was 1.6%, 1.4% and 5.1%, respectively (December 31, 2019 for the Shekel, Euro and Yuan loans 1.4%, 1.3%, and 4.2%, respectively).[2]The fair value of the marketable debentures is based on the quoted stock exchange price and is classified as Level 1 in the fair value hierarchy.[3]The fair value of the non‑marketable debentures is based on calculation of the present value of the cash flows in respect of the principal and the interest and is discounted at the Libor rate customary in the market for similar loans having similar characteristics and is classified as Level 2 in the fair value hierarchy. The average discount interest as of December 31, 2020 was 2.6% (December 31, 2019 – 3.7%).

Financial Instruments and Ri_18

Financial Instruments and Risk Management (Hierarchy of Fair Value) (Details) - Level 2 [Member] - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Disclosure of financial instruments [Line Items]
Derivatives designated as economic hedge, net	$ (25)	$ 15
Derivatives designated as cash flow hedge, net	9	120
Total	$ (16)	$ 135

Earnings per Share (Narratives)

Earnings per Share (Narratives) (Details)	12 Months Ended
Earnings per Share (Narratives) (Details)	Dec. 31, 2022
Notes to Consolidated Financial Statements [Abstract]
Description of instruments with potential future dilutive effect not included in calculation of diluted earnings per share	As of December 31, 2022, the outstanding options in the amount of 7 million, representing 2.6 million shares, were included in the diluted weighted average number of ordinary shares calculation. As of December 31, 2021, all 12 million outstanding options were included. As of December 31, 2020, 27 million options, were not included since they did not have a diluting effect.

Earnings per Share (Basic earni

Earnings per Share (Basic earnings per share) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Notes to Consolidated Financial Statements [Abstract]
Earnings attributed to the shareholders of the Company	$ 2,159	$ 783	$ 11

Earnings per Share (Weighted-av

Earnings per Share (Weighted-average Number of Ordinary Shares) (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Notes to Consolidated Financial Statements [Abstract]
Balance as at January 1	1,285,585	1,280,242	1,279,379
Shares issued during the year	0	223	29
Shares vested	1,719	2,342	618
Weighted average number of ordinary shares used in the computation of the basic earnings per share	1,287,304	1,282,807	1,280,026

Earnings per Share (Weighted-_2

Earnings per Share (Weighted-average Number of Ordinary Shares Diluted) (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Notes to Consolidated Financial Statements [Abstract]
Weighted average number of ordinary shares used in the computation of the basic earnings per share	1,287,304	1,282,807	1,280,026
Effect of stock options and restricted shares	2,643	4,244	247
Weighted average number of ordinary shares used in the computation of the diluted earnings per share	1,289,947	1,287,051	1,280,273

Related and Interested Partie_2

Related and Interested Parties (Narratives) (Details) $ in Thousands	1 Months Ended		12 Months Ended
	Jan. 30, 2020 USD ($)	Dec. 31, 2017 USD ($) BCM	Dec. 31, 2022 USD ($)	Dec. 31, 2021
Disclosure of transactions between related parties [line items]
Margin loans			As of December 31, 2022, 73 million ordinary shares have been pledged by Israel Corporation to secure certain liabilities, almost entirely comprised of margin loans with an aggregate outstanding principal amount of $150 million.
Explanation of relationships between parent and subsidiaries			Israel Corp. is a public company listed for trading on the Tel Aviv Stock Exchange (TASE). Based on the information provided by Israel Corp., Millenium Investments Elad Ltd. (“Millenium”) and Mr. Idan Ofer are considered as controlling shareholders jointly of Israel Corp., for purposes of the Israeli Securities Law (each of Millenium and Mr. Idan Ofer hold shares in Israel Corp. directly, and Mr. Idan Ofer serves as a director of Millenium and has an indirect interest in it as the beneficiary of the discretionary trust that has indirect control of Millenium, as stated below). Millenium holds approximately 44.44% of the share capital in Israel Corp., which holds as of December 31, 2022 approximately 43.98% of the voting rights and approximately 43.16% of the issued share capital, of the Company. To the best of Israel Corp.’s knowledge, Millenium is held by Mashat (Investments) Ltd. (“Mashat”) and by XT Investments Ltd. (“XT Investments”), with 84.73% and 15.27% holding rates in the issued share capital, respectively. Mashat is wholly owned by Ansonia Holdings Singapore B.V. (“Ansonia”). Ansonia is a wholly owned subsidiary of Jelany Corporation N.V., which is wholly owned by Court Investments Ltd. (“Court”). Court is wholly owned by a discretionary trust, in which Mr. Idan Ofer is the beneficiary. XT Investments is wholly owned by XT Holdings Ltd. (“XT Holdings”). To the best of Israel Corp.’s knowledge, ordinary shares of XT Holdings are held in equal shares by Orona Investments Ltd. (which is indirectly controlled by Mr. Ehud Angel) and by Lynav Holdings Ltd. ("Lynav"), which is controlled by a discretionary trust in which Mr. Idan Ofer is the beneficiary. Mr. Ehud Angel holds, among other things, a special share that grants him, inter alia, under certain limitations and for certain issues, an additional vote on the Board of Directors of XT Holdings. Lynav also holds directly 1.25% of the issued share capital of Israel Corp. In addition, Kirby Enterprises Inc., which is to the best of Israel Corp.’s knowledge, indirectly held by the same trust that holds Mashat, in which, as stated, Mr. Idan Ofer is the beneficiary, holds approximately 0.74% of the issued share capital of Israel Corp. Furthermore, Mr. Idan Ofer holds directly approximately 3.85% of the issued share capital of Israel Corp. Even though Israel Corp. holds less than 50% of the Company’s ordinary shares, it still has decisive influence at the General Meetings of the Company’s shareholders and, effectively, it has the power to appoint directors (other than the external directors) and to exert significant influence with respect to the composition of the Company’s Board of Directors.
Name of parent entity			Israel Corporation LTD.
Payments for annual management fee			$ 1,000
New Framework Transaction [Member]
Disclosure of transactions between related parties [line items]
Term of framework transaction	3 years
Millenium Investments Elad Ltd. (“Millenium”) [Member]
Disclosure of transactions between related parties [line items]
Percentage of holding of share capital				44.44%
Percentage of voting rights and issued share capital			43.98%
Percentage of issued share capital			43.16%
Mashat (Investments) Ltd. (“Mashat”) [Member]
Disclosure of transactions between related parties [line items]
Percentage of holding of share capital			84.73%
XT Investments Ltd. (“XT Investments”) [Member]
Disclosure of transactions between related parties [line items]
Percentage of holding of share capital			15.27%
Lynav Holdings Ltd [Member]
Disclosure of transactions between related parties [line items]
Percentage of holding of share capital				1.25%
Israel Corp. [Member]
Disclosure of transactions between related parties [line items]
Percentage of holding of share capital				0.74%
Percentage of constituting voting rights of shares				50%
Payments for annual management fee			$ 500
Israel Corp. [Member] \| New Framework Transaction [Member]
Disclosure of transactions between related parties [line items]
Amount of joint primary tier of liability cap	$ 20,000
Amount of separate tier covering liability cap	330,000
Total amount of joint liability cap and separate tier covering of liability cap	$ 350,000
Annual premium shall not exceed cap for joint primary tier and separate tier			$ 10,000
Percentage of division of premium amount paid by company			80%
Percentage of division of premium amount paid by parent company and others			20%
Percentage of premium allocation will not exceed entire transaction period			25%
Liability limit of directors and officers insurance policy			$ 150,000
Amount of liability comprised limit of directors and officers insurance policy			40,000
Additional coverage of liability limit of directors and officers insurance policy			$ 110,000
Israel Corp. [Member] \| Mr. Idan [Member]
Disclosure of transactions between related parties [line items]
Percentage of holding of share capital				3.85%
Energean PLC [Member]
Disclosure of transactions between related parties [line items]
The company share In the end of the year, agreements for supply of natural gas		$ 1,800,000
Number of natural gas acquire \| BCM		13
Period of natural gas acquire		15 years

Related and Interested Partie_3

Related and Interested Parties (Benefits to Key Management Personnel including Directors) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Related party transactions [abstract]
Short-term benefits	$ 14	$ 12
Post-employment benefits	1	1
Share-based payments	12	5
Total	27	18
To interested parties employed by the Company	7	3
To interested parties not employed by the Company	$ 1	$ 1

Related and Interested Partie_4

Related and Interested Parties (Transactions with Related and Interested Parties) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Related party transactions [abstract]
Sales	$ 7	$ 7	$ 3
Cost of sales	13	6	3
Selling, transport and marketing expenses	15	13	7
Financing income, net	0	(2)	(1)
General and administrative expenses	1	1	1
Management fees to the parent company	$ 1	$ 1	$ 1

Related and Interested Partie_5

Related and Interested Parties (Balances with Interested Parties) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Related party transactions [abstract]
Other current assets	$ 34	$ 40
Other current liabilities	$ 2	$ 4

Group Main Entities (Informatio

Group Main Entities (Information) (Details)	12 Months Ended
Group Main Entities (Information) (Details)	Dec. 31, 2022	Dec. 31, 2021
ICL Israel Ltd. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	ICL Israel Ltd.
Principal location of the company's activity	Israel
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
Dead Sea Works Ltd. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	Dead Sea Works Ltd.
Principal location of the company's activity	Israel
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
Dead Sea Bromine Company Ltd. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	Dead Sea Bromine Company Ltd.
Principal location of the company's activity	Israel
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
Rotem Amfert Negev Ltd. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	Rotem Amfert Negev Ltd.
Principal location of the company's activity	Israel
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
Mifalei Tovala Ltd. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	Mifalei Tovala Ltd.
Principal location of the company's activity	Israel
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
Dead Sea Magnesium Ltd. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	Dead Sea Magnesium Ltd.
Principal location of the company's activity	Israel
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
Bromine Compounds Ltd. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	Bromine Compounds Ltd.
Principal location of the company's activity	Israel
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
Fertilizers and Chemicals Ltd. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	Fertilizers and Chemicals Ltd.
Principal location of the company's activity	Israel
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
Iberpotash S.A. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	Iberpotash S.A.
Principal location of the company's activity	Spain
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
Fuentes Fertilizantes S.L. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	Fuentes Fertilizantes S.L.
Principal location of the company's activity	Spain
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
ICL Europe Cooperatief U.A. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	ICL Europe Coöperatief U.A.
Principal location of the company's activity	The Netherlands
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
ICL Europe B.V. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	ICL Europe B.V.
Principal location of the company's activity	The Netherlands
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
ICL IP Terneuzen B.V. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	ICL IP Terneuzen B.V
Principal location of the company's activity	The Netherlands
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
ICL Finance B.V. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	ICL Finance BV
Principal location of the company's activity	The Netherlands
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
Everris International B.V. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	Everris International B.V.
Principal location of the company's activity	The Netherlands
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
ICL Puriphos B.V. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	ICL Puriphos B.V.
Principal location of the company's activity	The Netherlands
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
ICL-IP America Inc. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	ICL-IP America Inc
Principal location of the company's activity	United States of America
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
ICL Specialty Products Inc. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	ICL Specialty Products Inc
Principal location of the company's activity	United States of America
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
Everris NA, Inc. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	Everris NA, Inc.
Principal location of the company's activity	United States of America
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
Growers Holdings, Inc. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	Growers Holdings, Inc.
Principal location of the company's activity	United States of America
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
BK Giulini GmbH [Member]
Disclosure of subsidiaries [Line Items]
Name of company	BK Giulini GmbH
Principal location of the company's activity	Germany
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
ICL Holding Germany GmbH [Member]
Disclosure of subsidiaries [Line Items]
Name of company	ICL Holding Germany GmbH
Principal location of the company's activity	Germany
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
ICL Bitterfeld GmbH [Member]
Disclosure of subsidiaries [Line Items]
Name of company	ICL Bitterfeld GmbH
Principal location of the company's activity	Germany
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
Prolactal GmbH [Member]
Disclosure of subsidiaries [Line Items]
Name of company	Prolactal GmbH
Principal location of the company's activity	Austria
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
Cleveland Potash Ltd. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	Cleveland Potash Ltd.
Principal location of the company's activity	United Kingdom
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
Everris Ltd. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	Everris Ltd.
Principal location of the company's activity	United Kingdom
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
ICL America do Sul [Member]
Disclosure of subsidiaries [Line Items]
Name of company	ICL America do Sul
Principal location of the company's activity	Brazil
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
ICL Aditivos E Ingredientes LTDA [Member]
Disclosure of subsidiaries [Line Items]
Name of company	ICL Aditivos E Ingredientes LTDA
Principal location of the company's activity	Brazil
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
Qualyquímica Industria e Comercio de Produtos Quimicos Ltda [Member]
Disclosure of subsidiaries [Line Items]
Name of company	Qualyquímica Industria e Comercio de Produtos Quimicos Ltda
Principal location of the company's activity	Brazil
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
ICL Investment Co. Ltd. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	ICL Investment Co. Ltd.
Principal location of the company's activity	China
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
Yunan Phosphate Haikou Co. Ltd. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	Yunnan Phosphate Haikou Co. Ltd.
Principal location of the company's activity	China
Ownership interest in it's subsidiary and investee companies for the year ended December 31	50%	50%
ICL Asia Ltd. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	ICL Asia Ltd
Principal location of the company's activity	Hong Kong
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
ICL Trading (HK) Ltd. [Member]
Disclosure of subsidiaries [Line Items]
Name of company	ICL Trading (HK) Ltd.
Principal location of the company's activity	Hong Kong
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%
Scora S.A.S., France [Member]
Disclosure of subsidiaries [Line Items]
Name of company	Scora S.A.S., France
Principal location of the company's activity	France
Ownership interest in it's subsidiary and investee companies for the year ended December 31	100%	100%